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Low-energy  collision-induced  dissociation-tandem  mass  spectrometry  (CID-
MS/MS)  is  a  well-established  approach  for  identifying  pharmaceutical  drug 
metabolites.  The technique fulfils many necessary requirements for this task, 
such  as  a  low  limit  of  detection,  simple  interfacing  to  chromatographic 
techniques,  capability  of  fast  analyses  and  automation,  and  high  sensitivity, 
selectivity and accuracy.  However, one of the main limitations of low-energy 
CID-MS/MS is that unambiguous assignment of the site of metabolism is often 
not possible, particularly for oxidised metabolites.  Further, data interpretation 
can  be  time-consuming,  thus  producing  a  bottleneck  to  high-throughput 
analyses.  The aim of the presented study was to identify structurally dependent 
dissociation pathways using low-energy CID-MS/MS that could facilitate rapid 
and definitive assignment of the sites of metabolism of new chemical entities. 
  Chapter 4 details a specific loss of 50 m/z units in a model S-oxide that 
arises due to an ortho-effect.  This loss could be used to definitively assign the 
site of oxidation and discriminate between multiple sulfur atoms in a parent 
compound.  The 50 m/z unit loss was also shown to be a two-step process 
involving  sequential  radical  losses;  a  rare  observation  for  even-electron 
precursor  ions  under  low-energy  CID  conditions.    Chapter  5  discusses  the 
experimental  investigation  of  two  unexpected  rearrangements  during  the 
dissociation of a model S-oxide that could prevent correct assignment of the site 
of  metabolism.    Chapter  6  presents  a  rapid  and  definitive  approach  to  the 
characterisation of dialkyl tertiary amine-N-oxides.  The work also elucidated 
generic  dissociation  behaviour  under  low-energy  CID  conditions.    Finally, 
chapter  7  considers  an  observation  of  site-specific  intra-ionic 
hydrogen/deuterium  exchange  in  the  gas  phase.    Seven  sets  of  compounds 
were analysed to investigate the substructures that facilitate the exchange.  The 
work demonstrates a method by which a deuterium label can be inserted into 
the carbon skeleton of a small molecule without having to synthetically produce 
the compound, which could be useful in performing timely and cost-effective 
structural elucidation studies.  In summary, the presented study provides two 
potentially  useful  approaches  for  the  rapid  and  definitive  identification  of 
oxidised metabolites, as well as increasing the body of knowledge relating to 
ion-chemistry under low-energy CID conditions. Dedication 
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Chapter 1 
 
Introduction to mass spectrometry 
 
1.1  Synopsis 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-
charge (m/z) ratio of gas-phase ions.  It is capable of providing qualitative and 
quantitative information with high sensitivity, selectivity, speed, accuracy and 
precision, and at low limits of detection.
1  In this study, structural elucidation of 
pharmaceutically  relevant  compounds,  including  model  oxidised  drug 
metabolites,  was  performed  using  MS.    The  aim  was  to  identify  structurally 
dependent dissociation pathways that were indicative of sites of oxidation of 
pharmaceutical  compounds,  thus  facilitating  rapid  and  definitive 
characterisation.    Additionally,  an  increased  understanding  of  ion-chemistry 
under low-energy collision-induced dissociation (CID) conditions was sought. 
 
1.2  Construction of a mass spectrometer 
A mass spectrometer is made up of six key components; an inlet, an ion source, 
a mass analyser, a detector, a data analysis system and a vacuum system.  These 
components are shown schematically in Figure 1.1.  Various technologies are 
available for each of these components.  Those that vary most, and also have 
the greatest impact on the analysis of compounds by MS, are the ion source and 
the mass  analyser.    This  is  because  the  selections  of  these  components  are 
dictated by the chemistry of the analyte(s) of interest and the information that 
is  required.    Detailed  discussions  of  the  ionisation  technique  and  the  mass 
analysers utilised in this study are given below. 
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Figure 1.1  Schematic of the key components of a mass spectrometer 
 
1.3  Ionisation techniques 
A fundamental requirement for an atom or compound to be analysed by MS is 
that it must exist as a gas-phase ion.  Many techniques have been developed to 
ionise analytes from the solid, liquid and gas phases.  These techniques can be 
broadly separated into two categories, the second of which being subdivided 
into  a  further  two  groupings;  those  performed  under  vacuum  and  those 
undertaken at atmospheric pressure with samples either in the solution or solid 
phases.  Table 1.1 gives commercially available examples from each of these 
categories.    The  ionisation  technique  used  throughout  this  study  was 
electrospray ionisation (ESI). 
 
Table 1.1  Commercially  available  ionisation  techniques  defined  by  the 
conditions under which ionisation takes place 
 
In vacuo ionisation 
techniques 
Atmospheric pressure ionisation (API) 
techniques 
 
Solution phase  Solid phase 
Electron ionisation (EI)
2   Electrospray ionisation 
(ESI)
3  
Desorption 
electrospray 
ionisation (DESI)
4  
Chemical ionisation (CI)
5   Atmospheric pressure 
chemical ionisation 
(APCI)
6  
Direct analysis in real 
time (DART)
7  
Matrix-assisted laser 
desorption/ionisation 
(MALDI)
8  
Atmospheric pressure 
photoionisation (APPI)
9  
Atmospheric pressure 
solids analysis probe 
(ASAP)
10  
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1.3.1  Electrospray ionisation (ESI) 
Electrospray was first demonstrated as a method for generating gas-phase ions 
by Malcolm Dole and co-workers.
11  This work provided the inspiration for the 
group of John Fenn to use MS as a method for detecting both positive and 
negative ions generated by electrospray, leading to the development of what is 
referred to today as ESI-MS.
3, 12  The pioneering work performed by Fenn led to 
him sharing the Nobel Prize in Chemistry in 2002.
13  
 
A  number  of  reviews  focussing  on  the  principles,
14  fundamentals,
15  and 
applications
16 of ESI have appeared in the literature.  ESI was selected for this 
study because it is the established ionisation technique in the pharmaceutical 
industry,    being  utilised  in  both  discovery  and  development  for  the 
identification,  characterisation  and  quantification  of  new  chemical  entities 
(NCEs),
17  metabolites,
18  degradants
19  and  impurities.
20  The  wide  application 
stems from the many strengths of the technique.  Firstly, compounds can be 
analysed directly from solution at atmospheric pressure.  This is advantageous 
in  a  pharmaceutical  setting  because  the  analytes  of  interest  are  frequently 
within the  liquid  phase  e.g.  a  plasma or urine  matrix or  stored  dissolved  in 
dimethylsulfoxide.
14, 21  A further benefit of directly sampling from solution is 
that non-volatile and/or thermally unstable species are amenable to analysis by 
MS.  This property broadened the range of compounds  that could be easily 
analysed  by  MS  to  include  biological  macromolecules,  such  as  peptides,
22 
nucleotides,
23 saccharides
24 and protein complexes.
25  These types of compound 
were difficult or impossible to ionise by techniques such as EI and CI because 
they  would  thermally  degrade  before  volatilising  due  to  their  high  boiling 
points.  A number of ionisation techniques, including fast atom bombardment 
(FAB),
26 field desorption (FD),
27 field ionisation (FI)
28 and thermospray (TSP),
29 
did  allow  the  ionisation  of  thermally  unstable  compounds  of  low  volatility.  
However, either limitations in the analytical performance or the requirement 
for  highly  skilled  analysts  to  conduct  the  experiments  meant  that  routine 
application was difficult to realise.  ESI alleviates the need to transfer analytes Chapter 1 
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to the gas phase prior to ionisation, thus allowing compounds not amenable to 
ionisation by EI and CI to be studied by MS.  Further, the ease of use meant that 
ESI  became  the  preferred  ionisation  technique  amongst  the  biological 
community.    Although  ESI  has  been  extensively  applied  to  the  analysis  of 
biological  macromolecules,  it  is  equally  suited  to  ionising  small  polar 
compounds.  It is frequently used in areas of science where small molecules are 
of  primary  interest,    including  environmental  science,
30  forensic  science,
31 
metabolomics
32 and toxicology,
33 as well as pharmaceutical science.
21  
 
Another useful property of ESI is that the ionisation event imparts very little 
energy  to  the  analyte,  leading  to  it  being  referred  to  as  a  “soft”  ionisation 
technique.
34  The result of this phenomenon is that predominately molecular 
species  are  observed  in  an  ESI  mass  spectrum  with  rarely  any  evidence  of 
fragmentation,  unless  induced  via  in-source  CID.    Depending  upon  the 
experimental conditions used, either positive or negative ions are produced by 
the ion source.  Molecules with basic or acidic sites can be analysed by virtue of 
protonation or deprotonation respectively (Equations 1.1 and 1.2, where M = 
molecule).  Adduct ions can also be formed, especially for those compounds not 
possessing strongly basic or acidic sites.  Examples of adducts observed using 
positive ion ESI are cationised molecules, particularly with alkali metals such as 
sodium ions (Equation 1.3).  Adducts with deprotonated acid molecules, for 
example  formate  anions  (Equation  1.4)  and  halide  anions  are  common  in 
negative ion ESI.
35  The soft nature of the ionisation event, and the consequent 
lack of dissociation, means that molecular mass information, and additionally 
elemental formulae when high-resolution mass spectrometers are employed, is 
easily obtainable using ESI-MS.
36, 37  
 
Equation 1.1    M + H
+ → [M + H]
+ 
Equation 1.2    M → [M – H]
- + H
+ 
Equation 1.3    M + Na
+ → [M + Na]
+ 
Equation 1.4    M + HCO2
- → [M + HCO2]
- 
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An analytically useful characteristic of ESI is that multiple-charging is observed 
for macromolecules i.e. [M + nC]
n+, where C represents a charged species such 
as a proton or an ammonium ion.  This was first demonstrated by Wong and co-
workers, who showed data for oligomers of poly(ethylene)glycol bearing up to 
twenty-three  sodium  cations.
38  Multiple-charging  thus  leads  to  a  range  of 
species of a given analyte existing in solution, differentiated only by the number 
of  positive  or negative  charges  on the  ion  for positive  and negative  ion  ESI 
respectively.  When the solution is electrosprayed into the mass spectrometer, 
these species will be recorded at different m/z values due to the relationship 
shown in Equation 1.5; 
 
Equation 1.5   
z
n
n C]     [M
 
 
where:  M = Molecule 
C = Charged species 
  n = Number of charged species 
  z = Number of charges on ion 
 
The resultant distribution of peaks is referred to as the “charge envelope”.  An 
example is shown in Figure 1.2 for the proteins cytochrome C and myoglobin.
39  
The reduction of the m/z value of a macromolecule through multiple-charging 
means that it can be analysed on mass spectrometers that have a low value 
upper mass range limit e.g. quadrupole mass spectrometers.
40  This increases 
the  scope  of  biological  MS  by  allowing  a  greater  number  of  researchers  to 
perform analyses in this area.
14  Another advantage of multiple-charging is that 
the molecular mass determination can be averaged over all of the observed 
charged states, leading to mass accuracies with errors of ± 0.01% i.e. 1 Dalton 
(Da) error at 10,000 Da molecular weight.
41 
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Figure 1.2  ESI mass spectra of A) cytochrome C and B) myoglobin.  The 
annotations show the number of protons associated with each 
peak.  Deconvolution of the spectrum allows the determination 
of the molecular weight of the protein analysed 
  Reproduced  from  reference  39  with  kind  permission  from  the 
American Association for the Advancement of Science 
 
Multiple-charging is generally restricted to analytes in excess of approximately 
1000 Da.  Below this value, most molecules are sufficiently small that coulombic 
repulsion prevents the addition or removal of a second charge.  Thus, small 
molecules are typically observed as singly charged ions, although Kaufmann and 
co-workers  reported  doubly  charged  ions  in  the  ESI  mass  spectrum  of 
difloxacin.
42  All of the compounds investigated in this study were analysed as 
singly protonated molecules i.e. [M + H]
+. 
 
Finally, ESI also enables the simple coupling of separation science techniques, 
such  high  performance  liquid  chromatography  (HPLC)
43  and  capillary 
electrophoresis,
44  to  MS.    A  number  of  interfaces  were  evaluated  for  the 
coupling of the two techniques,
45 such as TSP and continuous-flow (CF)-FAB,
46 
with varying degrees of success.  However, ESI provided one of the most robust 
and user-friendly approaches, and thus has become widely applied.
47  The ease 
of  coupling,  along  with  the  high  sensitivity  of  ESI,
48  has  led  to  LC-ESI-MS 
becoming  the  staple  technology  for  the  analysis  of  pharmaceutical 
metabolites.
49 These analytes are typically at low levels in complex matrices, 
thus necessitating the strengths of LC-ESI-MS for their successful analysis. Chapter 1 
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Figure 1.3 shows a schematic of the production of ions at the tip of the capillary 
in an ESI ion source, which is operated at atmospheric pressure.  To ionise a 
sample, it is first dissolved in a polar solvent; typically acetonitrile, methanol or 
water, or combinations thereof.
50  In the design shown, the resultant solution is 
passed through a metal capillary to which a high voltage of several kilovolts (kV) 
is  applied.   If positive  ion  ESI  is  being  performed, this  voltage  is  of positive 
polarity.  The polarity is reversed for negative ion ESI.  A counter electrode is 
held at 0 volts (V), causing a strong electric field to be created.  A different 
approach to creating the strong electric field is to hold the capillary at 0 V, 
typically using a glass capillary, whilst applying a high voltage to the counter 
electrode;  a  negative  voltage  is  used  for  positive  ion  ESI,  whilst  a  positive 
voltage is applied when performing negative ion ESI.  Upon reaching the end of 
the capillary, the electric field causes the positive ions to be attracted towards 
the  counter  electrode,  leading  to  charge  separation  at  the  surface  of  the 
solution.  The result is that the liquid forms a “Taylor cone”, which protrudes 
from the end of the capillary with charge of the same polarity localised on the 
surface (Figure 1.3).
15  Subsequent evaporation of solvent causes the charge 
density on the surface of the Taylor cone to increase until the “Rayleigh limit” is 
reached i.e. when the forces of coulombic repulsion between the like charges 
and surface tension of the solution are equal.
40  At this point, fission occurs, 
thus producing smaller droplets that carry the same amount of charge.
51 
 
 
Figure 1.3  Schematic of a Taylor cone and subsequent droplet fission in an 
ESI ion source operated with a positive polarity Chapter 1 
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Repeated  evaporation  and  fission  eventually  leads  to  the  production  of 
desolvated ions.
52  The ions present in solution are thus transferred to the gas 
phase.  However, gas-phase reactions can cause the ions to be qualitatively 
different to those present in the solution phase.
53, 54 
 
More efficient ion production, and the capability to accept  faster HPLC flow 
rates,  is  achieved  by  using  pneumatically-assisted  ESI  (Figure  1.4).    In  this 
design, a counter-current drying gas is applied to the source; typically nitrogen.  
Collisions between ion-solvent complexes and the drying gas destroys the non-
covalent  interactions  and  releases  desolvated  ions.
55  Most  ESI  ion  sources 
nowadays  also  use  a  sheath  gas,  which  helps  nebulise  the  solution,  aids 
desolvation  and  collimates  the  spray;    a  modification originally proposed  by 
Bruins and co-workers.
56  Application of heat can also assist desolvation, and 
prevent resolvation, of the ions.
57-59  
 
Figure 1.4  Schematic of a pneumatically-assisted ESI ion source 
 
Two desolvation mechanisms have been proposed for the formation of isolated 
gas-phase ions produced by ESI.  Dole and co-workers suggested the charged 
residue model (CRM) (Figure 1.5), whereby the repeated solvent evaporation 
and  droplet  fission  eventually  leads  to  a  complex  of  an  analyte  with  a  few 
molecules  of  solvent.
11,  60  Evaporation  of  these  solvent  molecules,  with 
concurrent retention of the droplet’s charge by the analyte, forms an isolated 
gas-phase ion that can be sampled into the mass spectrometer.
61  Iribarne and 
Thomson proposed an alternative mechanism; the ion evaporation model (IEM) 
(Figure 1.5).
62, 63  This model begins as being qualitatively the same as the CRM, 
with repeated solvent evaporation and droplet fission steps.  However, it differs 
when the droplets reach approximately 10 nm in radius.  The model proposes Chapter 1 
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that at this point, the electrostatic force on the surface of the charged droplet is 
sufficiently  high  to  overcome  the  solvation  forces.    As  a  result,  direct  field 
desorption of an analyte ion into the gas phase is able to take place.
53  
 
There  is  much  conjecture  as  to  which  model  applies,  with  conflicting 
experimental evidence and opinion.
61  However, a general consensus is that 
multiply-charged macromolecules are formed via the CRM,
64 whilst small ions 
are  proposed  to  form  by  either  the  IEM
53,  65-67  or  the  CRM.
68,  69  These 
generalisations are based on a number of rationalisations, including the fact 
that  a  high  activation  energy  barrier  would  exist  to  the  desorption  of 
macromolecules directly from the charged droplet, thus precluding the IEM.
70  
However,  various  authors  acknowledge  that  there  are  assumptions  in  the 
proposals as to which model applies for different types of analyte.  There is an 
acceptance that a combination of the models could be involved at any one time 
in the formation of gas-phase ions.
71 
 
 
Figure 1.5  Schematic of the desolvation of gas-phase ions as described by 
the  charged  residue  model  (CRM)  and  the  ion  evaporation 
model (IEM) Chapter 1 
10 
The  mixture  of  ions  and  solvent  molecules  generated  from  the  tip  of  the 
capillary supersonically expands as it passes through the ESI ion source.
72  The 
desolvated ions, along with any surviving ion-solvent clusters, pass through the 
orifice in the counter electrode into the mass analyser because they experience 
limited diffusion over the distance traversed.  The lighter solvents molecules 
diffuse much faster from the centre of the spray and thus are less likely to be 
sampled  into  the  mass  analyser.    Various  source  configurations  have  been 
developed to maximise ion transmission whilst minimising sampling of solvent 
molecules, neutrals and salts.
73  For example, Voyksner and Lee demonstrated 
an  off-axis  nebuliser,  positioned  90-95
o  from  the  sampling  orifice,  which 
increased the signal for the protonated molecule of lincomycin by a factor of 
six.
74  Upon passing through the orifice, the ions experience a pressure gradient 
as they travel to the mass analyser.  A gradient is required to gradually lower 
the  pressure  from  atmospheric  pressure  at  the  source  to  the  high  vacuum 
required in the mass analyser, in order to make them compatible.  This gradient 
is  created  using  a  differentially  pumped  interface  made  up  of  a  series  of 
compartments separated by skimmers, which act as baffles, between the source 
and the mass analyser (Figure 1.3).
75  Initially, rotary vane vacuum pumps are 
used to decrease the pressure to approximately 0.01 mbar.
41  Once pressures of 
this  order  are  reached,  high  vacuum  pumps  can  be  utilised.
76  Typically,  a 
turbomolecular vacuum pump is attached to the mass analyser to quickly attain 
the high vacuum at which it operates.
41  The ion motion must be controlled 
during  the  passage  along  the  pressure  gradient  to  ensure  high  transmission 
efficiency.  This is achieved using ion optics.
77  The use of radio frequency (RF)-
only multipoles,
78 charged lenses
76 and ion funnels
79 collimates the beam of 
ions, thus allowing efficient transfer.  The exertion of electrostatic forces also 
accelerates  the  ions  and  prevents  their  removal  by  the  vacuum  pumps.  
Collisions caused by accelerating the ions desolvates any remaining ion-solvent 
complexes, with the solvent removed by the vacuum system.
75 
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1.4  Mass analysers 
Once an isolated gas-phase ion has been formed, a mass analyser is used to 
determine its m/z value.  The three mass analysers used in this study were a 
quadrupole  ion  trap  (QIT)  mass  spectrometer,  a  quadrupole  time-of-flight 
(QqTOF) mass spectrometer and a Fourier transform-ion cyclotron resonance 
(FT-ICR) mass spectrometer.  All three instruments are capable of performing 
the tandem mass spectrometry (MS/MS) experiment. 
 
The use of soft ionisation techniques has had a significant positive impact on the 
field of MS.  However, the limitation of these ionisation techniques is that little 
or no dissociation occurs due to the low amounts of energy imparted to the 
molecule.  Thus, little or no structural information can be derived from a single 
stage  of  mass  analysis.    This  limitation  is  overcome  through  the  use  of  the 
MS/MS  experiment,  which  involves  two  stages  of  mass  analysis.
80  Bridging 
these two analytical scans is a period where an “ion activation” method is used 
to impart energy to the ions.
81  This leads to their dissociation, thus allowing the 
elucidation of structural information. 
 
1.4.1  Tandem mass spectrometry (MS/MS) 
The MS/MS experiment can be performed either “in-time” or “in-space”.
82  Of 
the  mass  spectrometers  used  in  this  study,  the  QIT  and  FT-ICR  mass 
spectrometers  are  “in-time”  MS/MS  platforms,  whilst  the  QqTOF  mass 
spectrometer performs MS/MS “in-space”.  “In-time” MS/MS platforms perform 
the two stages of mass analysis and the ion activation in the same mass analyser 
but at different points in time.  “In-space” MS/MS instruments have two mass 
analysers  separated  by a  collision  cell  where the  ions  are dissociated,  all  of 
which  are  arranged  in  series.
83  The  type  of  MS/MS  platform  i.e.  the  mass 
analyser(s) used and whether MS/MS is performed “in-time” or “in-space”, has 
a bearing on the MS/MS scans that can be performed.  Figure 1.6 shows the 
four MS/MS scan modes that can be conducted. 
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Figure 1.6  The MS/MS scan modes; a) product ion scan; b) precursor ion 
scan;  c)  constant  neutral  loss  scan;  d)  selected  reaction 
monitoring
1 
 
The different scan types can enable different information to be obtained about 
an ion of interest.  All of the MS/MS experiments performed in this study were 
product ion scans.  This experiment involves selecting a specific m/z value, for 
example  that  related  to  the  protonated  molecule  of  an  analyte  of  interest, 
which is then isolated.  The ions (precursor ions) then undergo activation, and 
all of the fragment ions (product ions) within a defined mass range are recorded 
by scanning the mass analyser during the second stage of mass analysis.  This 
allows the analyst to determine structural components of the precursor ion.  
The  precursor  ion  scan  involves  detecting  a  specific  product  ion  during  the 
second stage of mass analysis whilst scanning over a mass range during the first 
stage.    This  scan  is  useful  for  screening  experiments  where  a  group  of 
compounds  all  dissociate  to  produce  a  common  product  ion.    A  frequent 
application of this experiment is the detection of the product ion at  m/z 85 
produced via the dissociation of butylester derivatives of acylcarnitines, which 
are biomarkers for inborn errors of fat metabolism.
84, 85  The constant neutral Chapter 1 
13 
loss scan is also useful for screening for a specific class of compounds.  In this 
experiment, both mass analysers are scanned at the same rate during mass 
analysis.  However, the second mass analyser is scanned with an offset in m/z 
value equal to the mass of a diagnostic neutral loss from the precursor ion.  
Thus, a signal is only generated when the specific neutral loss takes place during 
ion activation, allowing the recording of the product ion during the second stage 
of  mass  analysis.    A  recent  application  of  this  approach  was  reported  by 
Bessette and co-workers, who used the constant neutral loss of 116 m/z units 
from  protonated  DNA  adducts  to  identify  different  classes  of  carcinogens.
86  
Finally, selected reaction monitoring experiments are used in quantitative MS to 
improve the limit of detection.  A precursor-product ion pair is detected by 
scanning only for the m/z value of the precursor ion during the first stage of 
mass analysis and only for the m/z value of the product ion during the second.  
As well as lowering the limit of detection, this MS/MS scan mode also improves 
the selectivity of the experiment.
87  
 
1.4.2  Collision-induced dissociation (CID) 
The  MS/MS  experiment  requires  an  ion  activation  technique  to  induce 
dissociation of the precursor ions, with a variety of approaches reported.
81  The 
technique used throughout this study was CID (Figure 1.7).  In this process, the 
precursor ion is accelerated and collides with an inert gas of high ionisation 
potential; typically helium, nitrogen or argon.
88  The collisions cause conversion 
of the translational energy of the precursor ions to internal energy.
89  In low-
energy CID, such as that used in this study, the precursor ions undergo multiple 
collisions that gradually increase the internal energy.
90  High-energy CID can also 
be performed, using sector and time-of-flight (TOF) mass spectrometers, which 
can  produce  qualitatively  different  mass  spectra.
91-93  The  increased  internal 
energy provides the activation energy for the dissociation reactions to occur.  
The stepwise heating due to multiple collisions produces a spread of energies in 
the  precursor  ions  that  tend  towards  a  Boltzmann  distribution.
83  Thus, 
precursor ions with different internal energies are produced, allowing a range ofChapter 1 
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dissociations to take place. 
 
 
Figure 1.7  Schematic  of  the  collision-induced  dissociation  (CID)  process 
where (A) a precursor ion (purple circle) is accelerated and (B) 
collides  with  a  neutral  gas  (green  circles)  (C)  leading  to  the 
formation of product ions (red circles) 
 
The centre-of-mass (Ecom) reference describes the inelastic ion-neutral collision 
and is used to represent the maximum amount of translational energy that can 
be converted into internal energy.
81  Equation 1.6 shows that increasing the 
translational energy of the precursor ion and/or the mass of the inert gas will 
allow greater internal energies to be attained.
41  Greater collision gas pressures, 
as well as increasing the cross-sectional area of the atom or molecule used, also 
increase the likelihood of a collision.
76,  81  Given that multiple collisions take 
place under low-energy CID conditions, these approaches provide alternative 
methods of increasing the internal energies of the precursor ions.  
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where:  Elab = translational energy of the precursor ion provided by the 
electric fields in the mass spectrometer 
  mi = mass of the precursor ion 
  mc = mass of the inert gas 
 
1.4.3  Quadrupole ion trap-mass spectrometry (QIT-MS) 
The  low-energy  CID-MS/MS  platform  upon  which  much  of  this  study  was 
conducted was the QIT mass spectrometer.  This instrument has a single mass 
analyser in which MS/MS is performed i.e. it is an “in-time” MS/MS platform.  Chapter 1 
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The QIT mass spectrometer became commercially available as a result of the 
development of the mass-selective instability mode of operation.
94  Until this 
point, the QIT had mainly garnered interest amongst the physics community as 
a method of trapping and studying ions, either via mass-selective detection or 
mass-selective storage.
95  However, limited analytical performance in terms of 
mass  range,  mass  resolution  and  sensitivity  meant  that  its  use  as  a  mass 
spectrometer was not widespread until the work of Stafford and co-workers.
96  
The  QIT  mass  spectrometer  used  in  this  study  was  an  LCQ  Classic,  which 
operated  in  the  mass-selective  instability  mode.    The  key  features  of  this 
process on this particular instrument are described below. 
 
A schematic of the QIT is shown in Figure 1.8.  The mass analyser is constructed 
from  three  electrodes;  a  ring  electrode  and  two  end-cap  electrodes.    An 
oscillating electric field is generated through the application of an RF voltage to 
the ring electrode, whilst the end-cap electrodes are held at ground potential.
97  
The electric field that is created allows ions of a range of  m/z values to be 
trapped.
98 
 
 
Figure 1.8  Schematic of the two-dimensional cross section of a quadrupole 
ion trap (QIT) mass analyser Chapter 1 
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The ions with a stable trajectory undertake a motion that has been likened to a 
“figure-of-eight”.
99  The  stability  of  ion  motion  within  the  QIT  can  be 
determined from solutions of the Mathieu equation.  These solutions allow the 
construction  of  a  stability  diagram  in  az,  qz  space  (Figure  1.9)  where  the 
following relationships apply (Equations 1.7 and 1.8);
94  
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where:  U = Maximum direct current (DC) potential between end-cap and 
ring electrodes 
    V = Maximum RF potential between end-cap and ring electrodes 
   m = Mass of ion in Da 
    z = Number of charges on ion 
    ro = Internal radius of ring electrode 
    Ω = Angular frequency of RF potential 
 
 
 
Figure 1.9  Stability diagram in (az, qz) space for a QIT mass analyser 
Reproduced from reference 105 with kind permission from John 
Wiley & Sons Ltd. Chapter 1 
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Ions which map onto the stability diagram within the defined boundaries have 
stable orbits within the electric field, and thus the QIT.
100  As no DC potential is 
applied using the mass-selective instability mode of operation, all of the ions 
have a value of zero for az, hence maximising the range of m/z values that can 
be trapped.
95  Ions are thus positioned along the qz axis, with values inversely 
proportional to their m/z value.  Mass analysis is achieved by linearly increasing 
the amplitude of the RF voltage applied to the ring electrode whilst maintaining 
a fixed frequency.
101  This increases the qz value associated with each m/z value.  
When  a  particular  m/z  value  reaches  the  qz  value  at  the  boundary  of  the 
stability region, the orbits of those ions become unstable in the axial direction.
96  
This leads to ejection of the ions, in order of increasing m/z value, through one 
of the end-cap electrodes where they impinge on an external detector.  The 
solutions of the Mathieu equation produce a boundary of the stability diagram 
at qz = 0.98 when az = 0.  However, this value is decreased to 0.83 in the LCQ 
Classic QIT mass spectrometer used in this study due to the application of a 
supplementary RF voltage to the end-cap electrodes during mass analysis.  This 
voltage is called the resonance ejection amplitude and is applied so that all ions 
of a given m/z value are ejected simultaneously.  This ensures correct m/z value 
assignment and improves the mass resolving power of the instrument.  When 
the ions begin to become unstable inside the QIT, their orbits increase in size 
and decrease in regularity.  At the point in time when qz = 0.98, some of the ions 
will  be  closer  to  the  end-cap  electrodes  than  others.    This  leads  to  the 
population of ions of a given m/z value leaving the trap and impinging upon the 
detector at different points in time.  Whilst these ions are exiting the end-cap 
electrodes,  the  amplitude  of  the  RF  voltage  on  the  ring  electrode  will  have 
increased.    As  the  QIT  is  calibrated  such  that  there  is  a  linear  relationship 
between m/z value and RF amplitude, the ions reaching the detector at a later 
point in time will be detected at a higher m/z value than their true value.  By 
applying the resonance ejection amplitude at the secular frequency of the m/z 
value  of  interest  i.e.  the  characteristic  frequencies  with  which  ions  oscillate 
within the QIT, which are dependent upon their qz values,
95 all ions of that m/z 
value are caused to oscillate as a group.  Thus, they are ejected from the trap Chapter 1 
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simultaneously when qz = 0.83 and before the amplitude of the RF voltage on 
the ring electrode has increased.  The resonance ejection amplitude is increased 
proportionally to the amplitude of the RF voltage on the ring electrode during 
mass analysis to ensure that ions of increasing m/z value are grouped. 
 
Electrostatic repulsion between like charges inside the QIT decreases the mass 
resolving power of the instrument.  The interferences between ions and the 
modifications  of  the  electric  fields  inside  the  QIT  caused  by  coulombic 
interactions  are  called  space  charge  effects.
102  One  method  of  overcoming 
space charge effects is by limiting the population of ions within the QIT using 
automatic  gain  control  (AGC).    AGC  determines  a  maximum  allowable  ion 
abundance that can be tolerated inside the QIT before space charge effects 
occur.  When this ion abundance is reached, the AGC prevents further ions 
entering the trap to allow optimal performance to be maintained.  Another 
method of improving the performance of the QIT, discovered by Stafford and 
co-workers, is to introduce a buffer gas of helium at a pressure of approximately 
1 μbar.
94  The buffer gas causes collisional cooling of the ions entering the trap.  
The removal of excess kinetic energy prevents collisions with the electrodes of 
the QIT, which would cause neutralisation and thus loss of the ions.
103  The 
collisional cooling also causes the ions to collapse towards the centre of the QIT 
where the electric field is homogeneous.
100  This enables a more uniform and 
efficient ejection process during mass analysis, which leads to an improvement 
in mass resolution, sensitivity and the limit of detection.
94  
 
The  QIT  allows  structural  information  about  an  analyte  of  interest  to  be 
obtained  using  the  MS/MS  and  mass  spectrometry  to  the  n
th  degree  (MS
n) 
experiments.    MS/MS  and  MS
n  are  performed  in  the  QIT  by  isolating  and 
dissociating a precursor ion of interest to yield product ions.  The ability of the 
QIT  to  perform  MS
n  means  that  the  genealogy  of  a  precursor  ion  can  be 
followed.
90  This allows extensive structural information to be obtained, with 
MS
12 having been demonstrated.
104  MS
n is achieved by performing multiple 
stages of dissociation i.e. repeated isolation and fragmentation steps.
105  The Chapter 1 
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isolation of ions is often achieved in two stages.  Firstly, the qz value of the ion 
of interest is increased to 0.83.  Thus, all ions of lower m/z values will be ejected 
from  the  trap.    This  process  also  increases  the  differences  in  the  qz  values 
between the remaining ions in the QIT to allow more efficient isolation during 
the second stage, which is termed resonance ejection.  This involves applying a 
range of RF frequencies to the end-cap electrodes in a similar manner to that 
used to eject the ions simultaneously during mass analysis.
101  However, the 
frequencies are chosen to resonate with the secular frequencies of the ions that 
are not required.  A large voltage (approximately 100 V) is used to ensure that 
the  ions  obtain  sufficient  energy  to  cause  them  to  undergo  unstable  orbits.  
Thus, they are ejected from the QIT.  No frequency that resonates with the 
secular frequency of the ion of interest is applied so that it remains in the QIT.  
Resonance ejection can also be utilised to eject all of the unwanted m/z values 
from the QIT without the prior increase of the qz value of the ion of interest to 
0.83.
106 
 
Dissociation of the isolated ion of interest is achieved using  low-energy CID, 
which  is  effected  in  the  QIT  by  initially  decreasing  the  amplitude  of  the  RF 
voltage applied to the ring electrode.  This reduces the qz value of the isolated 
ions.  The product ions, which for singly charged precursor ions will be of a 
lower m/z value, would instantly become unstable and be ejected from the QIT 
as they are formed if the qz value of the precursor ion was not decreased from 
qz = 0.83.  A qz value of 0.25 has been found to lead to optimal dissociation of 
the precursor ion.  Application of an RF voltage to the end-cap electrodes of 
secular frequency of the ion of interest leads to dissociation.  The amplitude 
used is smaller than that used to effect resonance ejection.  The voltage causes 
the  ions  to  become  excited;  hence  the  process  is  known  as  resonance 
excitation.  The excitation of the ions increases their kinetic energy to facilitate 
higher energy collisions with the helium buffer gas.
101  The gradual increase in 
the internal energy inside the QIT is a “slow heating” process, taking place over 
time  spans  of  the  order  of  tens  of  milliseconds  (ms).
107    Once  formed,  the 
product ions do not fragment further.  This is because they are not in resonance Chapter 1 
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with the applied RF voltage as their qz values are greater than 0.25 due to them 
being lower in m/z value, assuming that the precursor ion is singly charged.  The 
amplitude of the RF potential applied to the ring electrode is then increased 
linearly to eject the product ions in order of increasing m/z value.  A limitation 
of  performing  MS/MS  in  the  QIT  is  that  some  low  m/z  value  product  ions 
formed through dissociation of the precursor ion will have  qz values greater 
than 0.83.  Thus, they instantly have unstable orbits, causing their ejection from 
the QIT and preventing them from being recorded during the mass analysis 
stage.  This is referred to as the low mass cut-off (LMCO) and results in product 
ions with m/z values of approximately one-third of the precursor ion not being 
observed in the product ion spectrum.
108 
 
Two parameters allow improved acquisition of product ion spectra using the 
LCQ  Classic  QIT  mass  spectrometer.    These  are  WideBand  activation  and 
normalised collision energies.  WideBand activation allows dissociation of the 
product  ion  resulting  from  the  non-specific  water  loss  observed  for  many 
compounds in the QIT.  The transfer of energy to the precursor ion during low-
energy CID in the QIT is lower than in other mass spectrometers that perform 
low-energy CID, such as a triple quadrupole (QqQ) instrument with a collision 
cell.
109  This frequently leads to the dominant, and often only, product ion being 
[M + H – H2O]
+, as observed in the low-energy CID product ion spectrum of 
methyl  red  acquired  without  WideBand  activation  (Figure  1.10a).    The  non-
specificity of this dissociation provides little useful structural information about 
an analyte of interest.  MS
3 can be employed to fragment the [M + H – H2O]
+ 
product ion.  However, this is non-ideal when using chromatography because 
the extra scan event leads to fewer scans across an eluted peak.  This leads to a 
decrease in accuracy in quantitative experiments.  Further, the extra scan event 
decreases  the  number  of  co-eluting  compounds  for  which  structural 
information can be obtained.  WideBand activation overcomes this problem by 
applying  a  range  of  excitation  frequencies  during  low-energy  CID  such  that 
product  ions  within  a  20  m/z  unit  range  below  the  precursor  ion  are 
dissociated.
110  Thus,  WideBand  activation  allows  the  dissociation  of  a Chapter 1 
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protonated molecule and the [M + H – H2O]
+ product ion in a single scan i.e. a 
pseudo-MS
3 scan takes place (Figure 1.11).  This can lead to product ion spectra 
with greater structural information (Figure 1.10b).
110  
 
 
Figure 1.10  First-generation  low-energy  CID  product  ion  spectra  of 
protonated methyl red (m/z 270) acquired using a LCQ Classic 
QIT mass spectrometer with a) WideBand activation off and b) 
WideBand activation on 
 
 
 
Figure 1.11  Schematic of the operation of WideBand activation 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. Chapter 1 
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Normalised collision energies allow optimum dissociation of analytes covering a 
wide mass range.  A high mass ion requires a greater RF voltage i.e. a greater 
collision energy, than a low mass ion for effective dissociation by low-energy 
CID to be  achieved.
110  An approximately linear relationship exists between the 
m/z value of the precursor ion and the optimal collision energy (Figure 1.12).  
Collision energies could be applied as a percentage of the fixed maximum value 
of  which  the  LCQ  Classic  QIT  mass  spectrometer  is  capable.    In  this 
circumstance, approximately the same amount of energy would be applied for a 
given percentage regardless of the m/z value of interest.  Hence, the RF voltage 
used would only be optimal for a single m/z value.  This would result in the 
structural information for ions of other m/z values being less informative.  The 
normalised  collision  energy  parameter  scales  the  applied  RF  voltage  by 
accounting for the linear relationship shown in Figure 1.12.  The scaling of the 
RF  voltage  creates  equivalent  dissociation,  and  hence  potentially  structural 
information, for any precursor ion independent of its m/z value (Figure 1.13) 
 
 
Figure 1.12  Graph  of  optimal  collision  energy  against  precursor  ion  m/z 
value 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. 
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Figure 1.13  Scaling  of  applied  RF  voltage  with  increasing  m/z  values  for 
different values of normalised collision energy 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. 
 
1.4.4  Quadrupole time-of-flight-mass spectrometry (QqTOF-MS) 
The second low-energy CID-MS/MS platform used in this study was the QqTOF 
mass spectrometer.  This is a hybrid instrument made up of two different mass 
analysers; a quadrupole mass analyser and a TOF mass analyser, coupled via a 
collision cell where low-energy CID takes place.  The components are arranged 
in series.  Thus, the QqTOF mass spectrometer is an “in-space” MS/MS platform.  
The instrument benefits from the ability of the quadrupole to isolate precursor 
ions with unit mass resolution and the TOF’s low limit of detection and capacity 
to  record  mass  spectra  with  high  speed  and  mass  resolution,  thus  making 
accurate mass measurements (AMMs) of complex mixtures possible.
41, 111  
 
The first QqTOF mass spectrometer was reported by Glish and Goeringer.
112  
This instrument was constructed such that the quadrupole and the TOF were 
aligned on the same axis.  This configuration was compatible with the ionisation 
technique selected; thermal ionisation following desorption from a probe.  The 
compatibility arises from the requirement of the acceleration plates of the TOF 
to be operated in a pulsing fashion, thus facilitating transfer of ions along the 
flight tube (Figure 1.14).
1  Thus, TOFs can only accept packets of ions that are Chapter 1 
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created by pulsed ionisation techniques.  Therefore, the Glish and Goeringer 
designed  instrument  would  not  have  been  compatible  with  ionisation 
techniques that create ions continuously, such as ESI, because the TOF could 
not tolerate the ion beam. 
 
 
Figure 1.14  Schematic of a time-of-flight (TOF) mass analyser 
 
The interfacing of continuous ionisation techniques with TOFs was solved by 
Dawson and Guilhaus, who reported an orthogonal acceleration (oa)-TOF mass 
spectrometer.
113  This configuration involves arranging the TOF perpendicular to 
the beam of ions produced by the ion source (Figure 1.15).  The ion beam is 
collimated by a charged lens and then directed into the orthogonal accelerator.  
A voltage of like potential to the ions of interest is applied to the orthogonal 
accelerator for short time periods, typically 10-100 nanoseconds (ns), to repel 
the ions and direct them into the flight tube.
114  These short voltage pulses thus 
make the TOF compatible with the continuous ion source generating the ion 
beam.    The  orthogonal  accelerator  also  imparts  a  number  of  other 
advantages.
115  The filling time of the orthogonal accelerator is approximately 
equal to the time taken for ions to travel along the drift tube and reach the 
detector.  This means that mass analysis can take place whilst the orthogonal 
accelerator is filling with the next packet of ions, thus leading to a high dutyChapter 1 
25 
 
Figure 1.15  Schematic of an orthogonal acceleration-time-of-flight (oa-TOF) 
mass spectrometer 
Reproduced  from  reference  115  with  kind  permission  from 
Elsevier Ltd. 
 
cycle.    Further,  collimation  of  the  ion  beam  and  collisional  cooling  in  the 
orthogonal  accelerator  leads  to  a  population  of  ions  that  have  very  similar 
velocities in the axis of the TOF.
76  This leads to the ions passing through the 
acceleration plates at the same time, which results in an enhancement in mass 
resolving power.  Additional increases in mass resolving power are derived from 
the  ion  beam  being  dispersed  along  the  axis  of  the  orthogonal  accelerator, 
which means that the subset sampled into the TOF are spread sufficiently to 
obviate space charge effects.  Finally, any neutral species produced by the ion 
source will not be affected by the electric pulse generated by the orthogonal 
accelerator.  Hence, no neutrals will enter the TOF, which can lead to improved 
sensitivity and prevention of contamination of the mass analyser and detector. 
 
The  ability  of  an  orthogonal  accelerator  to  interface  continuous  ionisation 
techniques,  specifically  ESI,  with  TOFs  led  to  interest  from  the  biological Chapter 1 
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community  and  paved  the  way  for  the  development  of  the  QqTOF  mass 
spectrometer as a commercially available instrument.
116  The oa-TOF was used 
as  the  basis  for the design  of  the  QqTOF  mass  spectrometer,  which has  an 
additional quadrupole mass analyser and a hexapole collision cell preceding the 
orthogonal accelerator (Figure 1.16).  The construction and operation of the 
two mass analysers in this hybrid instrument will be discussed below. 
 
 
Figure 1.16  Schematic  of  a  quadrupole  time-of-flight  (QqTOF)  mass 
spectrometer with an orthogonal accelerator
116 
 
Quadrupoles are made up of four cylindrical metal rods arranged equidistant 
from one another.  Opposite pairs of rods are electrically connected as denoted 
by “A” and “B” in Figure 1.17. 
 
 
Figure 1.17  Schematic of a two-dimensional cross section of a quadrupole 
mass analyser Chapter 1 
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During the operation of a quadrupole, a positive potential with both a DC and 
an RF component is initially applied in the x direction i.e. to the “A” rods.  At the 
same time, an equal negative potential, also with DC and RF components, is 
applied in the y direction i.e. to the “B” rods.
117  Throughout the operation of 
the quadrupole, the polarities of the two pairs of rods are alternated rapidly i.e. 
from their initial states, the “A” rods change to a negative polarity and the “B” 
rods  to  a  positive  polarity,  and  then  back  to  their  initial  conditions.    The 
connection of the pairs of rods with opposite polarities creates an electric field 
in the x-y plane (Figure 1.17). Ions enter the quadrupole along the z-axis and 
begin  to  oscillate  in  the  x-y  plane.
99  Assuming  that  the  ions  are  positively 
charged and the polarities of the rods are in the initial state described above, 
the ions will be attracted towards the “B” rods.  However, the rapid switching of 
polarities  means  that  the  ions  will  then  be  repelled  by  the  “B”  rods  and 
attracted towards the “A” rods, a situation that will again be reversed when the 
polarities are changed once more.  These cycles of attraction and repulsion lead 
to the ions undergoing a spiralling motion as they travel along the quadrupole.  
As for the QIT, the stability of the ions within the electric field is determined by 
whether their a and q values from the simplified Mathieu equation, as given by 
Equations  1.9  and  1.10,  produce  a  coordinate  in  the  stable  region  of  the 
stability diagram.
118  
 
Equation 1.9  2
o
2r mω
U 4z
a a y x     Equation 1.10  2
o
2r mω
V 2z
qx y q  
 
where:   z = Number of charges on the ion 
    U = Amplitude of the applied DC voltage 
    V = Amplitude of the applied RF voltage 
    m = Mass of ion in Da 
    ω = Angular frequency of the applied RF voltage 
    ro = Distance from centre to an electrode 
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Because there is a DC component contributing to the a value, both components 
of the coordinate will have a positive value on the stability diagram (Figure 
1.18).  Ions with az, qz coordinates that map onto the stability diagram will have 
a stable trajectory through the quadrupole.  Those ions with az, qz coordinates 
outside of it will have unstable trajectories, thus leading to them striking the 
quadrupoles and becoming neutralised. 
 
 
Figure 1.18  Stability diagram in (a, q) space for a quadrupole mass analyser 
Reproduced from reference 117 with kind permission from John 
Wiley & Sons Ltd. 
 
The only variables in Equations 1.9 and 1.10 are the amplitudes of the DC and 
RF voltages.
1  Thus, these values are varied during mass analysis and determine 
whether an ion of given m/z value has a stable trajectory or not.  The ratio of 
the amplitudes is fixed at a constant value, which defines the operating line 
(Figure 1.18).
76  Judicious selection of the ratio will ensure that only ions that 
map onto the stability diagram at the apex are stable.  The stable region defines 
the mass resolving power of the instrument because it determines how many 
m/z values have stable trajectories through the quadrupole for a given DC:RF 
amplitude ratio.  Thus, fixing the ratio such that only a small range of m/z values 
have stable trajectories at any one time maximises the mass resolving power.
118  
In the example shown in Figure 1.18, m2 has a stable trajectory at the specific 
DC and RF amplitudes selected, whilst m1 and m3 have unstable trajectories.  
Thus, only m2 would travel the length of the quadrupole and reach the next 
mass analyser or detector, depending upon the configuration of the specific Chapter 1 
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instrument.  To acquire a mass spectrum, the amplitudes of the DC and RF 
voltages  are  increased  over  a  range  whilst  maintaining  a  fixed  ratio.    This 
sequentially changes, in an increasing fashion, the m/z values that have az, qz 
coordinates at the apex of the stability diagram, and thus stable trajectories 
through the quadrupole.
117  
 
The TOF mass spectrometer is structurally simple, consisting of a flight tube 
held in a vacuum, a set of acceleration plates to direct ions along the tube, and 
a  detector  (Figure  1.14).
119  The  depicted  configuration  is  referred  to  as  a 
“Wiley-McLaren” or linear TOF mass spectrometer.
120  The flight tube is referred 
to as a field-free region because neither electric nor magnetic fields are used in 
the  operation  of  a  TOF  mass  spectrometer.    Mass  analysis  in  a  TOF  mass 
spectrometer is performed by measuring the time that it takes for an ion to 
travel along the flight tube and strike the detector.  The variation in flight times 
for  ions  of  different  m/z  value  arises  from  the  relationship  between  the 
potential energy of the ion when present in the electric field created by the 
acceleration  plates,  and  its  subsequent  kinetic  energy  derived  through 
conversion of its potential energy.  An ion in the electric field created by the 
acceleration plates will have a potential energy given by Equation 1.11.  When 
the ion is pushed along the flight tube by the voltage of the acceleration plates, 
it  obtains  a  kinetic  energy  as  described  by  Equation  1.12.    Assuming 
quantitative conversion of this energy, Equation 1.13 can be formed.
1  
 
Equation 1.11   V Ep z   where: Ep = Potential energy 
            z = Number of charges on ion 
            V = Accelerating voltage 
 
Equation 1.12  
2
k v
2
1
E m   where: Ek = Kinetic energy 
            m = Mass of ion in m/z units 
            v = Velocity 
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Equation 1.13  
2 v
2
1
V m z  
 
The velocity term can be expressed in terms of the time, t, required to travel the 
length of flight tube, d (Equation 1.14); 
 
Equation 1.14  
t
d
v     where: v = Velocity 
            d = Distance 
            t = Time 
 
Substitution of Equation 1.14 into Equation 1.13 produces Equation 1.15; 
 
Equation 1.15  
2
t
d
(
2
1
V ) m z  
 
Rearrangement of Equation 1.15 to express t in terms of the other parameters 
shows that the time taken to travel the length of the flight tube is proportional 
to the square root of the m/z value of the ion (Derivation 1.1).
121  This can be 
simplified to Equation 1.16 because V and d are constant and hence can be 
expressed as k.  Thus, ions with lower m/z values will have shorter flight times 
than those of greater m/z values. 
 
Derivation 1.1    
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Equation 1.16  
z
m
k t  
 
Thus far, a linear TOF mass spectrometer has been discussed i.e. the ions travel 
in a straight line between the acceleration plates and the detector.  However, 
this arrangement leads to very poor mass resolution; approximately 300-500 full 
width at half maximum (FWHM).
122  This is because ions of the same m/z value 
generated by the ion source have both a spatial distribution i.e. they do not 
occupy an infinitesimally small space, and an energy distribution.  The spatial 
distribution means that ions of a given m/z value will reach the acceleration 
plates at different times.  Therefore, once accelerated, they will also reach the 
detector at different times, leading to peak broadening.  The energy distribution 
causes ions of the same m/z value to have different kinetic energies.  Derivation 
1.1 shows that the flight time is inversely proportional to the square root of the 
accelerating voltage.  Therefore, if ions of the same m/z value have different 
amounts  of  kinetic  energy,  their  flight  times  will  be  different  and  peak 
broadening will result.  Furthermore, there are variations in the effect that the 
electric field has on the ions, which results from their spatial distribution.  This 
leads to ions of the same m/z value receiving different amounts of energy when 
they are accelerated, thus leading to a spread of kinetic energies.  Again, this 
leads to broader peaks than would be obtained if all ions of the same m/z value 
had equal kinetic energies.  The combined effects of the spatial and energy 
distribution of the ions leads to a significant deterioration in the mass resolving 
power of the linear TOF mass spectrometer.
123 
 
Two approaches are used to improve the mass resolving power of TOF mass 
spectrometers.    The  first  is  the  use  of  time-lag  focussing  (TLF),
120  which  is 
sometimes referred to as pulsed-ion extraction (PIE)
124 or delayed extraction 
(DE).
125  This feature decouples the extraction of ions from the ion source and 
their acceleration down the flight tube i.e. ions are not continuously accelerated 
as soon as they are formed by the ion source.
123  By allowing a short period of Chapter 1 
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time (between hundreds of ns to several microseconds *μs+)
1 to elapse before 
applying the acceleration voltage, the ions are allowed to cool in the ion source.  
This helps to minimise the distribution of kinetic energies of ions of the same 
m/z value such that the spread of their flight times is tighter once accelerated.
50  
Further, the ions separate according to their kinetic energies during the period 
between their formation and their acceleration because no force is acting upon 
them.  This results in ions of the same m/z value with greater kinetic energies 
drifting  towards  the  detector  due  to  the  enhanced  effect  of  the  potential 
gradient.  When they are extracted from the ion source and accelerated along 
the flight tube, the applied voltage has a greater effect on those ions that have 
spent longer in the source and are further from the detector i.e. those with 
lower kinetic energies.
1  The net result of the ions receiving different amounts 
of kinetic energy from the application of the accelerating voltage is that the ions 
that initially possessed less kinetic energy catch up with those that were more 
energetic at the outset.  Thus, the kinetic energy and spatial distributions of the 
ions are reduced, resulting in improved mass resolving power.
41 
  
The  second  approach  to  improve  the  mass  resolving  power  of  a  TOF  mass 
spectrometer is the addition of a reflectron to the instrument (Figure 1.16).  
This is a stack of ring electrodes that typically have equal differences in voltage 
between them, creating a linear electric field.
41  The lowest voltage is applied to 
the electrode nearest the orthogonal accelerator and the detector, with the far 
most  electrode  having  the  highest  voltage.    The  applied  voltage  creates  an 
electric  field  that  acts  in  the  direction  opposite  to  that  produced  by  the 
orthogonal accelerator.
76  This has the effect of reversing the flight direction of 
the ions.  The purpose of the reflectron is to correct for the differing velocities 
of ions of the same m/z value, which results from them possessing different 
amounts  of  kinetic  energy.    This  is  achieved  by  causing  ions  with  greater 
amounts of kinetic energy to undergo longer flight paths than ions of slower 
velocities.
41  The ion beam penetrates into the reflectron after its passage from 
the  orthogonal  accelerator,  whereby  the  ions  are  eventually  repelled  back 
towards the detector.  However, the distance of penetration by a given ion is Chapter 1 
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dependent upon its kinetic energy.  Increasing kinetic energies allow increased 
penetration, and thus longer residence times in the reflectron, before the ion’s 
direction is reversed.
126  Therefore, for ions of the same m/z value but different 
kinetic energies, the faster travelling ions will traverse the flight tube quicker 
and enter the reflectron before the slower ones arrive.  However, the ions with 
greater kinetic energies will spend longer in the reflectron than the ions with 
less kinetic energy.  Hence, the difference in residence time, and thus flight path 
length, means that the ions of the same m/z value but different kinetic energies 
strike the detector at the same time, thus improving mass resolving power.
127  
The use of a reflectron further increases the mass resolving power of a TOF 
mass  spectrometer  because  the  flight  length  is  increased  without  having  to 
make the instrument bigger, which would necessitate greater vacuum pumping 
capacity.
121  Mass  resolving  power  is  increased  because  flight  times  scales 
linearly with the distance to be travelled (Derivation 1.1).  Thus, two ions of 
different  m/z  values  with  a  constant  difference  in  velocity  will  become 
increasingly  separated  in  arrival  time  at  the  detector  as  the  flight  length 
increases.  This leads to a lower chance of overlap between peaks of different 
m/z values, thus improving the mass resolving power. 
 
Low-energy CID is performed on a QqTOF mass spectrometer using a collision 
cell, which is positioned between the two mass analysers.  This is an RF-only 
quadrupole, hexapole or octopole that contains the gas with which the ions of 
interest collide, leading to an increase in their internal energy.
76  The pressure 
inside the cell is typically maintained at approximately 10 μbar, although this 
can be varied to affect the number of collisions that the ions undergo and thus 
the  extent  to  which  their  internal  energy  is  raised  (Equation  1.6).
128  The 
collision  energies  can  be  tuned  through  varying  the  accelerating  voltages 
applied to the poles of the cell.  Only RF voltages are used so that all of the 
precursor and product ions have stable trajectories inside the collision cell.  This 
is because the absence of a DC component means that all of the ions will be 
positioned on the q-axis of the stability diagram (Figure 1.18).  This region is 
within the boundaries that define whether an ion has a stable trajectory or not Chapter 1 
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as it passes through the poles.  Hence, as all of the ions have stable trajectories, 
no mass filtering will take place.  Thus, all of the ions will traverse the collision 
cell  and  enter  the  orthogonal  accelerator,  and  subsequently  the  TOF  mass 
analyser.  Unlike the QIT, dissociation of product ions can take place inside a 
collision cell.  This is because the acceleration of ions of as they pass through 
the collision cell does not discriminate between precursor and product ions c.f. 
QIT where resonance excitation only causes the precursor ion to undergo high-
energy  collisions  with  the  buffer  gas.    Thus,  the  formed  product  ions  can 
undergo energetic collisions with the gas atoms or molecules before exiting the 
cell,  which  causes  an  increase  in  their  internal  energies.    This  can  facilitate 
further fragmentation, which is referred to as second-generation dissociation. 
 
1.4.5  Fourier  transform-ion  cyclotron  resonance-mass 
spectrometry (FT-ICR-MS) 
The final low-energy CID-MS/MS platform used in this study was the FT-ICR 
mass spectrometer.  This instrument was used to acquire AMMs.  The ultra-high 
mass resolving power of this instrument makes AMMs possible, with accuracies 
of  sub-parts-per-million  (ppm)  having  been  reported  by  McKenna  and  co-
workers in the identification of vanadyl porphorins.
129  
 
FT-ICR-MS instruments have a trap mass analyser, which uses a combination of 
electric and magnetic fields to trap the ions c.f. a QIT which uses only electric 
fields.
130  The  magnetic  field  is  typically  generated  using  a  superconducting 
magnet rather than a permanent magnet or an electromagnet.  This is because 
the latter two varieties are only capable of producing weak magnetic fields, and 
as will be seen below, advantages are gained from using increasingly strong 
magnets.
131, 132  
 
Figure 1.19 shows a schematic of an FT-ICR-MS cell.  The cell is made up of 
three pairs of electrically connected plates; trapping plates, excitation plates 
and detection plates.  Ions enter the cell along the axis of the magnetic field but 
initially feel no force from it in this direction. Chapter 1 
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Figure 1.19  Schematic  of  a  cubic  FT-ICR-MS  cell  detailing  the  electrical 
connection  of  the  pairs  of  plates  and  the  direction  of  the 
magnetic field, B 
Reproduced from reference 134 with kind permission from John 
Wiley & Sons Ltd. 
 
To retain the ions in the cell, an electric current is applied to the trapping plates 
to create a potential well.
133  The plates are positioned perpendicular to the 
magnetic field and a low potential of approximately 1 V is  used to trap the 
ions.
130  The  magnetic  field  does  impart  a  force  on  the  ions  in  the  plane 
perpendicular to their motion as they enter the cell.  The force, known as the 
Lorentz force, is given by Equation 1.17. 
 
Equation 1.17   FL = zVB  where: z = Number of charges on ion 
            V = Velocity of ion 
            B = Magnetic field strength 
 
The  Lorentz  force  causes  the  ions  to  be  bent  into  a  circular  motion  that  is 
perpendicular to the plane of the magnetic field (Figure 1.20).  This is referred 
to as the cyclotron motion.
134  
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Figure 1.20  The cyclotron motion of ions in a uniform magnetic field.  The 
magnetic  field  is  in  the  direction  of  the  plane  of  the  paper.  
Positive and negative ions orbit in opposite directions 
 
The ions also describe two other motions inside the cell.  The ions undergo 
simple harmonic oscillation in the direction of the electric field created by the 
trapping plates; the so-called trapping motion.  Finally, the combination of the 
electric  and  magnetic  fields  induces  a  third  motion  called  the  magnetron 
motion.  This causes the ions to move in larger circular orbits in terms of radius 
than those described by the cyclotron motion, as shown in Figure 1.21.
133  
 
 
Figure 1.21  Three fundamental motions described by ions trapped in an FT-
ICR-MS cell 
Reproduced from reference 131 with kind permission from John 
Wiley & Sons Ltd. 
 
Only the cyclotron motion is analytically useful.  From the frequency of these 
orbits, the m/z value of an ion can be determined.  The equation for cyclotron 
frequency (Equation 1.18) shows that the only variable is the m/z value of the 
ion. Chapter 1 
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Equation 1.18  
m2π
B
fc
z
  where: z = Number of charges on ion 
            B = Magnetic field strength 
            m = Mass of ion in Da 
 
The high mass resolving power of FT-ICR-MS stems from the fact that the m/z 
value of the ions is the sole variable that dictates the cyclotron frequency.  Thus, 
the cyclotron frequency is independent of an ion’s velocity, which correlates 
with its kinetic energy, and its location in the cell.  Hence, no energy or spatial 
focussing  is  required to  allow  accurate  m/z  values  to be  determined, which 
results  in  the  ability  to  acquire  high-resolution  mass  spectra  c.f.  TOF  mass 
analysers whereby an increased spatial and energy distribution of the ions leads 
to a deterioration in the mass resolving power.
135 
 
To measure the cyclotron frequency of an ion, it is first excited to increase the 
radius  of the  cyclotron  motion.    The  initial  radius  is  much  smaller  than  the 
dimensions of the cell and is insufficient to generate a recordable signal in the 
detection plates.
133  The radius of the orbits of ions of a given  m/z value is 
increased by applying an RF voltage to the excitation plates with a frequency 
that is in resonance with the m/z value’s characteristic cyclotron frequency.
136  
This  causes  the  ions  to  experience  an  outward  force,  which  increases  their 
kinetic energies and results in them moving coherently to an orbit of larger 
radius in a spiralling motion (Figure 1.22).
133  A number of m/z values can be 
excited to larger radii cyclotron orbits by applying a range of frequencies.  This is 
achieved by performing a fast frequency sweep, referred to as an RF chirp.
133 
 
Detection of ions is achieved by measuring the alternating current induced in 
the detection plates by the orbiting packet of ions, referred to as the image 
current.
137  As the ions move past each detection plate, they attract electrons 
through the external circuit towards the plate (Figure 1.22).  The movement of 
electrons from one plate to the other as the ions orbit creates the alternating 
current, the frequency of which is equal to the reduced cyclotron frequency i.e.Chapter 1 
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Figure 1.22  Excitation  of ions  to  a  larger  radius  cyclotron motion  by  the 
application of a resonant frequency RF voltage to the excitation 
plates and detection of ions using the image current generated 
in an external circuit 
Reproduced from reference 134 with kind permission from John 
Wiley & Sons Ltd. 
 
the difference between the cyclotron frequency and the magnetron frequency.  
The  magnetron  frequency  is  proportional  to  the  trapping  voltage  used 
(Equation 1.19).
133  Therefore, the cyclotron frequency of a given m/z value will 
be  reduced  by  increasing  amounts  with  increasing  trapping  voltage.    This 
prevents the frequency of the image current being used to determine the m/z 
value of the ion creating it from Equation 1.18.  However, this does not prevent 
AMMs being acquired using FT-ICR-MS, because calibration of the instrument 
can account for the reduction in the cyclotron frequency that results from the 
applied electric field used to trap the ions.
133  The use of standard compounds 
of known elemental composition allows reduced cyclotron frequencies to be 
assigned to particular m/z values.  This allows for the production of a calibration 
line, applicable at the specific trapping voltage, from which the m/z value of an 
unknown can be interpolated from its recorded reduced cyclotron frequency.
133  
 
Equation 1.19  
B πa
αV
f 2 m        
 
where: α = Geometry factor dependent upon the shape of the cell 
  V = Amplitude of the applied trapping voltage Chapter 1 
39 
  a = Distance between the trapping plates 
  B = Magnetic field strength 
 
If multiple ion packets of different m/z values are detected, the signal that is 
produced  is  an  overlay  of  sinusoidal  waves  of  different  frequencies  and 
amplitudes (Figure 1.23).
130  This complex signal is referred to as a transient, 
and  is  in  the  time  domain.    The  complexity  of  the  signal  prevents  simple 
mathematical treatment to derive the m/z value of the ions from the calibration 
line  because  it  is  a  composite  of  a number  of  signals.    However,  frequency 
components from the time domain transient can be derived by applying a fast 
Fourier  transform.    This  deconvolutes  the  signal  and  generates  a  frequency 
spectrum, which can be converted to a mass spectrum using the previously 
determined calibration line.
133  
 
 
Figure 1.23  A time domain transient 
Reproduced from reference 133 with kind permission from John 
Wiley & Sons Ltd. 
 
Improved  signal-to-noise  ratio  and  mass  resolving  power  is  obtained  with 
transients  of  increasing  lengths  of  time,  as  detailed  by  the  relationships  in 
Equations 1.20 and 1.21.  Acquisition of long transients is possible because the 
detection process is non-destructive.  Thus, the ions can be remeasured on a 
number of occasions.  To prevent ion loss, and thus enable remeasurement, an Chapter 1 
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ultra-high vacuum is used to maintain pressures of 1 x 10
-8 – 1x10
-9 mbar inside 
the cell.  This minimises the numbers of neutrals present that can collide with 
the ions, thus causing their neutralisation.  Transient lengths are not infinite 
however, with residual neutral molecules eventually causing loss of coherence 
of  the  ion  packets.    The  longest  transients  are  of  the  order  of  a  minute  in 
length.
133  
 
Equation 1.20   n N : S   where: n = number of scans 
 
Equation 1.21  
2
T f
R
c   where: fc = cyclotron motion frequency 
            T = duration of transient 
 
Although  both  “in-time”  MS/MS  trapping  instruments,  low-energy  CID  is 
performed  in  a  slightly  different  manner  in  the  FT-ICR  mass  spectrometer 
compared to the QIT mass spectrometer.  Firstly, the collision gas is pumped 
into the FT-ICR cell in a pulsing fashion.  This briefly  increases the pressure 
inside the cell to facilitate low-energy CID, but can not be maintained there due 
to its hindering effect on detection and is thus rapidly pumped away c.f. QIT 
where  the  helium  gas  is  present  in  the  mass  analyser  throughout  the 
experiment.  This process can take several seconds (s), meaning that low-energy 
CID-MS/MS  experiments  using  FT-ICR  mass  spectrometers  have  a  low  duty 
cycle.
138  The second key difference is that there is no LMCO, meaning that all 
product ions can be trapped and mass analysed.
139  Like the QIT, the trapping 
capability of the FT-ICR mass spectrometer facilitates MS
n experiments.
138  
 
Isolation of the precursor ion of interest is most commonly performed using the 
stored-waveform  inverse  Fourier  transform  (SWIFT)  technique.
140  This 
waveform excites all ions present in the cell to orbits of larger radii.  The energy 
imparted to the undesired ions is sufficient to increase the radii such that they 
collide  with  the  walls  of  the  cell,  thus  leading  to  their  neutralisation  and 
subsequent removal by the vacuum system.
136  Concurrently, the ion of interest Chapter 1 
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is also excited to a larger cyclotron motion radius, leading to an increase in its 
kinetic energy.  However, only half the energy imparted to the undesired ions is 
applied to the ion of interest so that its cyclotron motion radius is not increased 
to such an extent that it strikes the walls of the cell.
133  The excited ions of 
interest then undergo collisions with the gas that is pumped into the cell, which 
increases their internal energy and facilitates dissociation. 
 
The excitation frequency used to excite the precursor ions of interest to a larger 
cyclotron motion radius is “off-resonance” i.e. not equal to the frequency of the 
ion’s  cyclotron  motion.    Hence,  the  activation  technique  is  referred  to  as 
sustained  off-resonance  excitation  (SORI)-CID.
141  This  approach  is  used  to 
enable more efficient detection of the product ions than is possible with an “on-
resonance” excitation frequency like the one used in the QIT.
133  Using an on-
resonance excitation frequency, the product ions are a significant distance from 
the centre of the cell when they are produced, which means that they cannot 
be formed into as coherent a packet for detection.  This has an adverse effect 
on the mass resolution of the resulting mass spectrum.
133  Low-energy SORI-CID 
overcomes this by applying an excitation frequency that is slightly off-resonance 
of the cyclotron frequency of the precursor ions of interest.  This results in the 
precursor  ions  being  alternately  in-phase  and  out-of-phase  with  the  applied 
frequency.
133  Hence,  the  precursor  ions  experience  periodic  increases  and 
decreases in their cyclotron motion radii, and therefore their kinetic energy.
136  
The amplitude of the applied frequency is maintained at a low value so that the 
precursor  ions  do  not  travel  far  from  the  centre  of  the  cell.
133  This,  in 
combination with their intermittent decrease in radii towards the centre of the 
cell, means that the product ions formed from dissociation of the precursor ion 
are also located at the centre of the cell.  This then allows them to be excited as 
a  coherent  packet  for  detection.    Thus,  low-energy  SORI-CID  improves  the 
efficiency and mass resolution with which the product ions can be detected.
133  
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Chapter 2 
 
The  use  of  mass  spectrometry  in  pharmaceutical 
drug metabolite identification and characterisation 
 
2.1  Introduction to pharmaceutical drug metabolism 
The term metabolism describes a reaction, or series of reactions, in a biological 
system  that  converts  a  given  molecule  into  a  different  compound  or 
compounds.
142  The intermediates and products of these reactions are called 
metabolites.
143  Metabolites are produced from compounds that have essential 
biological  functions  e.g.  carbohydrates,  lipids,  vitamins  etc.,  and  also 
xenobiotics.  A xenobiotic is defined as any compound that is not ordinarily 
present in a biological organism or is present at a concentration much higher 
than  usual  due  to  uptake  from  an  external  source.
144  A  pharmaceutical 
compound is therefore classed as a xenobiotic. 
 
Pharmaceutical compounds are metabolised because the biological organism 
(either human or animal) recognises it as a xenobiotic.  As a defence mechanism 
to prevent accumulation of xenobiotics, the organism reacts by attempting to 
eliminate  the  compound  through  a  combination  of  physical  and  chemical 
means.  Physical elimination takes place by means of excretion, primarily via 
urine or faeces.
144  To expedite the drug’s excretion, chemical changes are made 
to the compound, which constitutes its metabolism.  The urinary excretion of 
the lipophilic parent drug compound is an inefficient process due its limited 
solubility  in  water.    Therefore,  the  organism  metabolises  the  compound, 
typically  converting  the  lipid-soluble  parent  drug  compound  into  a  more 
hydrophilic  metabolite.
145  The  increased  hydrophilicity  of  the  metabolite 
compared to the parent compound makes it more water-soluble, and hence 
easier to excrete via the kidneys.  Thus, metabolism increases the rate of a 
drug’s excretion from the body.
146  Chapter 2 
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Metabolism of pharmaceutical drugs consists of two stages of reactions; phase I 
metabolism  and  phase  II  metabolism.    Phase  I  metabolism  involves 
functionalisation reactions that either produce or uncover a functional group 
through oxidation, reduction or hydrolysis.  Phase II metabolism involves the 
conjugation of  an  endogenous polar molecule,  such  as  glucuronic  acid,  to a 
functional group either produced by phase I metabolism
147 or already present in 
the parent compound.
144  The phase II reactions are those that generally cause a 
significant increase in the hydrophilicity of the drug.  This facilitates its excretion 
from the body, and also decreases its volume of distribution.
148  Thus, phase II 
metabolism is deemed to be the detoxifying process.  The phase I reactions do 
not deactivate the drug, and in some cases can create a metabolite that itself 
has pharmacological activity.  This behaviour can be used to positive effect in 
the  case  of  prodrugs,  which  become  pharmacologically  active  upon 
metabolism.
147  
 
The  focus  of  the  presented  study  was  to  identify  structurally  dependent 
dissociation pathways that could be used to characterise oxidised metabolites 
formed  during  phase  I  metabolism.    The  major  enzymes  involved  in  the 
oxidation of xenobiotics, including pharmaceutical drugs, are cytochrome P450s 
(CYP450s), which account for more than 90% of all oxidative reactions of this 
type.
149  CYP450s are a superfamily of haem-containing enzymes with many 
different  forms,  which  are  present  in  all  eukaryotic  organisms  and  some 
prokaryotes.
150  The different forms are divided into families based upon the 
similarity  in  their  DNA  sequences,  with  a  40%  overlap  indicating  that  two 
CYP450s are in the same family.  Further subdivision within a family can be 
obtained if the sequence similarity reaches 55%.  Each family has a number, and 
subfamilies are denoted by a letter in alphabetical order  e.g. CYP3A, CYP3B.  
Individual family members, which must differ in DNA sequence by greater than 
3% compared to the other family members, are denoted by a number after the 
subfamily letter e.g. CYP3A4.
151  A total of fifty-seven CYP450 genes belonging 
to different families have been identified in humans.
152  Although structurally 
different, all CYP450s are mono-oxygenases that metabolise xenobiotics via aChapter 2 
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redox reaction.
153  The generalised reaction is shown below;
154 
  
Drug + NADPH + O2 + H
+          →        Drug-O + NADP
+ + H2O 
 
Briefly, the mechanism of the redox reaction initially involves binding of the 
drug molecule to the active site of the CYP450 (Figure 2.1, step 1).  An electron 
is then transferred from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) to the haem portion of the CYP450, which is in the ferric (Fe
3+) state.  
This causes its reduction to a ferrous (Fe
2+) enzyme (Figure 2.1, step 2).
155  The 
reaction is mediated by a second enzyme; NADPH-CYP450 reductase.
156  The 
reduced haem then binds a molecule of oxygen (Figure 2.1, step 3).  Addition of 
a second electron to the complex, donated by NADPH, in conjunction with a 
proton  creates  an  iron-hydroperoxo  intermediate  i.e.  Fe(II)-OOH  (Figure  2.1, 
steps  4  and  5).
155  Cleavage  of  the  oxygen-oxygen  bond,  with  concomitant 
addition of a second proton, releases a molecule of water (Figure 2.1, step 6).
154  
This  leaves  an  electron-deficient  FeO
3+  complex,  which  abstracts  either  a 
hydrogen  atom  or  an  electron  from  the  drug  compound  depending  upon 
whether a carbon atom or heteroatom is being oxidised (Figure 2.1, step 7).
157  
The radical drug molecule then reacts with the hydroxyl group or the radical 
oxygen atom in the complex.  This results in the insertion of the oxygen atom 
into the molecular structure of the drug to form the metabolite (Figure 2.1, step 
8).
154  The  change  in  the  drug’s  molecular  structure  and  physicochemical 
properties are such that the complex separates to release the metabolite.  This 
final step converts the CYP450 back to its original form and allows it to catalyse 
the biotransformation of another substrate molecule.
157  
 
The variation in structure between CYP450s leads to different active site shapes, 
which  lends  a  degree  of  substrate  specificity  to  different  isozymes.
158  As  a 
result, five forms of CYP450 are responsible for the oxidation of a vast majority 
of  drug  molecules;  CYP1A2,  CYP2C9,  CYP2C19,  CYP2D6  and  CYP3A4.
159  In 
particular,  CYP3A4  is  very  prominent  in  the  metabolism  of  pharmaceutical 
compounds, catalysing the oxidation of greater than 50% of commonly usedChapter 2 
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Figure 2.1  Generalised catalytic cycle of the oxidation of xenobiotics by 
CYP450s 
  Reproduced from reference  154 with kind permission from the 
American Chemical Society 
 
clinical drugs.
160  These forms are predominately found in the liver, which is thus 
the primary site of pharmaceutical drug metabolism,
161 although CYP450s can 
be found throughout the human body.
151, 162  In the liver, CYP450s are situated 
on the membranes of mitochondria or endoplasmic reticula.
150  
 
Understanding  the  metabolism  of  a  NCE  is  of  key  importance  to  the 
pharmaceutical  industry.    Metabolite  identification  studies  are  performed 
throughout the drug discovery and development process to detect, structurally 
characterise  and  quantify  metabolites  of  pharmaceutical  compounds.
163  In 
early  drug discovery,  these  studies  provide  many  pieces  of  information  that 
indicate whether a given NCE is suitable to proceed further along the discovery 
stage and into development.  The structural characterisation of the metabolites 
of a NCE can indicate those parts of the molecule that are prone to alteration by 
the metabolising enzymes.  This information, in conjunction with quantitative 
data gained from clearance studies, can allow medicinal chemists to synthesise 
more  or  less  stable  analogues  of  the  NCE.    This  can  allow  tailoring  of  the 
pharmacokinetics  of  the  compound  by  altering  its  metabolic  stability.
164  
Another aim of metabolite identification studies is to identify those metabolites Chapter 2 
46 
that are not inactivated as a result of their structural change.  This can lead to 
the  formation  of  active  metabolites  i.e.  those  that  have  pharmacological 
activity.    This  activity  can  either  be  synergistic  or  inhibitory  to  the  parent 
compound, which would affect the organism’s response to a specific dosage.  In 
contrast, the active metabolite may elicit a different pharmacological response 
than that intended by the drug as a result of acting on a different target.
147  
Therefore, the identification of active metabolites can enable pharmacodynamic 
results to be rationalised.
165  Finally, metabolite identification studies need to 
determine whether any reactive metabolites are formed, which can result in 
drug-induced toxicity.
166  Identification of NCEs that form reactive metabolites 
in the early drug discovery stage allows a judicious selection of candidates to 
proceed to the more costly development stage.
167  The identification of active 
and reactive metabolites is of particular interest in the pharmaceutical industry 
at this current time due to the recent publication of the “Metabolites in Safety 
Testing” (MIST) guidelines by the Food and Drug Administration (FDA).
168  The 
MIST  guidelines  propose  that  additional  safety  assessments  should  be 
performed for compounds that produce metabolites that are only detectable in 
human plasma, or are present at much greater levels in man compared to the 
other species used to test the safety of the NCE.
169  Additional safety tests are 
required in this circumstance because the effect of the metabolite in man can 
not  be  extrapolated  from  the  results  in  animals  at  these  greater  levels  of 
production.  Further, any metabolite that has a systemic exposure of greater 
than  10%  of  the  parent  compound  at  steady  state  should  raise  a  safety 
concern.
169  If this metabolite is active and present at greater than 10% of the 
parent compound, then the body may be unable to tolerate the extra burden in 
pharmacological  terms  if  both  compounds  have  a  similar  effect.    Therefore, 
additional safety assessments should be conducted before the drug is used in 
further clinical studies. 
 
To obtain an understanding of how a compound is metabolised, a combination 
of in vitro and in vivo studies are utilised in drug discovery and development.
170  
Oxidised  metabolites,  which  are  the  focus  of  the  presented  study,  are Chapter 2 
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investigated in the early drug discovery process using in vitro assays that allow 
phase  I  metabolites  to be  formed.      The  most  commonly  used  in  vitro  test 
systems are liver microsomes and hepatocytes, with liver slices also being used 
on occasion.
171  Liver microsomes, either from human or animals, offer a simple 
system  to  assess  phase  I  metabolism.    Microsomes  are  artifactual  vesicles 
formed through disruption of endoplasmic reticula, which retain the activity of 
the key enzymes involved in phase I metabolism, including CYP450s.
170,  172  A 
group  of  enzymes  involved  in  phase  II  metabolism,  the  uridine  diphosphate 
(UDP)  glucuronyl  transferases,  are  also  microsomal.    However,  the  cofactor 
required for glucuronidation, UDP-glucuronic acid (GA), is cystolic and thus is 
not present.  Addition of the cofactor to the test system facilitates phase II 
metabolism  in  vitro.    Other  enzymes  involved  in  phase  II  metabolism,  for 
instance sulfotransferases, are not present in microsomes.
173  Thus, microsomes 
do not provide a complete representation of the metabolism of a NCE.  Further, 
cofactors required for metabolism, such as NADPH are not present and their 
addition to the system is required to activate it.
173  These limitations are offset 
by the accessibility of microsomes, which are commercially available, and their 
retention  of  activity  even  after  long-term  freezing.
171,  174  This  makes 
microsomes  a  suitable  in  vitro  test  system  for the  high-throughput  analyses 
required by the pharmaceutical industry.  Hepatocytes are whole-cell systems 
which offer the advantage of containing all of the metabolising enzymes and 
associated cofactors at physiologically relevant concentrations.
175  This means 
that both phase I and phase II metabolism can be investigated in a single test 
system.  However, hepatocytes quickly lose their activity, meaning that fresh 
cultures  are  favoured  to  provide  accurate  and  robust  results.    Thus,  the 
availability of fresh hepatocytes are a restriction to their usage in metabolite 
identification  studies.
176  Further,  isolated  hepatocytes  can  show  different 
enzymatic activity to those in a biological environment, limiting the in vitro-in 
vivo  correlation  that  can  be  deduced.
175  Liver  slices  represent  the  most 
complete in vitro model.
171  These systems closely replicate metabolism in vivo 
because all of the relevant enzymes and cofactors are present at physiological 
relevant concentrations and retain their activity.
170  However, liver slices are Chapter 2 
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more expensive and difficult to prepare than microsomes and hepatocytes, and 
are thus seldom used. 
 
2.2  Analytical  approaches  for  the  identification  of 
pharmaceutical drug metabolites 
A range of analytical approaches are used in metabolite identification studies to 
detect,  characterise  and  quantify  the  metabolites  of  a  NCE  during  drug 
discovery and development.  These include nuclear magnetic resonance (NMR) 
spectroscopy,
148 ultra-violet (UV) spectroscopy
176 and HPLC with radioactivity 
detectors.
177  The primary analytical approach utilised in early drug discovery 
metabolite identification studies is MS (see Chapter 1).
178  This is because only 
small  amounts  of  NCEs  are  typically  available  for  metabolite  identification 
studies.  Thus, the analytical techniques used must be capable of a low limit of 
detection  to  facilitate  the  analysis  of  all  of  the  metabolites  formed.    MS  is 
capable of very low limits of detection, and this characteristic, in addition to its 
high  selectivity  when  the  MS/MS  experiment  is  utilised,  means  that  it  has 
become  the  technique  of  choice  for  early  drug  discovery  metabolite 
identification  studies.    The  ability  of  MS  to  rapidly  provide  structural 
information about the metabolites using MS/MS experiments also means that 
its use is favoured.
148  Finally, MS is easily interfaced to HPLC.  A separation 
science is required because the matrices in which metabolites are present are 
complex mixtures containing biological molecules, such as proteins and lipids, 
salts  and  other  endogenous  compounds.
145  Reversed  phase  (RP)-HPLC  is 
favoured in pharmaceutical analyses because most drugs and metabolites are 
amenable to ionisation by ESI, which necessitates delivery of the sample in the 
solution phase using a polar solvent.
178  RP-HPLC can separate the mixture of 
compounds such that they enter the mass spectrometer at different times.  The 
separation  of  the  metabolites  from  the  matrix  components  is  critical to  the 
success of metabolite identification studies for two reasons.  Firstly, metabolism 
of  a  NCE  can  result  in  the  formation  of  isomeric  metabolites  e.g.  two 
metabolites that have both been oxidised but at different locations.
145  If these Chapter 2 
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two species are ionised and enter the mass spectrometer at the same time e.g. 
introduction  by  direct  infusion,  the  peak  due  to  the  protonated  parent 
compound plus 16 m/z units would be a composite of the two species.  Thus, 
the tandem mass spectrum would also be a composite, which could make the 
structural  characterisation  of  the  metabolites  a  more  time-consuming  and 
difficult task than if the species were separated in time.  Secondly, and arguably 
more importantly, separation helps to alleviate the problems related to matrix 
effects.  The term matrix effects refers to either enhancement or suppression of 
the  mass  spectrometric  signal  of  an  analyte  of  interest  by  a  co-eluting 
compound that is present in the sample matrix.
179  Ion suppression is the most 
problematic matrix effect in the context of metabolite identification studies.  
This is because a metabolite present in the sample may not be ionised, hence 
meaning that it is not detected nor identified i.e. a false negative result would 
be obtained.  King and co-workers conducted an in-depth comparative study to 
investigate whether solution or gas phase processes have a greater effect on 
the suppression of an analyte’s ionisation.
180  This was achieved by comparing 
the suppression of the ionisation of caffeine, phenacetin and urapidil, as well as 
two proprietary compounds, using both ESI and APCI.  They concluded that, 
although  gas  phase  processes  contribute  to  ion  suppression,  solution  phase 
processes predominate.  Their findings suggested that ESI is more sensitive to 
matrix effects than APCI, and thus greater ion suppression will be encountered 
using the former.  This conclusion has been supported by the research of other 
groups.
181-184  However, reports of ion suppression in bioanalytical assays using 
APCI  exist  in  the  literature.
184-186  This  indicates  that  approaches  towards 
eliminating, or at least minimising, matrix effects must be taken regardless of 
the  ionisation  technique  utilised  when  performing  metabolite  identification 
studies by API-MS/MS.  Separation of the matrix components from the analytes 
of interest in time using RP-HPLC, along with the removal of interferences using 
sample  preparation  techniques,  are  the  most  commonly  used  methods  of 
eliminating or reducing matrix effects.
187, 188 
 
The causes and mechanisms of ion suppression differ depending upon whetherChapter 2 
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ESI or APCI is being considered.
189  In ESI, interferences that increase the surface 
tension of the charged droplets prevent solvent evaporation.
190  This leads to 
fewer desolvated ions reaching the mass analyser, thus leading to a suppression 
of the signal compared to that obtained for a single component sample solely 
containing the analyte.  Matrix components that typically suppress ions by this 
mechanism  are  endogenous  phospholipids,  which  are  thought  to  coat  the 
surface of the charged droplet, preventing evaporation of the solvent and hence 
droplet fission.  Phosphotidylcholines, which are zwitterions, are a major cause 
of ion suppression because of their ability to ionise using both positive ion and 
negative  ion  ESI.
191  Non-polar  analytes,  such  as  phospholipids,  are  more 
difficult to separate from analytes of interest using RP-HPLC, and thus are more 
likely to co-elute and cause ion suppression.
192  The presence of non-volatile 
compounds,  such  as  salts,  is  proposed  to  have  numerous  ion  suppressing 
effects.
180  Firstly, the non-volatile compound may increase the boiling point 
and surface tension of the charged droplet.  This would slow the rate of solvent 
evaporation, potentially to the extent that the ions do not reach a radius of 
around  10  nm,  which  prevents  field  desorption  as  described  by  the  IEM.
189  
Further, the non-volatile compound will precipitate as the solvent evaporates 
from the charged droplet.  The analyte may co-precipitate with the non-volatile 
compound, leading to a reduction in the number of molecules which form gas-
phase ions.
180  A further posited mechanism of ion suppression in ESI is the 
competition between analytes for space at the surface of the charged droplet, 
as described by Enke’s equilibrium partitioning model for singly charged ions.
193  
Saturation of the surface with analyte is thought to occur at high concentrations 
of the order of greater than 10
-5 molar (M), which is when the ESI response 
typically becomes non-linear.
194  The competition between analytes leads to 
preferential ionisation of those at the surface, which have greater likelihood of 
entering the gas phase.
15  The analytes that are more solvated and positioned in 
the bulk of the charged droplet are prevented from being desorbed.  Thus, they 
fail to form gas-phase ions.
189  This form of ion suppression is proposed to affect 
polar analytes, which are more likely to be positioned in the bulk of the charged 
droplet.
195  A study by Cech and Enke demonstrated this by using a series of Chapter 2 
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peptides,  as  well  as  surface  active  analytes.
196  Their  work  showed  that  ESI 
response was related to the non-polar character of the peptide.  Further, it 
demonstrated that the ESI response of surface active analytes is not affected by 
a high concentration of solvated species.  Conversely, a suppression of the ESI 
response of solvated compounds was observed as the concentration of surface 
active analytes increased.  The final mechanism postulated for ion suppression 
using ESI is neutralisation of the analytes caused by reactions with interfering 
compounds after desolvation e.g. deprotonation of positively charged ions.
190  
This  is  a  gas-phase  mechanism  as  opposed  to  the  solution-phase  processes 
detailed above.  This mechanism is proposed to occur when the interferences 
have  high  gas-phase  basicities  or  acidities,  to  effect  deprotonation  or 
protonation respectively, and concentrations are sufficiently high to facilitate 
ion-molecule reactions.
189  
 
The mechanisms of ion suppression using APCI are different to those when ESI is 
employed because there is no competition between analytes and interferences 
to  enter  the  gas  phase,  and  much  less  competition  to  become  charged.  
Entrance into the gas phase is not competitive because all of the thermally 
stable neutral species are transferred from the solution phase by the heated gas 
stream in the source.
189  The competition to become charged occurs at higher 
concentrations than in ESI because an excess of reagent ions is typically formed.  
Thus,  more  interfering  compounds  can  be  tolerated  before  ion  suppression 
occurs.
197  Gas-phase reactions are a major source of ion suppression in APCI, as 
the ionisation technique is ideally suited to facilitating ion-molecule reactions.  
Therefore,  as  with  ESI,  suppression  can  occur  via  gas-phase  reactions  with 
interferences  possessing  high  gas-phase  basicities  or  acidities.
189  A  related 
mechanism is the change in the efficiency of charge transfer from the corona 
discharge needle as a result of the matrix components.
185  Finally, because APCI 
is a gas-phase ionisation technique, the precipitation of non-volatile interfering 
compounds as the solution evaporates may cause co-precipitation of analyte 
molecules, leading to their loss and thus suppression of the ion signal.
180 Chapter 2 
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Once a metabolite has successfully formed a gas-phase ion and been sampled 
into the mass analyser, the typical protocol to identify and characterise it by MS 
is to first acquire a full scan spectrum i.e. no ion activation technique is utilised 
to induce dissociation.  From the protonated molecule observed, the structural 
change  can  be  deduced.    For  example,  a  mass  shift  of  +16  m/z  units  for  a 
metabolite compared to the parent compound would suggest that oxidation has 
taken  place,  whilst  a  mass  shift  of  -14  m/z  units  would  indicate  that 
demethylation has occurred.  The metabolite is then dissociated, routinely by 
low-energy  CID,  so  as  to  facilitate  its  structural  characterisation.    The 
interpretation approach most commonly used to localise the site of metabolism 
is the “Shift technique”.
198  This involves comparing the low-energy CID product 
ion spectra of the parent compound and the metabolite and looking for major 
product  ions  that  are  mass  shifted.    Based  upon  the  assumption  that  the 
dissociation of the two ions are very similar as only a small modification has 
been made, the product ions of the metabolite that are mass shifted compared 
to the parent compound are those that have been structurally altered during 
metabolism (Figure 2.2).  The schematic shows a parent drug compound that 
dissociates to form three product ions; A, B and C (Figure 2.2a).  Upon oxidation 
of  the  portion  of  the  molecule  that  forms  product  ion  C,  the  metabolite 
dissociates to form product ions A and B at the same m/z values as for the 
parent compound (Figure 2.2b).  However, as the result of the addition of an 
oxygen atom, the product ion due to the C part of the molecule is mass shifted 
by +16 m/z units compared to that observed for the parent compound (Figure 
2.2b).  The peak denoted in red represents that originally observed in the low-
energy  CID  product  ion  spectrum  for  the  parent  compound,  which  is  mass 
shifted to the m/z value equal to “C + O” in the low-energy CID product ion 
spectrum of the oxidised metabolite. 
 
The  limitation  of  the  Shift  technique  is  that  unambiguous  assignments  are 
frequently not possible.  This is particularly true for oxidised metabolites.  For 
example, a product ion mass shifted by +16 m/z units in the low-energy CID 
product  ion  spectrum of  the metabolite  compared to the  parent  compoundChapter 2 
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Figure 2.2  Schematic of the Shift technique approach to the identification 
of the site of metabolism of a NCE using low-energy CID-MS/MS 
 
would lead to the deduction that oxidation has taken place on the portion of 
the molecule represented by that ion.  However, oxidation can take place at 
carbon, nitrogen and sulfur atoms; all common constituents of small molecule 
NCEs.  Thus, the product ion may contain more than one atom that can be 
oxidised,  precluding  the  definitive  identification  of  the  site  of  oxidation.    A 
recent example of this ambiguity was observed in the investigation of the in 
vitro metabolism of dasatinib in rat, monkey and human (Figure 2.3).
199  In this 
study, the authors were only able to localise oxidations to the N-(2-chloro-6-
methylphenyl)formamide  and  the  2-(piperazin-1-yl)ethanol  substructures.  
Many  other  such  examples  of  ambiguity  in  the  characterisation  of  oxidised 
metabolites formed both in vitro and in vivo exist in the literature.
175, 200-203 
 
 
Figure 2.3  Molecular structure of dasatinib Chapter 2 
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Being  able  to  specify  the  portion  of  a  NCE  that  is  metabolised  is  useful 
information to medicinal chemists in their endeavours to improve its metabolic 
stability.  However, faster and more efficient production of metabolically stable 
analogues could be achieved if the specific atom that has been oxidised could 
be identified. 
 
A number of approaches have been reported in the literature to discriminate 
between C-, N- and S-oxides, many of which can be achieved rapidly.  Further, 
some  of  the  methods  also  facilitate  the  definitive  localisation  of  the  site  of 
oxidation.  The approaches for the identification and characterisation of C-. N- 
and S-oxides will be considered in turn. 
 
A number of wet chemistry approaches have been reported for identifying C-
oxidised  metabolites,  one  of  the  most  commonly  applied  being  the  use  of 
solution-phase hydrogen/deuterium (H/D) exchange experiments.  These can be 
conducted either off-line
204 or on-line using HPLC.
205, 206 Further, gas-phase H/D 
exchange  has  also  been  demonstrated.
207,  208  Oxidation  of  a  carbon  atom 
creates a hydroxyl group, whilst oxidation at nitrogen and sulfur atoms forms 
N
+-O
- and S
+-O
- bonds respectively.  Thus, only C-oxidation creates a functional 
group with an exchangeable hydrogen atom.
171  This can be exchanged for a 
deuterium  atom  in  solution  when  the  metabolite  is  dissolved  in  a  solvent 
containing  acidic  deuterons  e.g.  deuterium  oxide  (D2O).    Therefore,  if  the 
oxidised metabolite has been hydroxylated, its recorded  m/z value will mass 
shift  according  to  the  number  of  deuterium  atoms  incorporated  into  its 
structure e.g. 1 m/z units for a mono-oxidised metabolite, 2 m/z units for a di-
oxidised metabolite etc., plus an equal number of m/z units to the number of 
exchangeable hydrogen atoms in the parent compound’s ion structure.  The 
absence  of  any  additional  exchangeable  hydrogen  atoms  in  a  N-  or  S-oxide 
compared to the parent compound means that both the parent compound and 
the metabolite will be mass shifted by the same number of m/z units.  Thus, a C-
oxide can be discriminated from an N- or S-oxide.  The drawback of this method 
is  that  it  can  not  always  determine  which  carbon  atom  has  been  oxidised.  Chapter 2 
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Instead, it can only provide information on the portion of the molecule that has 
been biotransformed.  Further, the cost of deuterated solvents is high, meaning 
that routine application may be precluded.  Derivatisation reagents can also be 
used to selectively react with hydroxyl groups to identify their presence.  The 
use of derivatisation in metabolite identification studies has been reviewed by 
Liu and Hop.
209  Many derivatisation reagents will not only show selectivity for 
hydroxyl functionalities, thus discriminating between and C-oxides and N- and S-
oxides, but will also demonstrate selectivity towards either aliphatic or aromatic 
hydroxyl groups.  This can aid in determining the site of oxidation.  For example, 
discrimination between aliphatic and aromatic hydroxyl groups can be achieved 
using acetic anhydride in water.  This reagent will selectively acetylate aromatic 
hydroxyl  groups  whilst  being  unreactive  towards  aliphatic  hydroxyl 
functionalities.    The  drawback  of  this  approach  is  that  partial  or  complete 
acetylation of amine groups can also occur.
171  This is particularly true under 
aqueous conditions, whereby the more nucleophilic amine groups are readily 
acetylated whilst the hydroxyl groups are prohibited from reacting due to the 
presence of water.
209  Therefore, more stringent control of reaction conditions 
is required for this method to be successful.  Diazomethane and diazoethane 
can also be used to selectively react with aromatic hydroxyl groups.  However, 
these reagents can also react with other functionalities, in this case carboxylic 
acids, which may complicate data interpretation.
209  The use of Jones reagent 
(chromium  trioxide  in  concentrated  sulfuric  acid)  can  allow  discrimination 
between  primary  and  secondary  alcohols,  because  the  former  produces  a 
carboxylic acid upon oxidation whilst the latter forms a ketone.
210  A reported 
example is the discrimination of two hydroxylated metabolites of pioglitazone 
(Figure 2.4).
211  
 
 
Figure 2.4  Molecular structure of pioglitazone 
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In this study, a previously unreported oxidised metabolite was identified.  The 
MS/MS dissociation pattern was used to identify the oxidation product as a 
hydroxylated  compound,  due  to  the  loss  of  water,  and  localise  the  site  of 
oxidation to the 2-(5-ethyl-2-pyridyl)ethyl substructure.  However, it was not 
possible to determine whether the hydroxylation site was a primary, secondary 
or aromatic carbon atom.  A known oxidised metabolite of pioglitazone (Figure 
2.5), which has a hydroxyl group on the α-carbon of the ethyl group, also has 
the same MS/MS dissociation pattern but a different retention time in the HPLC 
chromatogram. 
 
 
Figure 2.5  Molecular  structure  of  known  hydroxylated  pioglitazone 
metabolite 
 
Treatment  of  the  crude  sample  with  Jones  reagent  produced  two  different 
products.  The known metabolite formed a keto-product as expected, and thus 
formed a compound that gave a signal 2 m/z units lower than the precursor.  
The unknown metabolite formed a product that was 16 m/z units greater in 
mass  than  the  precursor.    This  indicated  that  a  carboxylic  acid-containing 
species  had  been  formed.    From  this  conclusion,  it  was  deduced  that  the 
precursor  must  contain  a  primary  alcohol  and  hence  the  metabolite  was 
definitively structurally characterised as shown in Figure 2.6. 
 
 
Figure 2.6  Molecular  structure  of  unknown  hydroxylated  pioglitazone 
metabolite deduced using derivatisation with Jones reagent and 
HPLC-MS/MS 
 
The limitations of all of these derivatisation methods are that extra analysisChapter 2 
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time  is  required,
212  which  also  increases  costs,  and  that  losses  of  trace 
metabolites can occur during the reaction.  In many cases, definitive localisation 
of the site of oxidation is also not possible.  A faster approach to derivatisation 
that minimises the possibility of sample degradation is the use of ion-molecule 
reactions in the gas phase between a protonated analyte and neutral reagent 
gas;  a  process  which  can  be  automated.    The  use  of  dimethylethoxyborane 
(DEMB)  facilitates  a  reaction  with  primary,  secondary  and  tertiary  hydroxyl 
groups,  resulting  in  the  formation  of  an  adduct  minus  a  molecule  of 
methanol.
213  However,  DEMB  is  not  selective  and  will  also  react  with 
aldehydes, esters, ethers and ketones in the same manner.  This was overcome 
in the reported study by using gas-phase H/D exchange experiments after the 
derivatisation reaction.  The hydroxyl derivatives contain a single exchangeable 
hydrogen  atom;  a  structural  feature  that  is  not  found  in  any  of  the  other 
derivatives.  Hence, hydroxyl-containing precursors could be distinguished.
213  
The number of hydroxyl groups in a polyol can also be determined using ion-
molecule reactions with either DEMB
214 or trimethylborate (TMB).
215  This can 
discriminate a C-oxide from N- and S-oxides because the former will have one 
greater number of hydroxyl groups than the parent compound, whilst the other 
two types of metabolite will have the same number.  The study using DEMB was 
demonstrated  to  be  compatible  with  HPLC,  which  is  crucial  in  metabolite 
identification  studies.    However,  the  limitation  of  ion-molecule  reactions,  as 
with  condensed-phase  derivatisation,  is  that  definitive  identification  of  the 
carbon atom that has been oxidised is frequently not possible.  Further, the 
cited  studies  were  all  performed  on  FT-ICR  mass  spectrometers,  which  are 
expensive and thus not readily available.  Hence, implementation as a routine 
application is unlikely.  An analytical approach that can allow the discrimination 
of  aliphatic  and  aromatic  hydroxylation  is  through  the  use  of  diagnostic 
dissociation behaviour.  The loss of water under low-energy CID conditions has 
been suggested as being an indicator of aliphatic hydroxylation.
216  In a study of 
loratadine  metabolism,  the  loss  of  water  was  favoured  from  the  aliphatic 
hydroxylated metabolite compared to the aromatic hydroxylated desloratadine 
metabolite.  This allowed discrimination between the two metabolites in this Chapter 2 
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study.    However,  a  comprehensive  study  assessing  whether  aliphatic 
hydroxylation always leads to a more favourable loss of water than aromatic 
hydroxylation  has  yet  to  be  conducted.  Further,  the  robustness  of  this 
approach to discriminate between C-oxides and N- and S-oxides is questionable.  
This is because in the same study, the piperidine-N-oxide and pyridine-N-oxide 
metabolites  of  loratadine,  neither  of  which  contained  hydroxyl  groups,  also
showed losses of 18 m/z units, which corresponds to a molecule of water, in 
their low-energy CID product ion spectra.
216  
 
Both analytical and wet chemistry approaches have also been demonstrated to 
identify N-oxides.  Ramanathan and co-workers showed that N-oxides undergo 
thermally-induced deoxygenation when using APCI; a trait not reported for C- 
and S-oxides.
216  Subsequent work observed similar behaviour using an ESI ion 
source with a heated transport capillary and proved that the loss of oxygen was 
not due to in-source CID.
217  The abundance of the loss of oxygen was also 
shown  to  be  independent  of  the  length  of  the  heated  capillary/ion  transfer 
tube, indicating that the kinetics of the reaction are fast.
218  The same loss has 
also  been  observed  using  APPI.
219  Another  analytical  approach  utilises  the 
chromatographic behaviour of N-oxides using RP-HPLC.  Under these conditions, 
N-oxidised  metabolites  have  been  observed  to  elute  after  the  parent 
compound, despite being of greater polarity.
165, 199, 220-222  However, this is not 
generic behaviour, and examples of N-oxidised metabolites that elute prior to 
the parent compound are also reported in the literature.
216, 223  Wet chemistry 
approaches are also evident in the literature for the identification of N-oxides.  
Selective reduction of N-oxides back to their amine parent compounds has been 
achieved  by  adding  titanium  chloride  (TiCl3)  directly  to  plasma  and  urine 
matrices.
224  The  identification  of  an  N-oxide  was  demonstrated  for  a 
proprietary  compound where  the  low-energy CID  product ion  spectrum  was 
ambiguous and suggested the formation of either a C- or N-oxide.  Further, TiCl3 
was able to quantitatively reduce the N-oxide group in a di-oxidised metabolite 
containing  both  an  oxidised  piperidine  nitrogen  and  an  oxidised  thioether 
sulfur, thus demonstrating the selectivity of the reagent.  The drawback of the Chapter 2 
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method is the long reaction time (60-90 minutes), thus limiting its usage in a 
high-throughput environment.  The Kenttämaa group has published a number 
of papers detailing functional group selective ion-molecule reactions between 
protonated analytes and neutral reagent gases.  Reagents have been identified 
that  can  characterise  monofunctional  primary  amine-N-oxides,
225  aromatic 
tertiary  amine-N-oxides
226,  227  and  aliphatic  tertiary  amine-N-oxide.
227  The 
adduct-forming  reactions  with  dimethyl  disulfide,
225  2-methoxypropene,
226 
tri(dimethylamino)borane
227  have  potential  application  in  metabolite 
identification studies because the reagents selectively react with N-oxides but 
not amine functionalities.  However, as with the ion-molecule reactions used to 
identify hydroxyl-containing compounds, all of the studies were performed on 
instruments  with  limited  availability;  either  FT-ICR  or  modified  QqQ  mass 
spectrometers.  Thus, the experiments may not be possible in all laboratories.  
Further, the reactions occur on an extended time-scale; generally in the region 
of seconds.  Therefore, the duty cycle of the experiment i.e. the time taken for 
the  gas-phase  ion-molecule  reaction  to  take  place  and  the  products  to  be 
detected by the mass spectrometer, may not be compatible with the time-scale 
of the chromatographic separations used in metabolite identification studies.  
Indeed,  none  of  the  cited  studies  used  HPLC  as  a  method  to  introduce  the 
samples into the mass spectrometer.  Reaction times of the order of 500 ms 
have been suggested as being suitable for HPLC-MS applications.
228  A limitation 
common to all of the discussed approaches for N-oxide identification is that 
they give no indication of the site of oxidation, except for  the ion-molecule 
reaction between protonated primary N-oxides and dimethyl disulfide.
225  Two 
examples of definitive localisation of the site of oxidation for N-oxides involve 
structurally dependent dissociation pathways.  Ma and co-workers elucidated a 
thermally induced structurally dependent dissociation pathway that definitively 
identified  the  oxidised  nitrogen  atom  in  a  series  of  model  N-oxide 
metabolites.
219  They showed that a Meisenheimer rearrangement preceded 
the loss of an aldehyde or a ketone, which took place at a tertiary amine-N-
oxide containing an alkyl or benzyl group.  This structural specificity allowed the 
nitrogen atoms in the analysed compounds (both pharmaceuticals and other Chapter 2 
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small  molecules)  to  be  discriminated.    The  rearrangement  and  thermally 
induced dissociation was shown to be specific for the tertiary amines analysed 
because  the  analogous  loss  was  not  observed  for  the  aromatic  N-oxide 
metabolite of 2-(methylsulfonylmethyl)-pyridine-N-oxide.  Lay and co-workers 
utilised high-energy FAB-MS and FAB-CID-MS/MS to show that the losses of 
dimethylamine and N,N-dimethylhydroxylamine were observed for a series of 
ethylenediamine, ethanolamine and propylamine antihistamine drugs and their 
tertiary  amine-N-oxides  respectively.
229  These  diagnostic  losses  provided  an 
approach to localise the site of oxidation to the tertiary amine substructure.  
However,  equivalent  data  under  low-energy  CID  conditions  has  never  been 
reported.   
 
Of the three types of oxidised metabolite, S-oxides have the fewest reported 
rapid and definitive identification approaches in the literature.  No examples of 
derivatisation  reagents  that  are  selective  towards  S-oxide  functionalities  are 
evident in the literature.
148,  209  Further, no details of ion-molecule reactions 
that facilitate their identification could be sourced.  Thus, the only reported 
method for rapid and definitive identification of sulfoxides is based on their 
diagnostic dissociation behaviour.
230  This study showed that the group bonded 
to the sulfoxide functionality is lost as a radical using low-energy CID-MS/MS.  
The  corresponding  radical  loss  was  not  observed  for  the  parent  compound.  
Thus, a radical loss in the low-energy CID product ion spectrum of an oxidised 
metabolite could be indicative of an S-oxide.  Further, the site of oxidation could 
be inferred by characterising the radical loss, as the leaving group was originally 
bonded to the sulfoxide functionality. 
 
In summary, the existing approaches for identifying and discriminating between 
oxidised metabolites often do not provide definitive localisation of the site of 
oxidation.    Further,  those  that  can  are  often  not  applicable  to  routine 
application.    The  inability  to  localise  the  specific  site  of  oxidation  on  a 
pharmaceutical compound is problematic if there are two or more  potential 
oxidation sites for which a given approach is diagnostic e.g. two nitrogen atoms Chapter 2 
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that could be oxidised and then identified following reduction using TiCl3.  In 
this circumstance, the analyst must rigorously interrogate the low-energy CID 
product  ion  spectrum  of  the  metabolite  to  assign  the  site  of  oxidation.  
However,  this  approach  may  still  result  in  an  ambiguous  assignment,  as 
demonstrated in the case of dasantinib.
199  The work of Wright and co-workers, 
in conjunction with that performed by the groups of Ma and Lay, suggest that 
the elucidation of structurally dependent dissociation pathways could provide a 
means to definitively localise the site of oxidation in oxidised metabolites.  This 
is supported by the work of the Desaire and Langley groups, who have shown 
diagnostic  losses  for  the  identification  and  localisation  of  other  functional 
groups in small molecules  using low-energy CID-MS/MS.  The Desaire group 
have demonstrated that the loss of carbon dioxide (44 m/z units) in a negative 
ion low-energy CID-MS/MS product ion spectrum is indicative of a carboxylic 
acid.
231  The observation of the loss also provides structural information about 
the  chemical  environment  in  which  the  carboxylic  acid  functionality  is 
positioned, with certain substructures precluding the loss of carbon dioxide e.g. 
dicarboxylic acids where the acid groups are separated by three carbon atoms 
do not lose carbon dioxide under low-energy CID conditions.  A further paper 
showed that carboxylic acid-containing metabolites formed through hydrolysis 
of  lactones  can  be  differentiated  from  their  parent  compounds  through 
diagnostic neutral losses from both the parent molecule and the metabolite.
232  
Finally,  the  localisation  of  the  site  of  sulfation  in  phase  II  metabolism  was 
achieved, with diagnostic product ions and losses used to classify the sulfation 
site as one of four possibilities.
233  This enabled prediction of the metabolite’s 
biological  effect,  which  is  important  as  conjugation  of  the  sulfate  group  to 
benzylic alcohol, allylic alcohol or aromatic hydroxylamine functionalities gives 
rise to carcinogenic species.  The Langley group have also conducted work into 
the elucidation of structural motifs that drive dissociation pathways.
234, 235  Their 
studies showed that class-specific product ions and losses could be identified for 
a number of groups of small molecules.  Further, they demonstrated that the 
different  classes  of  compounds  would  cluster  using  principal  component 
analysis (PCA) based upon the ions observed in their low-energy CID product ion Chapter 2 
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spectra.  This therefore indicated that the structure of the molecule drives its 
dissociation under low-energy CID conditions.  The information in the literature 
therefore suggested that there was scope to elucidate structurally dependent 
dissociation  pathways  using  low-energy  CID-MS/MS  that  would  allow 
discrimination  and  characterisation  of  oxidised  pharmaceutical  drug 
metabolites.    It  was  envisaged  that  such  information  could  have  immediate 
benefit  to  the  metabolite  identification  community  by  enabling  faster 
interpretation  of  data;  a  recognised  bottleneck  in  metabolite  identification 
studies.
178  This is because an analyst would, as a first approach, be able to just 
look for key diagnostic information in a low-energy CID product ion spectrum of 
an unknown metabolite, rather than rigorously interrogating the data.  Thus, 
faster  throughput  would  be  possible  using  such  a  protocol,  and  hence  the 
presented study was conducted. 
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Chapter 3 
 
Experimental 
 
3.1  Introduction 
The experimental conditions detailed below are the generic protocols used for a 
majority  of  the  work  in  the  presented  study.    Deviations  from  the  generic 
protocol,  or  specific  experiments  not  conducted  throughout  the  study,  are 
detailed in the relevant chapters. 
 
3.2  Chemicals 
Solutions  were  prepared  in  LC-MS  grade  methanol  and  analytical  grade 
methanoic acid [99.9:0.1, volume by volume (v/v)] (Fisher Scientific UK Ltd., 
Loughborough, UK) for QIT-MS and FT-ICR-MS experiments.  The concentrations 
were  10 micrograms per  millilitre  (μg  mL
-1)  for  the  QIT-MS  experiments  and 
1 μg mL
-1  for  the  FT-ICR-MS  experiments.    QqTOF-MS  experiments  were 
performed  using  solutions  prepared  at  1 μg  mL
-1  in  LC-MS  Chromasolv® 
acetonitrile [1:1, v/v] (Sigma-Aldrich Company Ltd., Gillingham, UK) and HPLC 
grade  water  (Millipore,  Bedford,  MA,  USA).    Solution-phase  H/D  exchange 
experiments were performed by preparing the compound in >99.5% deuterated 
methanol with either 99.5% methanoic acid [99.9:0.1, v/v] or 99.5% ethanoic 
acid [99:1, v/v] (Apollo Scientific Ltd., Stockport, UK).  The concentration of the 
solutions for the solution-phase H/D exchange experiments were 10 μg mL
-1.  
Reserpine (Sigma-Aldrich Company Ltd., Gillingham, UK) was prepared at 100 
nanogram per millilitre (ng mL
-1) in LC-MS grade methanol and analytical grade 
methanoic acid [99.9:0.1, v/v] for calibration of the FT-ICR mass spectrometer.  
All chemicals were used without further purification. 
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3.3  Instrumental 
“In-time” low-energy CID product ion spectra were acquired using a LCQ Classic 
QIT mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA).  Positive 
ion ESI-MS/MS was performed by infusing the solutions directly into the ion 
source at a constant flow rate of 3 microlitres per minute (μL min
-1).  Nitrogen 
was used as the sheath and auxiliary gas.  The ion source conditions varied 
between  experiments  and  will  be  detailed  in  the  individual  chapters.    Low-
energy CID product ion spectra were acquired using an isolation width of 6 m/z 
units (1 m/z unit for solution-phase H/D exchange experiments), an activation Q 
of  0.250  and  an  activation time of  30 ms.    Acquisitions  were  performed for 
twenty scans.  Helium was used as the buffer gas.  The value of the normalised 
collision  energy  and  the  WideBand  activation  setting  were  varied  between 
experiments and will be detailed in the individual chapters.  Data acquisition 
was performed using XCalibur version 1.2 (Thermo Fisher Scientific, San Jose, 
CA, USA). 
 
“In-space” low-energy CID product ion spectra were acquired using a Premier 
QqTOF mass spectrometer (Waters Ltd., Elstree, UK) coupled to an Acquity ultra 
performance  liquid  chromatography  (UPLC)  instrument  (Waters  Ltd.,  Elstree, 
UK).  Separation was achieved using a Sunfire C18 column, 50 millimetre (mm) x 
2.1 mm internal diameter (i.d.), 3.5 μm particle size (Waters Ltd., Elstree, UK).  
The column oven temperature was set to 40
oC.  The mobile phases were; (A) 
HPLC grade water and LC-MS Chromasolv® acetonitrile [95:5, v/v] containing 
0.1% analytical grade methanoic acid and (B) LC-MS Chromasolv® acetonitrile 
containing 0.1% analytical grade methanoic acid.  The gradient conditions are 
shown in Table 3.1.  The eluent flow rate was 200 μL min
-1 and the injection 
volume was 5 μL. 
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Table 3.1  Gradient conditions for the UPLC-QqTOF-MS/MS analyses 
 
Time / min  % A  % B 
0  95  5 
1  95  5 
8  2  98 
9  2  98 
9.1  95  5 
13  95  5 
 
Positive  ion  ESI-MS/MS  was  performed  using  the  following  ion  source 
conditions;  cone  gas  flow,  40  litres  per  hour  (L  hr
-1);  desolvation  gas  flow, 
650 L hr
-1; capillary voltage, 3.2 kV; sampling cone, 25 V; extraction cone, 4 V; 
ion  guide,  2.5  V;  source  temperature,  120  degrees  Celsius  (
oC);  desolvation 
temperature, 350
oC.  Nitrogen was used as the cone and desolvation gas.  Low-
energy CID product ion spectra were acquired at collision energies of 15, 20 and 
25 electron volts (eV) using argon as the collision gas.  The mass spectrometer 
was operated in the “V” mode.  The scan time was 0.2 s and the interscan time 
was 0.05 s.  Data acquisition was performed using MassLynx version 4.1 (Waters 
Ltd., Elstree, Herts., UK). 
 
AMM “in-time” low-energy SORI-CID product ion spectra were acquired using 
an Apex III FT-ICR mass spectrometer (Bruker, Billerica, MA, USA) equipped with 
a  4.7  Tesla  actively  shielded  superconducting  magnet,  an  Infinity  cylindrical 
analyser  cell  and  an  Apollo  ESI  ion  source.    Positive  ion  ESI-MS/MS  was 
performed by infusing the solutions directly into the ion source at a constant 
flow rate of 3 μL min
-1.  Nitrogen was used as the drying gas.  The ion source 
conditions and excitation amplitude varied between experiments and will be 
detailed  in  the  individual  chapters.    Positive  ions  were  accumulated  in  the 
hexapole ion guide for 0.2 s prior to transfer into the ICR cell.  The conditions for 
the  acquisition  of  “in-time”  low-energy  SORI-CID  product  ion  spectra  varied 
between experiments and will be detailed in the individual chapters.  However, 
argon was always used as the collision gas.  The instrument was calibrated using 
the  first-generation  low-energy  SORI-CID  product  ion  spectrum  of  reserpine.  Chapter 3 
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Data  acquisition  was  performed  using  XMass  version  7.0.8  (Bruker,  Billerica, 
MA, USA). Chapter 4 
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Chapter 4 
 
Evidence for an ortho-effect on the fragmentation 
of 4-benzenesulfinyl-3-methylphenylamine 
 
4.1  Introduction 
Herein, an ortho-effect on the fragmentation of a model S-oxide leading to a 
50 m/z unit loss is described.  Ortho-effects are common observations in EI-MS 
and have been extensively investigated.
236-239  They are less frequent under low-
energy  CID  conditions,  although  reports  do  exist  for  protonated,
240,  241 
deprotonated
242-244  and  adduct  molecules.
241,  245  Further,  Mendes  and  co-
workers demonstrated an ortho-effect in both the EI and low-energy CID mass 
spectra  of  ortho-N-chlorophenyl-  and  ortho-N-bromophenyl-2-
aminobenzamidine.
246  The 50 m/z unit loss discussed below is of interest as a 
potential tool for metabolite identification because oxidation at a sulfur atom is 
a  common  phase  I  biotransformation,  both  in  vitro  and  in  vivo.
247  The 
dissociation behaviour discussed could possibly be of use during drug discovery 
for definitively identifying the sulfur atom in a pharmaceutical compound that 
has undergone S-oxidation. 
 
4.2  Experimental 
 
4.2.1  Chemicals 
4-Benzenesulfinyl-3-methylphenylamine  (Compound  4.1),  4-
benzenesulfinylphenylamine  (Compound  4.2),  3-methyl-4-
phenylsulfanylphenylamine  (Compound  4.4),  (4-methanesulfinyl-3-
methylphenoxy)acetic acid (Compound 4.5) and 3-dimethylaminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide  (Compound  4.6)  were 
provided  by  Pfizer  Global  Research  and  Development  (Sandwich,  UK).    2-
Aminofluorene (Compound 4.3) was purchased from Alfa Aesar (Heysham, UK).  Chapter 4 
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Solutions  of  Compounds  4.1-4.6  were  prepared  for  QIT-MS  experiments  as 
detailed in Chapter 3.  Further solutions of Compound 4.1 were prepared for 
FT-ICR-MS,  QqTOF-MS  and  solution-phase  H/D  exchange  experiments  as 
detailed in Chapter 3 and at 20 µg mL
-1 in LC-MS grade methanol and analytical 
grade methanoic acid [99.9:0.1, v/v] for the MS
4 experiment using QIT-MS. 
 
4.2.2  Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The ion source conditions were; 
sheath gas, 30 arbitrary units; auxiliary gas, 5 arbitrary units (45 arbitrary units 
for the solution-phase H/D exchange experiment); spray voltage, 4 kV; capillary 
voltage,  17 V;  capillary  temperature,  140
oC;  tube  lens  offset,  10 V.  The 
experiments performed, the setting of the WideBand activation parameter and 
the normalised collision energy value are shown in Table 4.1. 
 
Table 4.1  Experiment performed, WideBand activation parameter setting 
and normalised collision energy value for the QIT-MS analyses 
of Compounds 4.1-4.6 
 
Compound  Experiment  WideBand 
activation on/off 
Normalised 
collision energy 
/ % 
4.1  MS/MS  On  50 
4.1  MS/MS  Off  30 
4.1  MS
3  Off  35, 35 
4.1  MS
4  Off  40, 40, 30 
4.2  MS/MS  On  55 
4.3  MS/MS  Off  35 
4.4  MS/MS  On  60 
4.5  MS/MS  On  50 
4.6  MS/MS  On  50 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra of Compound 4.1. 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of Compound 4.1.  Chapter 4 
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The ion source conditions were; capillary voltage, -4.5 kV; end plate voltage, -
3.8 kV; capillary exit voltage, 100 V; skimmer 1, 11 V; skimmer 2, 6 V; offset, 
1.25; RF amplitude, 600 Hertz (Hz); dry gas temperature, 250
oC; dry gas flow 
rate,  30 arbitrary  units;  nebulising  gas  pressure,  50 pounds-per-square-inch 
(psi).  The excitation amplitude was 3.7 decibels (dB).  A low-energy SORI-CID 
product ion spectrum was acquired for eight scans using 512K data points.  The 
MS/MS  parameters  were;  corr  sweep  pulse  length,  1000  µs;  corr  sweep 
attenuation, 28.5 dB; ejection safety belt, 3000 Hz; user pulse length, 1000 µs; 
ion  activation  pulse  length,  250000 µs;  ion  activation  attenuation,  38.9 dB; 
frequency offset from activation mass, - 500 Hz; user delay length, 3 s. 
 
4.2.3  Molecular modelling 
The gas-phase proton affinity of Compound 4.1 was calculated using Spartan 
’02 (Wavefunction, Inc, CA, USA).  The gas-phase proton affinity is defined as 
the  negative  of  the  enthalpy  change  at  298  Kelvin  (K)  for  the  protonation 
reaction (Equation 4.1):
1 
 
Equation 4.1     
 
Four different conformers of the molecule were modelled.  For each of these 
models, one conformer protonated at the amine nitrogen and four conformers 
protonated at the sulfoxide oxygen were modelled through the addition of a 
proton  at  the  relevant  site.    Four  different  conformers  of  the  protonated 
sulfoxide  oxygen  were  modelled  from  each  neutral  species  to  account  for 
different spatial orientations that the proton can assume in the gas phase when 
protonation occurs at this functional group. 
 
The  structures  were  minimised  and  the  energies  calculated  at  the  density 
functional  theory  (DFT)  level  (B3LYP)  using  the  6-31G**  basis  set.    The 
equilibrium geometry was calculated at the ground state starting from AM1 
geometry.  The total charge was set to cation for the protonated species and Chapter 4 
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neutral for the molecule.  The calculated energies were converted from atomic 
units to kilocalories per mole (kcal mol
-1) using the conversion factor of 627.5.
248  
The enthalpy change was calculated by subtracting the energy of the molecule 
from the energy of each protonated species.  The obtained values corresponded 
to the ΔH value and were converted to proton affinities by multiplying by -1 (see 
Equation 4.1). 
 
4.3  Results and discussion 
The  fragmentation  of  protonated  4-benzenesulfinyl-3-methylphenylamine 
(Compound  4.1)  (Figure  4.1a)  was  investigated.    A  50 m/z  unit  loss  was 
observed in the first-generation low-energy CID product ion spectrum acquired 
with WideBand activation on (Figure 4.2).
110  It was proposed that this loss is 
the result of an ortho-effect due to the presence of the methyl group on the 
phenylamine  ring.    This  hypothesis  was  suggested  because  the  des-methyl 
homologue, protonated 4-benzenesulfinylphenylamine (Compound 4.2) (Figure 
4.1b), did not display a 50 m/z unit loss in the first-generation low-energy CID 
product ion spectrum acquired with WideBand activation on.  Instead, a 48 m/z 
unit  loss  was  observed,  which  corresponded  to  the  loss  of  sulfur  monoxide 
(Figure 4.3).  Thus, the 50 m/z unit loss from protonated Compound 4.1 was 
proposed to be a loss with the elemental formula H2SO.  Further experiments 
were conducted to confirm this loss and investigate the fragmentation. 
 
 
Figure 4.1  Molecular  structures  of  a)  4-benzenesulfinyl-3-
methylphenylamine  (Compound  4.1)  and  b)  4-
benzenesulfinylphenylamine (Compound 4.2) 
 
It was noted that the 50 m/z unit loss from protonated Compound 4.1 was only 
observed when the low-energy CID product ion spectrum was acquired with 
WideBand  activation  on.    With  the  parameter  switched  off,  no  signal  wasChapter 4 
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Figure 4.2  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.1  (m/z 232)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
observed at m/z 182 (Figure 4.4).  This is consistent with the suggestion that the 
product ion is not formed directly from protonated Compound 4.1.  It appeared 
that the 20 m/z unit activation window created with WideBand activation on 
was  required  to  form  the  product  ion.    Thus,  it  was  hypothesised  that  the 
product ion at m/z 182 is formed through a two-step fragmentation process via 
the other major ion in the activation window, namely  m/z 215. To test this 
hypothesis, an MS
3 experiment was performed with WideBand activation off 
using the ion at  m/z 215 as the precursor ion for the second stage of mass 
analysis.    The  second-generation  low-energy  CID  product  ion  spectrum  of 
protonated Compound 4.1 displays an ion at m/z 182 (Figure 4.5).  This proves 
that  the  product  ion  at  m/z 182  is  formed  by  fragmentation  of  the  ion  at 
m/z 215  and  not  directly  through  dissociation  of  the  protonated  molecule.  
Thus, the loss of 50 m/z units from protonated Compound 4.1 occurs in a two-
step process through sequential losses of 17 and 33 m/z units.  As a loss with 
the elemental formula H2SO had been proposed previously, the identities of the 
sequential  losses  were  thought  to  be  a  hydroxyl  radical  and  a  thiol  radical.  
However,  this  could  not  be  determined  by  means  of  the  preservation  orChapter 4 
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Figure 4.3  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.2  (m/z 218)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.4  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.1  (m/z 232)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation off 
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Figure 4.5  Second-generation  low-energy  CID  product  ion  spectrum  of 
protonated Compound 4.1 (m/z 232) using the ion at m/z 215 as 
the precursor ion for the second stage of mass analysis acquired 
using  a  LCQ  Classic  QIT  mass  spectrometer  with  WideBand 
activation off 
 
disappearance of the
  34S isotope pattern for the peaks of interest due to the 
difficulties associated with observing the true isotope pattern using a QIT mass 
spectrometer.  An alternative identity for the loss of 17 m/z units could have 
been ammonia, particularly if Compound 4.1 protonated at the amine nitrogen.  
Further experiments were utilised to investigate the identity of the losses. 
 
Molecular modelling calculations were utilised to support the proposed loss of a 
hydroxyl radical during the first stage of mass analysis.  The gas-phase proton 
affinities for the two most likely sites of protonation on Compound 4.1, the 
sulfoxide  oxygen  and  the  amine  nitrogen,  were  calculated.    A  number  of 
conformers of Compound 4.1 were modelled to represent some of the spatial 
orientations that the molecule can assume in the gas phase.  Using the neutral 
species, the protonated molecules were modelled by adding a proton at the 
relevant site.  Four different conformers protonated at the sulfoxide oxygen 
were modelled for each neutral species.  This is because rotation of the S-O 
bond alters the spatial orientation of the proton, which could affect the overall Chapter 4 
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energy  of  the  ion.    Only  a  single  protonated  amine  nitrogen  species  was 
modelled for each neutral conformer due to rotation of the C-N bond having no 
effect  on  the  overall  structure  of  the  ion.    A  number  of  conformers  were 
investigated for the molecules, and the corresponding protonated species, to 
verify that the same site of protonation was favoured regardless of the spatial 
orientation.  However, it must be noted that this approach does not define the 
absolute site of protonation; the conformers investigated were not exhaustive 
of all of those that can exist in the gas phase.  The energies of the protonated 
species were compared to the relevant neutral conformer to determine the 
most likely site of protonation.  The lower the energy of the protonated species 
then the more likely it is to occur in the gas phase due to the ion being more 
energetically  stable.    The  calculations  showed  that  the  protonated  sulfoxide 
oxygen  species  were  lower  in  energy  by  between  21.9  and  24.7  kcal  mol
-1 
compared to the protonated  amine  nitrogen  species  across  the  investigated 
conformers.  These values are comparable to those used to assign the sulfoxide 
oxygen  as  the  site  of  protonation  in  a  previous  study.
230    Hence,  it  can  be 
concluded  that  the  most  energetically  favourable  site  of  protonation  for 
Compound 4.1 is the sulfoxide oxygen.  This finding suggested that the 17 m/z 
unit  loss  from  protonated  Compound  4.1  was  more  likely  to  be  a  hydroxyl 
radical  than  the  alternative,  a  molecule  of  ammonia.    This  is  because 
protonation at the sulfoxide oxygen facilitates the loss of a hydroxyl radical.  To 
support  the  molecular  modelling  calculations  and  determine  the  number  of 
exchangeable hydrogen atoms in the overall 50 m/z unit loss, solution-phase 
H/D exchange experiments were performed.  The 18 m/z unit loss indicated that 
a  deuterohydroxyl  radical  was  lost  from  the  fully  exchanged,  deuterated 
molecule, [M + D]
+ (Figure 4.6).  This definitively proved that Compound 4.1 
protonates  at  the  sulfoxide  oxygen.    The  experiment  also  showed  that  one 
exchangeable hydrogen atom was involved in the overall 50 m/z unit loss due to 
the mass difference between the precursor ion and the product ion of interest 
being  51 m/z  units  under  deuterated  conditions.  Isomerisation  prior  to 
dissociation i.e. scrambling of the deuterium label, prior to dissociation can be 
excluded because the relative abundance of the ion at m/z 185 is insufficient toChapter 4 
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Figure 4.6  First-generation low-energy CID product ion spectrum of fully 
exchanged, deuterated Compound 4.1 (m/z 235) acquired using 
a LCQ Classic QIT mass spectrometer with Wideband activation 
on 
 
suggest  that  a  combination  of  50  and  51 m/z  unit  losses  have  occurred 
concurrently. 
 
The single exchangeable hydrogen atom is accounted for in the first stage of 
fragmentation through the loss of the hydroxyl radical.  Thus, the 33 m/z unit 
loss during the second stage of fragmentation is likely to be accounted for by a 
thiol radical involving a non-exchangeable hydrogen atom.  As an ortho-effect 
had been postulated, the source of this non-exchangeable hydrogen atom was 
proposed to be the methyl group bonded to the phenylamine ring.  To confirm 
the elemental formulae of the losses, AMMs were performed using a FT-ICR 
mass  spectrometer.    The  elemental  formulae  with  the  lowest  mass 
measurement error (MME) values were consistent with the loss of a hydroxyl 
radical and a thiol radical (Figure 4.7).  The rings plus double bond equivalents 
values were 8 for the product ion at m/z 215.0762 and 8.5 for the product ion at 
m/z 182.0965.  These values indicate that the structures were odd- and even-
electron  ions  respectively,
249  supporting  the  hypothesis  of  sequential  radicalChapter 4 
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Figure 4.7  First-generation low-energy SORI-CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) acquired using an Apex III 
FT-ICR mass spectrometer 
 
losses.  Because of the deficiency of the even-electron ion value by 0.5 due to 
the addition of a proton to the molecule,
250 it was deduced that the number of 
rings and double bond equivalents in the product ion was 9.  This is consistent 
with a protonated aminofluorene, which was proposed as the structure of the 
product ion at m/z 182 (Figure 4.8).  To verify this conclusion, a commercially 
available sample of 2-aminofluorene (Compound 4.3) was used to acquire the 
first-generation  low-energy  CID  product  ion  spectrum  of  the  protonated 
molecule,  m/z 182  (Figure  4.9).    The  spectrum  was  compared  to  the  third-
generation low-energy CID product ion spectrum of protonated Compound 4.1 
i.e. acquired using m/z 182 as the precursor ion (Figure 4.10).  Both spectra 
displayed a loss of 17 m/z units.  For protonated Compound 4.3, this correlated 
to the loss of a molecule of ammonia.  It is expected that, regardless of the 
position of the amine group on the fluorene substructure, the dissociations of 
the different protonated aminofluorenes will be the same i.e. loss of a single 
molecule of ammonia.  It has been shown previously that the hydroxyl group is 
lost  during  the  first  stage  of  mass  analysis  for  protonated  Compound  4.1.  
Therefore, it was concluded that the further loss of 17 m/z units was the loss of 
a molecule of ammonia.  Hence, the results are consistent with a protonated 
aminofluorene being the structure of the product ion at m/z 182. 
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Figure 4.8  Proposed structure of the product ion at m/z 182, a protonated 
aminofluorene 
 
 
Figure 4.9  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.3  (m/z 182)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation off 
 
 
Figure 4.10  Third-generation  low-energy  CID  product  ion  spectrum  of 
protonated Compound 4.1 (m/z 232) using the ions at m/z 215 
and 182 as the precursor ions for the second and third stages of 
mass  analysis  acquired  using  a  LCQ  Classic  QIT  mass 
spectrometer with WideBand activation off Chapter 4 
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A dissociation mechanism for the formation of protonated Compound 4.3 from 
protonated  Compound  4.1  is  proposed  (Figure  4.11).    The  production  of 
protonated 4-aminofluorene can not be precluded and a mechanism for this 
dissociation is also suggested (Figure 4.12).  However, this could not be verified 
because 4-aminofluorene was not commercially available. 
 
 
Figure 4.11  Proposed  dissociation  mechanism  for  the  formation  of 
protonated  Compound  4.3  by  dissociation  of  protonated 
Compound 4.1 through sequential losses of a hydroxyl radical 
and a thiol radical 
 
 
 
Figure 4.12  Proposed  dissociation  mechanism  for  the  formation  of 
protonated  4-aminofluorene  by  dissociation  of  protonated 
Compound 4.1 through sequential losses of a hydroxyl and a 
thiol radical Chapter 4 
79 
In both cases, the driving force for the dissociation appears to be product ion 
stability, with the planar structures likely to make the transitions energetically 
favourable (Figure 4.13). 
 
 
Figure 4.13  Molecular model of protonated Compound 4.3 demonstrating 
the planar structure of the ion 
 
The discussed dissociation behaviour has potential as a tool for identifying the 
site of oxidation of a NCE during the drug discovery process.  This is because the 
loss  was  not  observed  for  protonated  3-methyl-4-phenylsulfanylphenylamine 
(4), the unoxidised analogue of the model S-oxide i.e. equivalent to the parent 
compound (Figure 4.14).  The hydroxyl radical can not be lost without prior 
oxidation of the sulfur atom.  Therefore, a 50 m/z unit loss in the low-energy 
CID product ion spectrum of a drug metabolite may suggest oxidation at a sulfur 
atom that is positioned ortho to a methyl group.  This may rule out other sulfur 
atoms  in  the  molecule  as  sites  of  oxidation  because  they  lack  the  required 
chemical environment.  Thus, rapid and definitive assignment of the site of S-
oxidation could be achieved based  upon a single loss in the  low-energy CID 
product ion spectrum.  The observed loss could be used as a tool to identify S-
oxidised  metabolites  using  both  “in-time”  and  “in-space”  MS/MS  platforms.  
This  is  because  the  same  dissociation  was  recorded  using  a  QqTOF  mass 
spectrometer  operated  over  a  range  of  collision  energies  (Figure  4.15).  
However, the investigation of the observed loss and the understanding of the 
mechanism were more effectively achieved using the QIT mass spectrometer.Chapter 4 
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Figure 4.14  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.4  (m/z 216)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.15  First-generation  low-energy  CID  product  ion  spectra  of 
protonated Compound 4.1 (m/z 232) acquired using a Premier 
QqTOF mass spectrometer operated at collision energies of a) 
15 eV, b) 20 eV and c) 25 eV Chapter 4 
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The inability of the QqTOF mass spectrometer to perform MS
n experiments, in 
addition to the assumption that even-electron precursor ions dissociate to form 
even-electron product ions,
251 could result in an analyst proposing that the loss 
of 50 m/z units takes place in a single step.  It is unlikely that sequential radical 
losses from even-electron precursor ions would be postulated under low-energy 
CID conditions, as a rationalisation based upon a neutral molecule loss would be 
sought in agreement with extensive experimental observations.
252  However, 
the  ability  of  the  QIT  mass  spectrometer  to  acquire  MS
3  data  allowed  the 
elucidation of the sequential radical losses that constitute the loss of 50 m/z 
units. 
 
It  is  hypothesised  that  two  aromatic  substructures  bonded  to  the  sulfoxide 
group, as well as the ortho methyl group, are required for the 50 m/z unit loss 
to be observed.  This is because the loss was not observed for two compounds 
with sulfoxide functionalities bonded to a single aromatic ring and a methyl 
group; (4-methanesulfinyl-3-methylphenoxy)acetic acid (Compound 4.5) and 3-
dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide  (Compound  4.6)  (Figures  4.16a  and 
4.16b). 
 
 
Figure 4.16  Molecular  structures  of  a)  (4-methanesulfinyl-3-
methylphenoxy)acetic  acid  (Compound  4.5)  and  b)  3-
dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide (Compound 4.6) 
 
The  absence  of  a  50  m/z  unit  loss  in  their  first-generation  low-energy  CID 
product ion spectra, acquired with WideBand activation on, (Figures 4.17 and 
Figure 4.18) suggests that the loss of a hydroxyl radical and a thiol radical is notChapter 4 
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Figure 4.17  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.5  (m/z 229)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.18  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  4.6  (m/z 383)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
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energetically favourable without a second aromatic ring bonded to the sulfoxide 
group.    Without  two  aromatic  groups,  a  planar  fluorene  product  ion-type 
structure can not be formed.  Hence, it is hypothesised that the planar structure 
of the product ion is the driving force for the dissociation in this case.  A further 
proposal concerning the dissociation is that the identity of the functional group 
positioned ortho to the sulfoxide functionality that facilitates the 50 m/z unit 
loss may not be restricted to a methyl group.  However, suitable compounds to 
test these hypotheses were not available for this study. 
 
4.4  Conclusions 
 
The experimental investigation of the loss of 50 m/z unit loss from protonated 
Compound 4.1 has been presented.  Comparison of the low-energy CID product 
ion  spectrum  with  that  of  the  homologue  lacking  a  methyl  group  on  the 
phenylamine ring, Compound 4.2, led to the proposal of an ortho-effect on the 
dissociation.    The  findings  indicated  that  the  dissociation  was  a  two-step 
process  involving  sequential  losses  of  a  hydroxyl  radical  followed  by  a  thiol 
radical; a rare observation under low-energy CID conditions when even-electron 
precursor  ions  are  fragmented.    Solution-phase  H/D  exchange  experiments 
showed  that  only  one  exchangeable  hydrogen  atom  was  involved  in  the 
fragmentation and that it was located on the hydroxyl group formed during 
protonation.    Thus,  definitive  assignment  of  the  site  of  protonation  was 
achieved using the solution-phase H/D exchange approach.  The involvement of 
a  non-exchangeable  hydrogen  atom  during  the  loss  of  the  thiol  radical 
supported  the  hypothesis  of  an  ortho-effect  due  to  the  methyl  group.  
Molecular  modelling  calculations  complemented  these  findings  by 
demonstrating that the most likely site of protonation was the sulfoxide oxygen, 
thus  facilitating  the  loss  of  the  hydroxyl  radical.    Accurate  mass  FT-ICR-MS 
product ion data confirmed the elemental formulae of the two radical losses.  
The elemental formula derived from the AMM of the resultant product ion was 
consistent  with  the  calculated  rings  plus  double  bond  equivalents  for  a 
protonated  aminofluorene.    The  hypothesised  product  ion  structure  was Chapter 4 
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verified  by  comparison  of  the  low-energy  CID  product  ion  spectrum  of 
commercially  available  protonated  Compound  4.3  with  that  acquired  by 
dissociation of the product ion derived through the loss of 50 m/z units from 
protonated Compound 4.1.  Possible dissociation mechanisms are proposed. 
 
The loss of H2SO has potential application in fields where structural elucidation 
is of interest, particularly the pharmaceutical industry.  In this area, a 50 m/z 
unit loss in the low-energy CID product ion spectrum of a drug metabolite may 
indicate  that  S-oxidation  has  taken  place  at  a  sulfur  atom  bonded  to  two 
aromatic  rings  with  a  methyl  group  positioned  ortho  to  it.    During  drug 
discovery, this could facilitate rapid and definitive identification of S-oxidation.  
Further, it could discriminate between multiple sulfur atoms in a compound as 
the site of oxidation based upon the chemical environment required for the loss 
to take place. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 
85 
Chapter 5 
 
An  example  of  how  unexpected  dissociation 
behaviour  could  preclude  correct  assignment  of 
sites of metabolism 
 
5.1  Introduction 
The principal method of assigning the site of metabolism of a NCE using MS/MS 
involves  comparing  the  low-energy  CID  product  ion  spectrum  of  the  parent 
compound with that of the metabolite.  The analyst interrogates the spectra for 
mass shifts of the major peaks to determine which part of the molecule has 
been altered i.e. the Shift technique.
198  However, unambiguous assignments by 
this approach are frequently not possible (see Chapter 2).  Furthermore, the 
high-throughput nature of modern drug discovery means that multiple mass 
spectrometric-related structural elucidation experiments e.g. isotopic labelling, 
derivatisation  etc.,  which  could  assist  in  definitively  identifying  the  site  of 
metabolism,  may  not  be  performed.    Thus,  there  is  a  risk  that  incorrect 
assignment of sites of metabolism could arise, which is restrictive on timely 
completion of metabolite identification studies.  This is a particular likelihood 
given  that  fragmentation  under  low-energy  CID  conditions  is  still  not  fully 
understood, with unexpected rearrangements being previously reported in the 
literature  for  both  peptidic  and  small  molecules.
253-256    Herein,  a  further 
example  of  unanticipated  dissociation  behaviour,  observed  for  the  model 
sulfoxide  metabolite  3-dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide, demonstrates how incorrect assignment 
of the sites of metabolism of a NCE could occur if a rigorous analytical approach 
is not applied. 
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5.2  Experimental 
 
5.2.1  Chemicals 
3-Dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide  (Compound  5.1)  and  3-dimethyl-
2H6-
aminomethyl-4-(4-methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound  5.2)  were  provided  by  Pfizer  Global  Research  and  Development 
(Sandwich,  UK).    Solutions  of  both  compounds  were  prepared  for  QIT-MS 
experiments as detailed in Chapter 3.  Further solutions of Compound 5.1 were 
prepared  for  FT-ICR-MS,  QqTOF-MS  and  solution-phase  H/D  exchange 
experiments as detailed in Chapter 3. 
 
5.2.2  Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.   The ion source conditions were; 
sheath gas, 35 arbitrary units; auxiliary gas, 5 arbitrary units; spray voltage, 4.5 
kV; capillary voltage, 11 V; capillary temperature, 220
oC; tube lens offset, 35 V.  
For both MS/MS and MS
3 experiments, the normalised collision energy was set 
to 50% and WideBand activation was switched on. 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra of Compound 5.1. 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of Compound 5.1.  
The ion source conditions were; capillary voltage, -4.5 kV; end plate voltage, -
3.8 kV; capillary exit voltage, 100 V; skimmer 1, 11 V; skimmer 2, 6 V; Offset, 
1.25;  RF  amplitude,  600 Hz;  dry  gas  temperature,  250
oC;  dry  gas  flow  rate, 
30 arbitrary units; nebulising gas pressure, 50 psi.  The excitation amplitude was 
3.7 dB.  A low-energy SORI-CID product ion spectrum was acquired for eight 
scans using 1024K data points.  The MS/MS parameters were; corr sweep pulse 
length, 1000 µs; corr sweep attenuation, 37.5 dB; ejection safety belt, 3000 Hz; Chapter 5 
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user pulse length, 1000 µs; ion activation pulse length, 250000 µs; ion activation 
attenuation,  37.2 dB;  frequency  offset  from  activation  mass,  -  500 Hz;  user 
delay length, 3 s. 
 
5.3  Results and discussion 
As  part  of  the  presented  study,  a  series  of  pharmaceutical  compounds  and 
model metabolites were analysed using QIT-MS to identify product ions and 
losses that could facilitate rapid and definitive identification of pharmaceutical 
drug metabolites.  During these studies, the dissociation of a model S-oxidised 
metabolite,  3-dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide  (Compound  5.1)  (Figure  5.1),  was 
investigated. 
 
 
Figure 5.1  Molecular  structure  of  3-dimethylaminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound 5.1) 
 
The first-generation low-energy CID product ion spectrum of the protonated 
molecule is shown in Figure 5.2.  A loss of 62 m/z units was observed, forming 
the  product  ion  at  m/z 321.    The  same  loss  was  not  seen  for  the  parent 
compound (data not shown).  The dissociation thus appeared dependent upon 
the  biotransformation  i.e.  oxidation.    Hence,  the  loss  was  thought  to  be  of 
potential use in metabolite identification.  This proposal was supported by the 
observation of the same loss using a QqTOF mass spectrometer (Figure 5.3).  
This  demonstrated  that  the  dissociation  could  be  recorded  using  both  “in-
space”  and  “in-time”  MS/MS  platforms  i.e.  the  dissociation  was  instrument-Chapter 5 
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Figure 5.2  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  5.1  (m/z 383)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 5.3  First-generation  low-energy  CID  product  ion  spectra  of 
protonated Compound 5.1 (m/z 383) acquired using a Premier 
QqTOF mass spectrometer operated at collision energies of a) 
15 eV, b) 20 eV and c) 25 eV Chapter 5 
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configuration  independent.    This  was  important  to  establish  because  mass 
spectrometers  with  many  different  mass  analysers  are  employed  for  the 
purpose of metabolite identification.
175, 257-261   
 
Involvement of the oxygen atom was inferred and the loss was assigned as 
methanethial,  S-oxide  (CH2SO).    This  hypothesis  was  attractive  because  S-
oxidation of the parent compound produces an ideal candidate for the loss of 
62  m/z  units  through  the  well-documented  processes  of  charge-remote 
fragmentation
262  and  1,3-proton  shifts
263  via  four-centred  rearrangements 
(Figure 5.4).  The dissociation was thought to be energetically favourable due to 
the conformance of the proposed product ion with the even-electron rule.
251  
However, the loss could not be confirmed by a change in the 
34S isotope pattern 
for  the  product  ion  compared  to  the  precursor  ion  due  to  the  difficulties 
associated  with  observing  the  true  isotope  pattern  using  a  QIT  mass 
spectrometer.  The overlapping of the second isotope peak of the product ion at 
m/z 321 with the  monoisotopic peak of the product ion at  m/z 323 further 
precluded this approach to structural elucidation. 
 
 
Figure 5.4  Proposed mechanism for the loss of methanethial, S-oxide from 
protonated Compound 5.1 via a four-centred rearrangement 
 
It was noted that the proposed 62 m/z unit loss did not involve any of the three 
exchangeable hydrogen atoms on the precursor ion.  Thus, if the assignment of 
the loss were correct, the m/z of the product ion for the loss of methanethial, S-
oxide would mass shift by 3 m/z units to m/z 324 in the low-energy CID product 
ion  spectrum  of  the  fully  exchanged,  deuterated  species  (Figure  5.5).    TheChapter 5 
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Figure 5.5  First-generation low-energy CID product ion spectrum of fully 
exchanged, deuterated Compound 5.1 (m/z 386) acquired using 
a LCQ Classic QIT mass spectrometer with WideBand activation 
on 
 
absence of a peak at m/z 324 under deuterated conditions indicated that the 
initially posited loss was incorrect.  Further, an additional peak was observed at 
m/z 323 in the low-energy CID product ion spectrum of the fully exchanged, 
deuterated species that was not seen for the protonated molecule.  It should be 
noted that this product ion was different to that seen at m/z 323 in the low-
energy CID product ion spectrum of the protonated molecule, which is mass 
shifted  to  m/z 325  under  deuterated  conditions.    The  observation  of  an 
additional peak led to the deduction that two nominally isobaric product ions 
were formed through dissociation of the protonated molecule.  The product 
ions  only  became  mass-resolved  when  the  fully  exchanged,  deuterated 
molecule  was  dissociated  due  to  the  retention  of  different  numbers  of 
deuterium  atoms  by  the  two  product  ions.    Thus,  the  solution-phase  H/D 
exchange  experiment  showed  that  two  losses  of  62  m/z  units  took  place, 
neither of which being that initially postulated.  The loss of all of the deuterium 
atoms to form the product ion at m/z 321 indicated that the primary amine 
group had been lost during the dissociation.  This was because exchange of the Chapter 5 
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two  hydrogen  atoms  in  the  primary  amine  group  for  two  deuterium  atoms 
would have occurred in solution.  The peak at m/z 323, formed through a loss 
involving  one  deuterium  atom,  indicated  that  this  product  ion  retained  the 
primary amine.  Further, it suggested that the ionising deuteron was lost during 
the dissociation, and hence the loss included a site of ionisation. 
 
Further experimentation was undertaken to characterise the two losses of 62 
m/z  units.    To  this  end,  the  first-generation  low-energy  CID  product  ion 
spectrum of a deuterium-labelled analogue, 3-dimethyl-
2H6-aminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide  (Compound  5.2) 
(Figure 5.6), was acquired (Figure 5.7). 
 
 
Figure 5.6  Molecular  structure  of  3-dimethyl-
2H6-aminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound 5.2) 
 
In  the  mass  range  of  interest,  the  low-energy  CID  product  ion  spectrum 
resembled  that  of  protonated  Compound  5.1,  with  only  two  peaks  being 
observed.  This indicated that the product ions were nominally isobaric again 
and neither product ion retained the six deuterium labels.  Thus, both losses of 
62 m/z units in Figure 5.2 involved the tertiary amine group.  The solution-phase 
H/D exchange experiment had shown that one product ion also lost the primary 
amine group; thus, the overall loss was postulated to be C2H10N2.  The same 
experiment had also shown that one product ion retained the primary amine 
and lost the ionising deuteron.  From this information, it was deduced that the 
tertiary amine group was a site of protonation.  Further, it suggested that the 
remaining loss of 17 m/z units for the product ion that retained the primaryChapter 5 
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Figure 5.7  First-generation  low-energy  CID  product  ion  spectrum  of 
protonated  Compound  5.2  (m/z 389)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
amine group (62 m/z units minus 45 m/z units for the tertiary amine group plus 
the ionising proton) was likely to be a hydroxyl radical; an overall proposed loss 
of C2H8NO
•. 
 
To  confirm  the  hypothesised  losses,  AMMs  were  acquired  using  FT-ICR-MS.  
Figure  5.8  shows  the  first-generation  low-energy  SORI-CID  product  ion 
spectrum of protonated Compound 5.1 in the mass range of interest.  The high 
resolving power of the FT-ICR mass spectrometer allowed mass resolution of 
the two nominally isobaric product ions at m/z 321.  The lowest MME elemental 
formulae,  given  the  precursor  ion  formula,  were  consistent  with  those 
postulated and confirmed that the two losses of 62 m/z units were C2H10N2 and 
C2H8NO
•. 
 
The verification of the elemental composition of the losses allowed postulation 
of dissociation mechanisms leading to the decomposition of the precursor ion.  
The product ion with an elemental formula of C15H13O4S2
+ (Compound 5.3) had 
a ring plus double bond equivalents value of 9.5, confirming that it is an even-Chapter 5 
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Figure 5.8  First-generation low-energy SORI-CID product ion spectrum of 
protonated Compound 5.1 (m/z 383) acquired using an Apex III 
FT-ICR mass spectrometer 
 
electron  ion.
249    Because  of  the  deficiency  of  this  value  by  0.5  due  to  the 
addition of a proton to the molecule,
250 it was deduced that the number of rings 
plus double bond equivalents in the product ion was 10.  Figure 5.9 shows a 
proposed mechanism leading to the formation of a product ion which satisfies 
this value; the double bonds of the sulfone group are discounted due to sulfur 
not  being  in  its  lowest  valence  state.
249    Protonation  is  postulated  on  the 
primary amine to facilitate the loss of the two exchangeable hydrogen atoms as 
part of a molecule of ammonia. 
 
The speculative product ion structure is predominately planar as evinced by the 
molecular model in Figure 5.10.  This is likely to provide the driving force for the Chapter 5 
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energetic rearrangement that involves a high-energy proton shift and leads to 
the loss of dimethylamine.
237  The planar structure allows easy delocalisation of 
the  charge,  making  the  formation  of  the  product  ion  thermodynamically 
favourable. 
 
 
Figure 5.9  Proposed  mechanism  for  the  formation  of  Compound  5.3 
through  the  loss  of  C2H10N2  as  molecules  of  ammonia  and 
dimethylamine from protonated Compound 5.1 
 
 
 
Figure 5.10  Molecular  models  of  Compound  5.3  demonstrating  the 
predominately planar structure of the proposed product ion 
 
The product ion with an elemental formula of C15H15NO3S2
+• (Compound 5.4) 
has  a  ring  plus  double  bond  equivalents  value  of  10  i.e.  an  odd-electron 
species.
249  Figure 5.11 shows a proposed mechanism to form a radical product 
ion structure that is consistent with this value.   The speculative product ion 
structure  is  again  predominately  planar,  (Figure  5.12),  thus  allowing  facile 
delocalisation  of  both  the  charge  and  the  radical  site.    This  is  particularly 
important due to the energetically unfavourable formation of a radical product Chapter 5 
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ion from an even-electron precursor.
264  However, the resonance stabilisation 
across the two aromatic rings, and the sulfone and sulfoxide functionalities, is 
likely to facilitate this dissociation. 
 
 
Figure 5.11  Proposed  mechanism  for  the  formation  of  Compound  5.4 
through the loss of C2H8NO
• as a molecule of dimethylamine 
and a hydroxyl radical from protonated Compound 5.1 
 
 
 
Figure 5.12  Molecular  models  of  Compound  5.4  demonstrating  the 
predominately planar structure of the proposed product ion Chapter 5 
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Both  proposed  dissociation  mechanisms  involve  the  loss  of  dimethylamine.  
However, the pathways leading to this loss differ for the two product ions.  The 
formation of Compound 5.3 is postulated to involve the loss of dimethylamine 
facilitated by the shift of a non-exchangeable hydrogen atom.  Conversely, the 
formation  of  Compound  5.4  proceeds  via  protonation  of  the  tertiary  amine 
followed by a charge-directed inductive cleavage of the carbon-nitrogen bond.  
Thus,  an  exchangeable  hydrogen  atom  i.e.  the  ionising  proton  (deuteron)  is 
proposed to facilitate the loss of dimethylamine in this instance.  The loss of 
dimethylamine  was  also  observed  in  the  first-generation  low-energy  CID 
product ion spectrum of protonated Compound 5.1 (Figure 5.2; product ion at 
m/z 338).  The dissociation of the fully exchanged, deuterated species (Figure 
5.5) showed that the loss increased by 1 m/z unit to produce a peak at m/z 340, 
demonstrating the involvement of a single exchangeable hydrogen atom in the 
dissociation.  The protonated molecule can not be spatially arranged such that 
the two exchangeable hydrogen atoms on the primary amine can be in close 
proximity to the tertiary amine functionality to allow intra-ionic transfer.  Thus, 
they can be excluded as being the source of the exchangeable hydrogen atom 
involved in the loss of dimethylamine.  Hence, the exchangeable hydrogen atom 
must be the ionising proton (deuteron).  From the two mechanisms postulated 
for  the  losses  of  62  m/z  units  (Figures  5.9  and  5.11),  only  one  involves 
protonation at the tertiary amine and the loss of dimethylamine facilitated by 
an exchangeable hydrogen atom i.e. the loss of C2H8NO
•.  Protonation at the 
primary amine is inferred for the loss of C2H10N2 to facilitate elimination of a 
molecule of ammonia from the precursor ion.   This could not be confirmed 
using solution-phase H/D exchange experiments because the loss of ammonia is 
not observed in the first-generation low-energy CID product ion spectrum of 
protonated Compound 5.1 (Figure 5.2).  However, supportive evidence for the 
proposed  mechanisms  was  obtained  through  the  acquisition  of  the  second-
generation low-energy CID product ion spectrum of fully exchanged, deuterated 
Compound 5.1 using the ion at m/z 340 as the precursor ion for the second 
stage of mass analysis (Figure 5.13).  The dissociation of the fully exchanged, 
deuterated molecule, rather than the protonated molecule, was investigated soChapter 5 
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Figure 5.13  Second-generation  low-energy  CID  product  ion  spectrum  of 
fully exchanged, deuterated Compound 5.1 (m/z 386) using the 
ion at m/z 340 as the precursor ion for the second stage of mass 
analysis  acquired  using  a  LCQ  Classic  QIT  mass  spectrometer 
with WideBand activation on 
 
that the product ions would be mass-resolved on the QIT mass spectrometer if 
they  were  both  formed.    In  the  mass  range  of  interest,  a  product  ion  was 
observed at m/z 323, which suggested that Compound 5.4 is formed through 
protonation at the tertiary amine, followed by the loss of dimethylamine and 
then elimination of a hydroxyl radical.   The mass difference of 17 m/z units 
between the precursor ion for the second stage of mass analysis and the final 
product  ion  indicated  that  the  loss  of  the  hydroxyl  radical  involved  a  non-
exchangeable hydrogen atom.  If an exchangeable hydrogen atom was involved, 
the loss would become a deuterohydroxyl radical, and thus the mass loss would 
increase to 18 m/z units, under deuterated conditions.  The observations were 
consistent with the proposed mechanism for the dissociation (Figure 5.11).  No 
peak  was  observed  at  m/z  321,  which  indicated  that  a  second  dissociation 
pathway  existed  for  the  loss  of  dimethylamine.    This  provided  supportive 
evidence  for  a  loss  of  dimethylamine  facilitated  by  the  shift  of  a  non-
exchangeable  hydrogen  atom,  which  is  consistent  with  the  proposed Chapter 5 
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mechanism  (Figure  5.9).    The  absence  of  the  losses  of  ammonia  and 
dimethylamine facilitated by a non-exchangeable hydrogen atom in the first-
generation low-energy CID product ion spectrum of protonated Compound 5.1 
suggested that the dissociation is concerted, or at least that the intermediates 
undergo rapid decomposition to the final product ion.  Further, the solution-
phase H/D exchange experiments suggested that Compound 5.1 had more than 
one site of protonation in the gas phase because the loss of the tertiary amine 
group was not via protonation at that site in the formation of Compound 5.3.  
Thus, it was plausible that the molecule could protonate at the primary amine, 
further supporting the mechanism proposal. 
 
The discussed work has implications for structural elucidation using low-energy 
CID product ion spectra, particularly for metabolite identification studies.  To 
identify  the  sites  of  metabolism  on  a  NCE  using  MS,  the  structures  of  the 
metabolites must be deduced from their low-energy CID product ion spectra.  
From the low-resolution low-energy CID product ion spectrum of protonated 
Compound  5.1,  S-oxidation  is  likely  to  be  proposed  based  upon  the  initial 
assignment of the 62 m/z unit loss as methanethial, S-oxide via a four-centred 
rearrangement.  In this case, the proposal of S-oxidation would be correct but 
the assignments of the product ions leading to it would be wrong.  If this were 
an  unknown  metabolite,  oxidation  of  the  parent  compound  could  have 
occurred,  for  example,  through  aromatic  hydroxylation  of  the  1-methyl-2-
methylsulfanylbenzene  ring  and  potentially  not  affected  either  of  the  actual 
losses  of  62  m/z  units.    Nevertheless,  the  attractive  nature  of  S-oxidation 
facilitating the loss of methanethial, S-oxide via a four-centred rearrangement 
could lead to an incorrect assignment.  Hence, time and money may be spent 
synthesising  analogues  and/or  homologues  to  protect  the  methyl  sulfide 
functionality of the parent compound only to discover that the hypothesised 
site of oxidation is incorrect.  The discussed example highlights the possibility of 
unexpected  rearrangements  under  low-energy  CID  conditions,  which  could 
easily lead to incorrect assignments of product ion structures, and hence sites of 
metabolism in drug discovery studies.  A simple and cost-effective approach to Chapter 5 
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reduce  the  likelihood  of  this  occurrence  is  the  use  of  solution-phase  H/D 
exchange experiments, which provide a straightforward method of introducing 
isotopic  labels  into  the  compound.    Thus,  dissociations  proposed  to  involve 
exchangeable hydrogen atoms can be verified.  Further, employment of mass 
spectrometers  capable  of  high-resolution  mass  measurement,  even  when 
coupled to fast chromatography as utilised in metabolite identification studies, 
would also reduce the possibility of incorrect product ion structure assignment.  
The study has also been of relevance to the understanding of fragmentation 
under  low-energy  CID  conditions.    The  dissociations  involve  more  complex 
rearrangements  than  that  initially  proposed.    Further,  the  formation  of  an 
energetically  unfavourable  radical  product  ion  occurred.    However,  the  final 
shapes  of  the  product  ions  appear  to  have  a  bearing  on  the  dissociation 
pathways  followed.    The  initially  proposed  product  ion  structure  formed 
through the  loss  of  methanethial,  S-oxide has free  rotation  about  the  ether 
linkage.    The  product  ions  actually  formed  are  posited to  be  predominately 
planar, thus allowing easier delocalisation of the charge.  This may suggest that 
rearrangements  leading  to  the  formation  of  planar  product  ion  structures 
predominate  under  low-energy  CID  conditions.    Furthermore,  the  study 
indicated  that  solution-phase  H/D  exchange  experiments  can  be  useful  in 
determining sites of gas-phase protonation under ESI-low-energy CID-MS/MS 
conditions,  as  previously  reported,
265  thus  allowing  rationalisation  of 
dissociation mechanisms. 
 
5.4  Conclusions 
The  experimental  investigation  of  the  dissociation  of  a  model  S-oxidised 
metabolite, Compound 5.1, has been presented.  The product ion at m/z 321 in 
the low-resolution low-energy CID product ion spectrum was initially assigned 
as being formed through the loss of methanethial, S-oxide from the protonated 
molecule.   It  was thought that this  loss  could  be used  to  assign  the site  of 
oxidation  as  the  sulfur  of  the  methyl  sulfide  group.    Subsequent  deuterium 
labelling experiments and AMMs acquired using a high-resolution low-energy Chapter 5 
100 
CID  product  ion  spectrum  proved  that  the  initial  assignment  was  incorrect.  
Instead,  two  unexpected  rearrangements  led  to  the  formation  of  nominally 
isobaric product ions.  Only through the use of solution-phase H/D exchange 
experiments  and  high-resolution  MS  was  it  possible  to  mass-resolve  these 
species.    Mechanisms  consistent  with  the  experimental  findings  were 
postulated.  Supportive evidence for the proposals was obtained through the 
acquisition of a second-generation low-energy CID product ion spectrum.  The 
speculative planar product ion structures were concluded to provide the driving 
force for the rearrangements, particularly in the formation of an energetically 
unfavourable radical cation.  The study is of relevance to pharmaceutical drug 
metabolite  identification  because  it  demonstrated  that  a  rigorous  analytical 
approach  is  required  to  ensure  that  incorrect  assignment  of  the  sites  of 
metabolism of NCEs is precluded.  A greater understanding of fragmentation 
under  low-energy  CID  conditions  was  also  obtained,  with  the  shape  of  the 
product ion apparently offsetting the complexity of the rearrangement required 
to  form  it.    Further,  the  data  verified  the  usefulness  of  solution-phase  H/D 
exchange experiments in determining sites of protonation under ESI-low-energy 
CID-MS/MS conditions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 6 
101 
Chapter 6 
 
A  rapid  methodology  for  the  characterisation  of 
dialkyl  tertiary  amine-N-oxide  metabolites  using 
structurally  dependent  dissociation  pathways  and 
reconstructed ion current chromatograms 
 
6.1  Introduction 
Many pharmaceutical compounds contain amine groups that act as hydrogen 
bond  acceptors  to  affect  the  solubility  and  permeability  of  the  molecule  in 
biological organisms.
266  A particularly common substructure is a dialkyl tertiary 
amine group.  The literature cites many examples of the loss of the nitrogen-
containing  group  in  this  substructure  under  low-energy  CID  conditions.
267-277 
However,  only  small  libraries,  or  structurally  similar  compounds,  were 
investigated  in  each  case.    Thus,  there  is  no  reported  comprehensive 
understanding  of  the  dissociation  behaviour  of  this  substructure,  such  as 
whether  the  loss  of  the  group  is  always  observed  under  low-energy  CID 
conditions when it is present in structurally diverse compounds.  Further, little 
knowledge is available as to whether the oxidised analogue of a dialkyl tertiary 
amine  group,  representative  of  an  N-oxidised  metabolite,  also  displays  the 
corresponding loss mass shifted by 16 m/z units to account for the addition of 
the  oxygen.    Lay  and  co-workers  utilised  high-energy  FAB-MS  and  FAB-CID-
MS/MS  to  show  that  the  losses  of  dimethylamine  and  N,N-
dimethylhydroxylamine  were  observed  for  a  series  of  ethylenediamine, 
ethanolamine and propylamine antihistamine drugs and their tertiary amine-N-
oxides  respectively.
229    However,  equivalent  data  under  low-energy  CID 
conditions has never been reported.  To address these voids in knowledge, a 
library  of  structurally  diverse  commercially  available  pharmaceutical 
compounds containing dialkyl tertiary amine groups, as well as  a number of 
model, synthetic N-oxides, were analysed by ESI-low-energy CID-MS/MS to gain Chapter 6 
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a  greater  understanding  of  the  gas-phase  ion  chemistry.    The  acquired 
information allowed the development of a rapid and definitive approach for the 
characterisation  of  dialkyl  tertiary  amine-N-oxide  metabolites  using 
reconstructed ion current chromatograms (RICCs).  The approach uses existing, 
readily available HPLC-MS/MS technology, thus allowing facile implementation.  
This approach could be of benefit in definitively characterising N-oxides early in 
the drug discovery process, which is important as this type of metabolite has 
long been recognised as being a potentially toxic species.
278  
 
6.2  Experimental 
 
6.2.1  Chemicals 
A  library  of  seventy  commercially  available  pharmaceutical  compounds  and 
model,  synthetic  N-oxides  were  provided  by  Pfizer  Global  Research  and 
Development  (Sandwich,  UK)  (The  full  library  can  be  found  in  Appendix  1, 
Tables A1-4).  Solutions were prepared for QqTOF-MS experiments as detailed 
in  Chapter  3.    The  same  solutions  were  used  for  the  QIT-MS  experiments.  
Solutions of amitriptyline, amitriptyline-N-oxide, sunitinib and sunitinib-N-oxide 
were prepared for FT-ICR-MS and solution-phase H/D exchange experiments as 
detailed in Chapter 3. 
 
An incubation was performed in a shaking water bath at 37
oC.  Tetracaine at a 
concentration of 10 micromolar (µM) was pre-incubated for 15 minutes with rat 
liver microsomes at a concentration of 0.5 µM in 50 millimolar (mM) phosphate 
buffer (pH 7.4).  In addition, 5 mM magnesium chloride (MgCl2), 5 mM isocitric 
acid and 1 unit mL
-1 isocitric dehydrogenase were present in the incubation 
mixture.  The incubation was initiated by adding 40 microlitres (µL) of 20 mM 
nicotinamide adenine dinucleotide phosphate (NADP
+).  After 60 minutes, the 
incubation was terminated by the addition of 4 mL of cold acetonitrile.  The 
incubate was centrifuged at 3000 revolutions per minute (rpm) for 40 minutes 
at  4
oC  to  precipitate  the  protein.    The  supernatant  was  removed  and 
evaporated to dryness under nitrogen.  The sample was then resuspended in Chapter 6 
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200 µL of LC-MS grade Chromasolv
® acetonitrile and HPLC grade water (1:1) in 
preparation for analysis by QqTOF-MS. 
 
6.2.2  Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The source conditions were; sheath 
gas, 25 arbitrary units; auxiliary gas, 0 arbitrary units (45 arbitrary units for the 
solution-phase  H/D  exchange  experiments);  spray  voltage, 4.5  kV;  capillary 
voltage,  10 V;  capillary  temperature,  160
oC;  tube  lens  offset,  -  5 V.    The 
normalised collision energy was set to either 50% or 60% to cause complete 
dissociation of the precursor ion.  Acquisitions were performed with WideBand 
activation both on and off. 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra.  Further, full scan spectra of the 
tetracaine incubate were acquired by setting the collision energy to 4 eV.  Low-
energy CID product ion spectra were acquired at 20 eV. 
 
FT-ICR-MS  experiments  were  performed  as detailed  in  Chapter  3  to  acquire 
AMM  “in-time”  low-energy  SORI-CID  product  ion  spectra  of  amitriptyline, 
amitriptyline-N-oxide,  sunitinib  and  sunitinib-N-oxide.    The  ion  source 
conditions were; capillary voltage, - 4.5 kV; end plate voltage, - 3.8 kV; capillary 
exit voltage, 85 V; skimmer 1, 15 V; skimmer 2, 8.5 V; Offset, 1.25; RF amplitude, 
600 Hz;  dry  gas  temperature,  250
oC;  dry  gas  flow  rate,  30 arbitrary  units; 
nebulising  gas  pressure,  50 psi.    The  excitation  amplitude  was  7.0 dB.  Low-
energy SORI-CID product ion spectra were acquired for thirty-two scans using 
512K  data  points.  The  MS/MS  parameters  were;  corr  sweep  pulse  length, 
1000 µs; corr sweep attenuation, 28.5 dB; ejection safety belt, 3000 Hz; user 
pulse  length,  1000 µs;  ion  activation  pulse  length,  250000 µs;  ion  activation 
attenuation,  38.9 dB;  frequency  offset  from  activation  mass,  -  500 Hz;  user 
delay length, 3 s. Chapter 6 
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6.3  Results and discussion 
In an attempt to understand the dissociation of molecules containing dialkyl 
tertiary amine groups, and their corresponding N-oxidised analogues, a library 
of  seventy  structurally  diverse  commercially  available  pharmaceutical 
compounds were analysed by ESI-low-energy CID-MS/MS.   Figures 6.1a-d show 
the  composition  of  the  library  in  terms  of  the  nitrogen-containing  groups 
present in the compounds analysed.  The numbers of compounds containing 
each substructure are also shown. 
 
 
Figure 6.1  Composition  of  the  investigated  library  with  respect  to  the 
nitrogen-containing groups represented.  The number of each 
substructure type analysed are shown below the structures 
 
Two  hypotheses  were  under  scrutiny.    The  first  was  that  the  loss  of  the 
nitrogen-containing group was generic i.e. always observed in the low-energy 
CID product ion spectrum.  The second was that oxidation of the dialkyl tertiary 
amine group did not change the dissociation behaviour of the compound i.e. if 
the  loss  of  the  nitrogen-containing  group  was  observed  for  the  protonated 
parent compound, the corresponding loss was also seen for the protonated N-
oxidised metabolite, and vice versa.  Low-energy CID product ion spectra were 
acquired using both QIT and QqTOF mass spectrometers to assess whether the 
dissociation  was  observed  using  both  “in-time”  and  “in-space”  MS/MS 
platforms.    Spectra  were  acquired  using  QIT-MS  with  a  sufficient  collision 
energy value to fragment the entire population of protonated molecules for 
each compound.  Using QqTOF-MS, low-energy CID product ion spectra were 
acquired  over  a  range  of  collision  energies  to  determine  whether  second-
generation product ions were formed, thus allowing inferences to be drawn 
regarding the stability of the ions produced through the loss of the nitrogen-
containing group.  The results were collated and are represented in four pie Chapter 6 
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charts  (Figures  6.2a-d; relatives  abundances for  the  relevant  loss  from  each 
compound under the various experimental conditions can be found in Appendix 
1, Tables A5-8). 
 
 
Figure 6.2  Frequency  of  the  losses  of  interest  in  percentage  terms.  
Absolute  numbers  of  compounds  are  shown  in  parentheses.  
The pie charts represent the following losses, as denoted by the 
molecular  structures  shown;  a)  dimethylamine;  b) 
diethylamine;  c)  N,N-dimethylhydroxylamine;  d)  N,N-
diethylhydroxylamine  
 
Figure  6.2a  shows  that  64%  of  the  compounds  containing  a  dimethylamine 
substructure  showed  the  loss  of  this  group  at  all  collision  energies  utilised.  
Further,  the  loss  of  dimethylamine  was  observed  at  some  of  the  collision 
energies, but not all, for 24% of the compounds.  A smaller number of the 
compounds, 12%, did not display the loss of dimethylamine despite containing 
the necessary substructure to facilitate it.  Similar percentages were observed 
for the equivalent bins for the compounds that could lose diethylamine and 
N,N-dimethylhydroxylamine  (Figures  6.2b-c).    The  loss  of  N,N-
diethylhydroxylamine  was  observed  at  all  collision  energies  utilised  for  both 
compounds  containing  this  group  (Figure  6.2d).    Although  not  analytically 
rigorous due to the small size of the subset, the data gives an indication that the 
loss  of  N,N-diethylhydroxylamine  can  be  observed  for  the  N-oxides  of Chapter 6 
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pharmaceutical compounds containing a diethylamine substituent.  AMMs were 
acquired using FT-ICR-MS to confirm the identities of the losses. Amitriptyline, 
amitriptyline-N-oxide,  sunitinib  and  sunitinib-N-oxide  were  selected  as  test 
analytes  to  represent  each  subsection  of  the  library.    The  greatest  MME 
recorded for the four losses was 0.6 ppm, giving confidence that they had been 
correctly assigned. 
 
A number of conclusions can be drawn from the results of the library analysis.  
Combining  the  four  subsets  of  data  shows  that  the  loss  of  the  nitrogen-
containing group is observed in 89% of the low-energy CID product ion spectra 
under all or some of the experimental conditions used.  Thus, the loss of dialkyl 
tertiary amine groups and their N-oxidised analogues will be observed a vast 
majority of the time for compounds containing these substructures, and can 
thus  be  considered  generic.    Further,  using  the  low-energy  CID  product  ion 
spectra for the compounds for which a model, synthetic N-oxide was available, 
it  was  possible  to  determine  that  the  dissociation  was  not  altered  by  the 
oxidation.  All of the pairs of compounds of this nature that were considered 
showed the loss of the dialkyl tertiary amine group as well as the corresponding 
oxidised  substructure,  with  the  exception  of  diphenhydramine  and 
diphenhydramine-N-oxide.  This compound did not show loss of either nitrogen-
containing group.  The coverage of pairs of compounds for which the losses of 
interest were observed for either both or neither of the compounds, but not 
only for one, lends support to the conclusion that oxidation does not change the 
dissociation  behaviour.    Finally,  comparison  of  the  “in-time”  and  “in-space” 
MS/MS  datasets  suggested  that  second-generation  dissociation  takes  place.  
When the loss of interest was observed at only certain collision energies, the 
absence  was  generally  at  higher  collision  energies  using  the  QqTOF  mass 
spectrometer (see Appendix 1, Tables A5-8).  Further, there was a general trend 
of decreasing relative abundance as the collision energy was increased, again 
using QqTOF-MS.  These observations suggest that the product ions are formed, 
as evinced by their recording at lower collision energies, but are sufficiently 
unstable that an increase in collision energy causes their decomposition.  This Chapter 6 
107 
conclusion is supported by the observation that the relative abundances of the 
product ions formed through the losses of interest were generally greater using 
QIT-MS  compared  to  QqTOF-MS.    As  fragmentation  is  effected  by  resonant 
excitation using QIT-MS,
95 the product ions can not undergo second-generation 
dissociation, regardless of their susceptibility to further decomposition.  Thus, 
they survive to detection.  The higher relative abundances using QIT-MS are 
hence  consistent  with  the  explanation  that  the  product  ions  of  interest  are 
formed  via  favourable  fragmentation  pathways  under  low-energy  CID 
conditions, but a significant proportion of the ions undergo second-generation 
dissociation using QqTOF-MS. 
 
To understand the dissociation further, a mechanism was proposed and tested 
using  solution-phase  H/D  exchange  experiments.    Figure  6.3  shows  a 
generalised  mechanism  that  covers  the  range  of  structures  present  in  the 
library. 
 
 
Figure 6.3  Generalised proposed mechanism for the loss of the nitrogen-
containing group 
 
The  mechanism  proposed  protonation  at the tertiary  amine  nitrogen or  the 
oxygen atom of the N-oxide group.  This is a reasonable assumption given the 
high solution-phase basicity of these atoms.  Protonation at these sites was Chapter 6 
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proposed to lead to charge-directed inductive cleavage of the R-N bond, thus 
causing the loss of the nitrogen-containing group as a neutral molecule.  Thus, 
involvement of a single exchangeable hydrogen atom would mean that if the 
mechanism  were  correct,  the  loss  of  interest  should  increase by  1  m/z  unit 
under deuterated conditions.  The proposed mechanism is also consistent with 
the observation of second-generation dissociation.  For a large proportion of the 
library, the nitrogen-containing group was bonded initially to the rest of the 
molecule  via  a  methylene  group.    Thus,  cleavage  of  the  C-N  bond  would 
produce a primary carbocation; an unstable species that would be susceptible 
to  further  dissociation.    Amitriptyline,  amitriptyline-N-oxide,  sunitinib  and 
sunitinib-N-oxide were selected as test analytes from each sub-section of the 
library to probe the hypothesised mechanism.  The first-generation low-energy 
CID product ion spectra acquired using QIT-MS are shown in Figure 6.4. 
 
 
Figure 6.4  First-generation  low-energy  CID  product  ion  spectra  of  a) 
deuterated  amitriptyline  (m/z  279);  b)  fully  exchanged, 
deuterated sunitinib (m/z 403); c) deuterated amitriptyline-N-
oxide  (m/z  295);  d)  fully  exchanged,  deuterated  sunitinib-N-
oxide  (m/z  419)  acquired  using  a  LCQ  Classic  QIT  mass 
spectrometer with WideBand activation on 
 
All four compounds demonstrated an increase in the mass of the neutral loss by 
1 m/z unit compared to that observed in protic solvents.  Thus, the low-energy Chapter 6 
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CID  product  ion  spectra  indicated  that  one  exchangeable  hydrogen  atom  is 
involved in the loss, and are hence supportive of the proposed mechanism.  The 
understanding of the mechanism allows a rationalisation for the absence of the 
loss of the nitrogen-containing group for some of the compounds analysed to 
be  postulated.    The  loss  requires  protonation  at  either  the  nitrogen  or  the 
oxygen atom, depending upon the character of the nitrogen-containing group, 
and  does  not  appear  to  be  facilitated  by  the  shift  of  a  non-exchangeable 
hydrogen  atom.    So,  if  the  compound  does  not  protonate  at  the  nitrogen-
containing group, its loss will not be observed in the resultant low-energy CID 
product ion spectrum.  Thus, the compounds that did not show the loss of the 
nitrogen-containing  group  may  preferentially  protonate  elsewhere  on  the 
molecule.    Molecular  modelling  experiments  would  allow  calculation of  gas-
phase proton affinities for the different sites of protonation on each compound 
not showing the loss of the nitrogen-containing group.  This would determine 
the likelihood of protonation at the nitrogen or oxygen atom relative to other 
possible sites of ionisation.  Thus, deductions could be made as to whether the 
necessary precursor ions exist in the population of protonated molecules to 
facilitate  the  loss  of  the  nitrogen-containing  group  for  each  compound.  
Previous studies have shown that computational calculations at the DFT level 
can be a useful tool to determine the gas-phase proton affinities of analytes and 
rationalise fragmentation under low-energy CID conditions.
230, 265, 279 However, 
such an in-depth study is beyond the scope of the presented work. 
 
At  this  juncture,  an  understanding  of  the  fragmentation  of  pharmaceutical 
compounds  containing  dialkyl  tertiary  amine  groups  and  their  N-oxidised 
metabolites under low-energy CID conditions has been established.  It appears 
that  the  losses  of  N,N-dimethylhydroxylamine  and  N,N-diethylhydroxylamine 
can be diagnostic for oxidised dialkyl tertiary amine groups.  The losses are 
particularly  useful  in  the  context  of  characterising  pharmaceutical  drug 
metabolites because they are both of reasonably high mass (61 and 89  m/z 
units).  Thus, the likelihood of a false positive result i.e. characterising a mono-
oxidised  metabolite  as  a  dialkyl  tertiary  amine-N-oxide  when  the  site  of Chapter 6 
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oxidation is elsewhere on the molecule, is reduced compared to using a lower 
mass loss. 
 
The diagnostic loss can be integrated into a data interpretation approach that 
allows rapid and definitive characterisation of dialkyl tertiary amine-N-oxides.  
This methodology could be of benefit to metabolite identification scientists, as 
data  interpretation  is  a  recognised  bottleneck  to  high-throughput  studies.
178  
The approach is demonstrated below using the QqTOF mass spectrometer with 
tetracaine  as  a test  analyte  (Figure  6.5),  which  was  incubated  with  rat  liver 
microsomes  to  produce  phase  I  metabolites.    This  compound  was  selected 
because it contains two possible sites for N-oxidation. 
 
 
Figure 6.5  Molecular structure of tetracaine 
 
Using  the  tools  described  in  Chapter  2,  an  N-oxidised  metabolite  could  be 
rapidly identified.  However, none of the approaches, apart from the difficult to 
implement ion-molecule reactions, would determine whether the secondary or 
tertiary amine had been oxidised.  Using the methodology described below, 
rapid and definitive characterisation is possible by incorporating the structurally 
dependent  dissociation  behaviour  that  is  known  to  be  diagnostic  of  dialkyl 
tertiary  amine-N-oxides  but  not  secondary  amines.    A  positive  result  would 
indicate  that the  parent  compound  has  been oxidised  at the dialkyl  tertiary 
amine.  From a negative result, an analyst could infer that the site of oxidation is 
the secondary amine.  Although the approach is described using an “in-space” 
MS/MS platform, it is equally applicable to a mass spectrometer that performs 
“in-time” MS/MS. 
 
The approach requires a dual scan mass spectrometric experiment, which the 
instrument alternates between throughout the analysis.  The first scan involves Chapter 6 
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the acquisition of a full scan mass spectrum.  This will record all of the species 
produced from the ESI ion source at that time point within the mass range 
employed, including any protonated mono-oxidised metabolites of tetracaine in 
this  example.    Combination  of  all  of  the  full  scan  mass  spectra  acquired 
throughout  the  analysis  produces  a  total  ion  current  chromatogram  (TICC) 
(Figure 6.6a).  The second scan is a product ion scan MS/MS experiment.  This 
scan involves dissociating all or some of the precursor ions entering the mass 
spectrometer, either using an MS
E experiment
280 or data-dependent acquisition 
(DDA).
281  An MS
E experiment was performed to acquire the presented data.  
The second scan allows structural information about the precursor ions, such as 
the metabolites of tetracaine in the exemplar, to be derived.  Thus, another 
TICC, this time of the low-energy CID product ion spectra, is produced (Figure 
6.6b).  The TICCs are used to characterise any dialkyl tertiary amine-N-oxides 
present by extracting the ion current related to specific m/z values of interest 
i.e.  forming  RICCs.    From  the  full  scan  TICC,  the  m/z  value  related  to  the 
protonated molecule of the parent compound is extracted; m/z 265 in the case 
of tetracaine (Figure 6.6c).  This RICC provides useful information about the 
retention  time  of  the  protonated  parent  compound.    Another  RICC  is 
constructed from the full scan TICC by extracting the ion current related to the 
m/z value of [M + H + 16 m/z unit]
+, which for tetracaine is m/z 281.  This trace 
(Figure 6.6d) shows peaks for all of the protonated mono-oxidised metabolites, 
plus  any  nominally  isobaric  species.    The  RICC  in  Figure  6.6d  shows  a  peak 
eluting  just  after  the  protonated  parent  compound  (Figure  6.6c)  at  5.12 
minutes.  An analyst may assign this chromatographic peak as an N-oxide based 
upon its elution after the protonated parent compound.   However, it is not 
possible  to  determine  whether  the  secondary  or  tertiary  amine  has  been 
oxidised using just the RICC in Figure 6.6d.  To achieve this, the analyst would 
have  to  interrogate  the  low-energy  CID  product  ion  spectra  related  to  the 
chromatographic  peak;  a  potentially  time-consuming  process.    A  faster 
approach to determining the site of oxidation would be to use the product ion 
scan TICC to create an RICC.  From the product ion scan TICC, the m/z value 
related to the diagnostic loss from the relevant dialkyl tertiary amine-N-oxideChapter 6 
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Figure 6.6  Total ion current chromatograms (TICCs) and reconstructed ion  
current chromatograms (RICCs) acquired using a Premier QqTOF 
mass spectrometer; a) Full scan TICC; b) Product ion scan TICC; 
c) RICC of m/z 265 from full scan TICC; d) RICC of m/z 281 from 
full scan TICC; e) RICC of m/z 220 from product ion scan TICC 
 
for the compound under investigation is extracted.  In the case of tetracaine, 
this is m/z 220 due to the loss of N,N-dimethylhydroxylamine from the oxidised 
dialkyl  tertiary  amine  substructure.    The  resultant  trace  shows  two 
chromatographic peaks (Figure 6.6e).  The peak at 5.10 minutes aligns with that 
of the protonated mono-oxidised metabolite at 5.12 minutes.  Because the m/z 
value selected is known to relate to diagnostic dissociation behaviour, this peak 
can be definitively assigned as a dialkyl tertiary amine-N-oxide.  The second 
peak in the RICC is due to the same m/z value being observed in the low-energy 
CID product ion spectrum of the protonated parent compound.  This signal is 
important because it confirms that the loss of the nitrogen-containing group is 
observed for the protonated parent compound.  As detailed above, the data 
indicated that the loss or retention of the dialkyl tertiary amine group by the 
protonated  parent  compound  is  accompanied  by  equivalent  dissociation 
behaviour for the nitrogen-containing group of the protonated dialkyl tertiary 
amine-N-oxide metabolite.  Therefore, the presence of a chromatographic peak Chapter 6 
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for the protonated parent compound in the product ion scan RICC proves that 
the loss of the nitrogen-containing group will be observed for the dialkyl tertiary 
amine-N-oxide if it is present in the sample.  Thus, if no chromatographic peak 
in  the  product  ion  scan  RICC  aligns  with  a  chromatographic  peak  of  a 
protonated mono-oxidised metabolite from the full scan RICC, an analyst can 
conclude that the metabolite is not formed.  The alternative conclusion, that the 
dialkyl tertiary amine-N-oxide is formed but the diagnostic loss is not observed 
in  its  low-energy  CID  product  ion  spectrum,  can  be  excluded  if  a 
chromatographic  peak  is  observed  in  the  product  ion  scan  RICC  for  the 
protonated parent compound.  In addition, the absence of a chromatographic 
peak that aligns with a protonated mono-oxidised metabolite, accompanied by 
the absence of a chromatographic peak for the protonated parent compound, 
would indicate that a dialkyl tertiary amine-N-oxide may have been formed but 
that it could not be characterised using the discussed approach.  This would be 
the case for diphenhydramine because the loss of the nitrogen-containing group 
was observed for neither the parent compound nor the N-oxide metabolite. 
 
6.4  Conclusions 
A rapid and definitive methodology for the characterisation of dialkyl tertiary 
amine-N-oxides  has  been  developed.    The  approach  builds  upon  the 
understanding of the fragmentation behaviour under low-energy CID conditions 
of  protonated  dialkyl  tertiary  amines  gained  through  the  analysis  of  a 
structurally  diverse  library  of  commercially  available  pharmaceutical 
compounds.    The  analyses  showed  that  the  loss  of  the  nitrogen-containing 
group occurred in 89% of the low-energy CID product ion spectra, suggesting 
that the dissociation behaviour was generic.  Further, the product ions formed 
were demonstrated to be relatively unstable due to the observation of second-
generation dissociation using QqTOF-MS.  The increased understanding of low-
energy CID and gas-phase ion chemistry could be of use to developers on in 
silico packages for fragmentation prediction by allowing them to create more 
robust algorithms and models upon which the programs work.  Further, the Chapter 6 
114 
increased understanding of low-energy CID and gas-phase ion chemistry could 
be useful to mass spectrometrists interested in structural elucidation. 
 
The  methodology  for  the  characterisation  of  dialkyl  tertiary  amine-N-oxides 
overcomes the limitation of other tools for N-oxide identification by utilising 
dissociation  behaviour  that  was  shown  to  be  diagnostic  for  a  particular 
structural  motif.    This  allowed  discrimination  between  potential  sites  of 
oxidation in different chemical environments in a mono-oxidised metabolite of 
tetracaine.  The approach is a high-throughput method because it removes the 
need for the analyst to interrogate the low-energy CID product ion spectrum of 
the metabolite, which reduces the data interpretation time.  The process could 
be automated, thus further decreasing the time taken.  The methodology is 
better  suited  to  trap-configured  mass  spectrometers  due  to  the  greater  ion 
current observed for the product ions of interest using QIT-MS.  However, with 
prudent selection of collision energy, it is amenable to collision cell-configured 
instruments,  as  evinced  by  the  example  of  tetracaine  on  the  QqTOF  mass 
spectrometer.    Thus,  the  approach  is  low-energy  CID-MS/MS  platform 
independent and hence has scope for wide employment. 
 
The methodology is not applicable for the characterisation of all dialkyl tertiary 
amine-N-oxides because of the absence of the diagnostic loss in its low-energy 
CID product ion spectrum e.g. diphenhydramine-N-oxide.  In this circumstance, 
full  interpretation  of  the  low-energy  CID  product  ion  spectrum  would  be 
required  to  localise  the  site  of  oxidation.    However,  attempting  the  RICC 
approach is not detrimental to throughput because full interpretation of the 
low-energy  CID  product  ion  spectrum  is  the  method  currently  used  for 
metabolite identification. 
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Chapter 7 
 
Evidence  for  site-specific  intra-ionic 
hydrogen/deuterium  exchange  in  the  low-energy 
collision-induced dissociation product ion spectra of 
protonated  small  molecules  generated  by 
electrospray ionisation 
 
7.1  Introduction 
The  use  of  isotopic  labelling  in  structural  elucidation  studies  and  the 
rationalisation  of  dissociation  mechanisms  is  a  well-established  approach  in 
MS.
282, 283  The use of solution-phase H/D exchange is particularly common due 
to the ease with which the number of exchangeable hydrogen atoms involved in 
a dissociation can be determined.
284  
 
It is known that isomerisation of activated ions in the gas phase, leading to 
“scrambling” of the isotopic labels, can occur i.e. transfer of the isotopic label 
from its original location in the ion to another position.
285  This observation has 
been documented extensively for ions formed by the highly energetic processes 
that  take  place  in  EI.    Under  these  conditions,  randomisation  of  alkyl  and 
aromatic hydrogen and carbons atoms has been detailed.
286-295  However, very 
few reports of scrambling under low-energy CID conditions exist for protonated 
small molecules formed by ESI.
296-299  Herein, an example of site-specific intra-
ionic H/D exchange in the gas phase for protonated molecules generated by ESI 
is  detailed.    This  example  of  ion-chemistry  could  be  used  to  introduce  an 
isotopic  label  into  the  carbon  skeleton  of  a  molecule  without  the  need  to 
produce an analogue synthetically. 
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7.2  Experimental 
 
7.2.1  Chemicals 
Amiodarone,  amitriptyline,  amitriptyline-N-oxide,  benzydamine,  cinchocaine, 
cinchocaine-N-oxide,  chlorphenamine,  chlorpromazine,  a  tri-oxidised 
chlorpromazine metabolite, a di-oxidised fluorinated chlorpromazine analogue, 
chloroquine,  dibenzepin,  dicycloverine,  doxepin,  hydroxychloroquine, 
levomepromazine,  metoclopramide,  nordoxepin,  promethazine,  protriptyline, 
sunitinib  and  sunitinib-N-oxide  were  provided by  Pfizer  Global  Research  and 
Development (Sandwich, UK).  Hexylamine was purchased from Sigma-Aldrich 
Company  Ltd.  (Gillingham,  UK).    Solutions  were  prepared  for  QIT-MS  and 
solution-phase H/D exchange experiments as detailed in Chapter 3.  A solution 
of amitriptyline was prepared for FT-ICR-MS experiments as detailed in Chapter 
3.  Further solutions of amitriptyline were prepared at 100 ng mL
-1 in LC-MS 
grade methanol and analytical grade methanoic acid [99.9:0.1, v/v] for QqQ-MS 
experiments and at 10 mg mL
-1 in both >99.5% deuterated methanol and 99.5% 
deuterated  methanoic  acid  [99.9:0.1,  v/v],  and  >99.9%  deuterated  acetone 
(Apollo Scientific Ltd., Stockport, UK) for NMR spectroscopy experiments. 
 
7.2.2  Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.   The ion source conditions were; 
sheath gas, 25 arbitrary units; auxiliary gas, 0 arbitrary units (45 arbitrary units 
for  the  solution-phase  H/D  exchange  experiments);  spray  voltage, 4.5  kV; 
capillary  voltage,  10 V;  capillary  temperature,  160
oC;  tube  lens  offset,  -  5 V.  
Low-energy CID product ion spectra were acquired using an isolation width of 1 
m/z unit and with WideBand activation on.  The normalised collision energy was 
set to 50%, except for the analyses of amiodarone (60%) and hexylamine (45%). 
 
“In-space” low-energy CID product ion spectra of amitriptyline were acquired 
using a Xevo TQMS QqQ mass spectrometer (Waters Ltd., Elstree, UK).  Positive 
ion ESI-MS/MS was performed by infusing the solutions directly into the nano-Chapter 7 
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ESI ion source at a constant flow rate of 0.25 μL min
-1.  Nitrogen was used as the 
cone, purge and nanoflow gas.  The ion source conditions were as follows; cone 
gas flow; 0 L hr
-1; purge gas flow, 0 L hr
-1; nanoflow gas flow, 0.1 bar; capillary 
voltage, 1.5 kV; sampling cone, 30 V; extraction cone, 3 V; source temperature, 
70 
oC.  Low-energy CID product ion spectra were acquired at a collision energy 
of  25  eV  using  argon  as  the  collision  gas.    Acquisitions  were  performed  for 
twenty scans.  The scan time was 0.5 s and the interscan time was 0.005 s.  Data 
acquisition  was  performed  using  MassLynx  version  4.1  (Waters  Ltd.,  Elstree, 
Herts., UK). 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of amitriptyline.  The 
ion  source  conditions  were;  capillary  voltage,  -  4.5 kV;  end  plate  voltage,  - 
3.8 kV; capillary exit voltage, 85 V; skimmer 1, 15 V; skimmer 2, 8.5 V; Offset, 
1.25;  RF  amplitude,  600 Hz;  dry  gas  temperature,  250
oC;  dry  gas  flow  rate, 
30 arbitrary units; nebulising gas pressure, 50 psi.  The excitation amplitude was 
7.0 dB.  A low-energy SORI-CID product ion spectrum was acquired for thirty-
two scans using 512K data points.  The MS/MS parameters were; corr sweep 
pulse  length,  1000 µs;  corr  sweep  attenuation,  28.5 dB;  ejection  safety  belt, 
3000 Hz; user pulse length, 1000 µs; ion activation pulse length, 250000 µs; ion 
activation attenuation, 38.9 dB; frequency offset from activation mass, - 500 Hz; 
user delay length, 3 s. 
 
Proton (
1H) NMR spectra were recorded using a DPX-400 (Bruker, Coventry, UK) 
at 298 K. Chemical shifts for the 
1H spectra are reported on the δ scale in ppm 
and were referenced to residual solvent references.  All coupling constants (J 
values) are reported in Hz.  Amitriptyline in deuterated acetone; δH (400 MHz) 
7.33-7.06 (m, 8H, aromatic H), 5.91 (t, 1H, J = 7.3), other peaks obscured by 
water  signal  at  3.13.    Amitriptyline  in  deuterated  methanol  and  deuterated 
methanoic acid; δH (400 MHz) 7.30-7.05 (m, 8H, aromatic H), 5.83 (t, 1H, J = 
7.3), 3.25 (t, 2H, J = 7.8), 2.81 (s, 6H), 2.59 (dt, 2H, J = 7.3), other peaks obscured 
by background signal. Chapter 7 
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7.3  Results and discussion 
The experimental data presented in Chapter 6 showed that under low-energy 
CID conditions, dialkyl tertiary amine-containing compounds frequently display 
the  loss  of dimethylamine  in their  product  ion  spectra.  Solution-phase  H/D 
exchange  experiments  were  conducted  to  determine  the  number  of 
exchangeable hydrogen atoms involved in this loss.  During these experiments, 
intra-ionic H/D exchange was noted upon comparison of the low-energy CID 
product ion spectra of protonated amitriptyline and deuterated amitriptyline 
acquired using QIT-MS (Figure 7.1).  Similar observations were made for the 
structurally similar compounds in  Compound set 1; doxepin and nordoxepin 
(Figures 7.2-7.4).  Based upon the hypothesis that the deuteron is localised on 
the nitrogen atom in solution (a reasonable assumption given the high solution-
phase basicity of the lone pair of electrons on the nitrogen atom relative to the 
delocalised π-electrons), it would be expected that the loss of dimethylamine 
would involve the deuteron i.e. a loss of deuterodimethylamine (46 m/z units) 
would  be  observed.    However,  dissociation  of  the  deuterated  molecule  of 
amitriptyline  generates  product  ions  formed  through  the  losses  of  both 
dimethylamine (m/z 234) and deuterodimethylamine (m/z 233).  Further, the 
other annotated product ions in Figure 7.1a appeared to undergo intra-ionic 
H/D exchange.  This is indicated by the presence of pairs of peaks along the 
mass scale under deuterated conditions of similar abundance relative to one 
another as those observed at m/z 233 and 234.  These observations suggested 
that  intra-ionic  H/D  exchange  takes  place  prior  to  fragmentation  when  the 
precursor  ion  is  activated  under  low-energy  CID  conditions.  Low-energy  CID 
product  ion  spectra  of  protonated  and  deuterated  amitriptyline  were  also 
acquired  using  QqQ-MS.    The  resultant  spectra  show  the  same  dissociation 
patterns (Figure 7.5).  This demonstrated that there was no involvement from 
possible traces of water present in the helium buffer gas used in the QIT-MS, 
which would affect the dissociation of ions using these types of instrument.
300  
Interferences from water could lead to some of the mass isolated deuterated 
molecules of amitriptyline being converted to protonated molecules prior toChapter 7 
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Figure 7.1  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  amitriptyline  (m/z  278)  and  b)  deuterated 
amitriptyline (m/z 279) acquired using a LCQ Classic QIT mass 
spectrometer  with  WideBand  activation  on.    AMMs  were 
acquired using an Apex III FT-ICR mass spectrometer 
 
 
 
Figure 7.2  Molecular structures in Compound set 1 
 
dissociation.    This  would  explain  the  losses  of  both  dimethylamine  and 
deuterodimethylamine.  However, the observation of the same losses using a 
beam-type  instrument,  where  no  interference  from  water  is  likely  to  occur, 
lends support to the hypothesis of intra-ionic H/D exchange.  The observation of 
intra-ionic H/D exchange using QqQ-MS also ruled out the involvement of an 
ion-neutral  complex  in  the  transfer  of  the  deuterium  label.    Extended  time 
frames,  such  as  those  afforded  by  the  millisecond  activation  times  utilised 
during low-energy CID using QIT-MS, are required to facilitate the formation of 
ion-neutral complexes.  Conversely, the microsecond time frame available forChapter 7 
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Figure 7.3  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  doxepin  (m/z  280)  and  b)  deuterated  doxepin 
(m/z 281) acquired using a LCQ Classic QIT mass spectrometer 
with WideBand activation on 
 
 
 
 
 
Figure 7.4  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  nordoxepin  (m/z  266)  and  b)  fully  exchanged, 
deuterated nordoxepin (m/z 268) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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ion  activation  during  low-energy  CID  on  QqQ  mass  spectrometers  does  not 
allow their formation.
301  Therefore, as the intra-ionic H/D exchange is seen 
irrespective of the time available for ion activation, it can be concluded that an 
ion-neutral complex does not facilitate the isomerisation that is observed. 
 
 
Figure 7.5  Product  ion  spectra  of  a)  protonated  amitriptyline  (m/z  278) 
and b) deuterated amitriptyline (m/z 279) acquired using a Xevo 
TQMS QqQ mass spectrometer 
 
Two  alternative  hypotheses  were  considered  and  excluded.    The  first 
postulation  was  that  the  peak  at  m/z  234  was  formed  through  the  loss  of 
dimethylamine  from  the 
13C-isotopologue  of  the  protonated  molecule  of 
amitriptyline.    This  hypothesis  was  discounted  because  a  high  auxiliary  gas 
pressure (45 arbitrary units) was utilised to prevent back-exchange in the gas 
phase.
296  This  led  to  a  low  intensity  of protonated  amitriptyline  relative  to 
deuterated  amitriptyline  (9%:100%)  being  observed  in  the  full  scan  mass 
spectrum (data not shown).  Thus, the contribution of the 
13C-isotopologue of 
protonated amitriptyline to the isolated precursor ion signal at  m/z 279 was 
deemed  negligible.    Further,  it  was  concluded  that  any 
13C-isotopologue  of 
protonated amitriptyline present would provide insufficient ion current to be 
exclusively  responsible  for  the product  ion  intensity  at  m/z  234,  particularly 
given  that  some  of  the  ion  current  would  be  distributed  through  the  other 
dissociation pathways that exist for amitriptyline.  The second hypothesis was Chapter 7 
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that  two  losses  of dimethylamine took place; one facilitated  by the  ionising 
proton and one involving the shift of a non-exchangeable hydrogen atom.  This 
postulation  was  consistent  with  the  experimental  observations  under 
deuterated conditions.  The loss involving the non-exchangeable hydrogen atom 
would remain as 45 m/z units whilst the ionising deuteron would cause the 
second  loss  to  become  46  m/z  units.    This  hypothesis  would  require  a 
heterogeneous population of protonated molecules to be produced by the ESI 
ion source.  Some of the members of the population would be protonated at 
the  nitrogen  atom  to facilitate the  loss  involving  an  exchangeable hydrogen 
atom.  Other members of the population would be ionised at a site other than 
the  nitrogen  atom  to  allow  the  loss  involving  a  non-exchangeable  hydrogen 
atom.  Ion  mobility  spectrometry  (IMS)  experiments  have  shown  that  small 
molecules ionised by ESI can protonate at more than one site.
42  Thus, this 
hypothesis could not be completely excluded on the basis of the experimental 
data obtained through the analysis of amitriptyline.  However, it was deemed 
less likely than the intra-ionic H/D exchange hypothesis due to the absence of a 
second heteroatom in the structure of amitriptyline to provide a plausible site 
of protonation under ESI conditions.  Hence, the most logical rationalisation was 
intra-ionic H/D exchange in the gas phase prior to dissociation.  
 
The  hypothesis  of  intra-ionic  H/D  exchange  was  investigated  further  by 
conducting  NMR  spectroscopy  measurements  in  deuterated  solvents.    The 
experiments were undertaken to determine whether intra-ionic H/D exchange 
took place in solution.  Two samples were prepared; one in solvents with acidic 
deuterons i.e. deuterated methanol and deuterated methanoic acid, and one 
without i.e. deuterated acetone.  Given that the pKa of amitriptyline is 9.4,
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the ionised form of the compound, by virtue of deuteration, would exist in the 
sample in deuterated methanol and deuterated methanoic acid.  Thus, intra-
ionic H/D exchange was feasible.  The sample in deuterated acetone acted as a 
control because amitriptyline would not be ionised through deuteration due to 
the absence of acidic deuterons in the solvent.  Thus, the amitriptyline would 
exist  as  the  free  base  and  no  intra-ionic  H/D  exchange  would  be  possible.  Chapter 7 
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Comparison of the signals in the two 
1H NMR spectra suggested that all of the 
hydrogen  atoms  were  localised  on  the  carbon  skeleton  of  amitriptyline  in 
solution, regardless of whether the solvents contained acidic deuterons or not.  
This  observation  supports  the  hypothesis  of  intra-ionic  H/D  exchange  taking 
place in the gas phase. 
 
Further investigations were undertaken using FT-ICR-MS.  AMMs were acquired 
and indicated that all of the product ions thought to undergo transfer of the 
deuterium label involve the loss of the nitrogen atom during their formation 
(Figure 7.1a).  Concurrent loss of the deuterium atom would be expected if 
intra-ionic H/D exchange did not take place, assuming that the deuteron was 
localised on the nitrogen atom.  However, the AMMs added confidence to the 
hypothesis that the deuterium atom was inserted into the carbon skeleton of 
the molecule via intra-ionic H/D exchange prior to dissociation. 
 
A sample of amitriptyline-N-oxide was analysed to determine the effect that a 
different site of ionisation would have on the intra-ionic H/D exchange.  For this 
compound, ionisation would be expected to take place at the oxygen of the N-
oxide substructure c.f. the nitrogen atom of amitriptyline.  The spectra in Figure 
7.6 show that intra-ionic H/D exchange of the deuterium atom does take place, 
although to a lesser extent than for amitriptyline. 
 
The observation of intra-ionic H/D exchange for the compounds analysed led to 
the  question  of  whether  the  proposed  exchange  is  site-specific,  or  whether 
complete  randomisation  of  all  of  the  hydrogen  and  deuterium  atoms  takes 
place.  It was hypothesised that the exchange involves the γ-hydrogen relative 
to the nitrogen atom.  To determine whether the intra-ionic H/D exchange is 
facilitated by the γ-hydrogen relative to the nitrogen atom, and is thus site-
specific, first-generation low-energy CID product ion spectra of dibenzepin and 
promethazine were acquired (Compound set 2, Figure 7.7).  These compounds 
lack a γ-hydrogen relative to the nitrogen atom and do not exhibit intra-ionic 
H/D  exchange  (Figures  7.8-7.9).    This  suggested  that  the  intra-ionic  H/DChapter 7 
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Figure 7.6  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated amitriptyline-N-oxide (m/z 294) and b) deuterated 
amitriptyline-N-oxide (m/z 295) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
 
exchange  is  dependent  upon  the  presence  of  a  γ-hydrogen  relative  to  the 
nitrogen  atom,  and  thus  is  site-specific.    By  extension,  this  excluded  the 
exchanged hydrogen atom in amitriptyline and amitriptyline-N-oxide from being 
originally located on the α, β or aromatic carbon atoms.  If any of the hydrogen 
atoms at these sites were exchanged, analogous behaviour would be expected 
of  dibenzepin  and promethazine.    The  combination  of  observations thus far 
leads  to  the  conclusions  that  the  intra-ionic  H/D  exchange  is  site-specific, 
requiring a γ-hydrogen relative to the nitrogen atom, and takes place in the gas 
phase.  The NMR spectroscopy measurements support the final conclusion by 
showing that the alkene hydrogen atom to aromatic hydrogen atom signal ratio 
 
 
Figure 7.7  Molecular structures in Compound set 2 Chapter 7 
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Figure 7.8  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated dibenzepin (m/z 296) and b) deuterated dibenzepin 
(m/z 297) acquired using a LCQ Classic QIT mass spectrometer 
with WideBand activation on 
 
 
 
 
 
Figure 7.9  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  promethazine  (m/z  285)  and  b)  deuterated 
promethazine (m/z 286) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
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stays  constant,  regardless  of  the  solvents  used.    This  indicates  that  the  γ-
hydrogen relative to the nitrogen atom remains bonded to the carbon atom in 
solution.  Thus, no intra-ionic H/D exchange takes place in solution, otherwise a 
decrease in the alkene hydrogen atom to aromatic hydrogen atom signal ratio 
would be observed. 
 
Two sets of compounds were analysed to further confirm the site-specificity of 
the  intra-ionic  H/D  exchange.    Compound  set  3  contained  amiodarone  and 
dicycloverine (Figure 7.10).  Instead of a γ-hydrogen relative to the nitrogen 
atom, both compounds have an oxygen atom at this position.  Thus, no intra-
ionic H/D exchange would be expected if the transfer were site-specific due to 
the  absence  of  the  relevant  hydrogen  atom.    The  comparison  between  the 
compound sets is like for like because  the hybridisation states of an oxygen 
atom and a methylene group are identical i.e. sp
3.  Thus, no significant change in 
the  shape  of  the  chain,  nor  its  ability  to  rotate,  should  result  from  the 
modification in substructure.  As a result, no difference in the likelihood of other 
hydrogen  atoms  exchanging  with  the  deuterium  label  should  result;  an 
occurrence that could affect the interpretation of the data.  The first-generation 
low-energy CID product ion spectra of amiodarone and dicycloverine in protic 
and deuterated solvents show no evidence of intra-ionic H/D exchange (Figures 
7.11-7.12). 
 
 
Figure 7.10  Molecular structures in Compound set 3 
 
The  second  group  of  compounds,  Compound  set  4,  contained  cinchocaine, 
cinchocaine-N-oxide,  metoclopramide,  sunitinib  and  sunitinib-N-oxide  (Figure 
7.13).  The molecules in Compound set 4 contain a γ-hydrogen relative to theChapter 7 
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Figure 7.11  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  amiodarone  (m/z  646)  and  b)  deuterated 
amiodarone (m/z 647) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.12  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  dicycloverine  (m/z  310)  and  b)  deuterated 
dicycloverine (m/z 311) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
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Figure 7.13  Molecular structures in Compound set 4 
 
nitrogen atom, but in this case it is an exchangeable hydrogen atom.  Thus, 
under deuterated conditions in solution, it exchanges for a deuterium atom.  If 
the  intra-ionic  H/D  exchange  in  the  gas  phase  were  indeed  site-specific  as 
postulated, the ionising deuteron localised at the tertiary amine group would 
exchange for another deuteron.  Thus, subsequent loss of the tertiary amine 
group in the low-energy CID product ion spectrum would show no evidence of 
transfer  of  the  deuterium  label  even  if  intra-ionic  H/D  exchange  had  taken 
place.    Figure  7.14  shows  the  first-generation  low-energy  CID  product  ion 
spectra of sunitinib in protic and deuterated solvents as an exemplar for the 
compound  set.    The  first-generation  low-energy  CID  product  ion  spectrum 
acquired  under  deuterated  conditions  only  displays  the  loss  of 
deuterodiethylamine, consistent with exchange of the deuteron at the tertiary 
amine group taking place with another deuterium atom.  The first-generation 
low-energy  CID  product  ion  spectra  of  the  other  four  compounds  in  the 
compound  set  also  only  show  the  losses  of  deuterodiethylamine  and 
deuterodiethylhydroxylamine,  depending  upon  whether  the  tertiary  amine 
group is oxidised or not (Figures 7.15-7.18).  The analysis of Compound sets 3 
and 4 provide supportive evidence for site-specific intra-ionic H/D exchange by 
showing that in the absence of a γ-hydrogen relative to the nitrogen atom, no 
evidence  for  the  transfer  of  the  deuterium  label  could  be  obtained.Chapter 7 
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Figure 7.14  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  sunitinib  (m/z  399)  and  b)  fully  exchanged, 
deuterated sunitinib (m/z 403) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.15  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  cinchocaine  (m/z  344)  and  b)  fully  exchanged, 
deuterated cinchocaine (m/z 346) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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Figure 7.16  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  cinchocaine-N-oxide  (m/z  360)  and  b)  fully 
exchanged, deuterated cinchocaine-N-oxide (m/z 362) acquired 
using  a  LCQ  Classic  QIT  mass  spectrometer  with  WideBand 
activation on 
 
 
 
 
 
Figure 7.17  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated metoclopramide (m/z 300) and b) fully exchanged, 
deuterated  metoclopramide  (m/z 304)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 Chapter 7 
131 
 
Figure 7.18  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated sunitinib-N-oxide (m/z 415) and b) fully exchanged, 
deuterated  sunitinib-N-oxide  (m/z 419)  acquired  using  a  LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
Thus far, the intra-ionic H/D exchange has been observed for compounds with 
the  exchanged  hydrogen  atom  bonded  to  an  alkene  carbon.    To  determine 
whether the exchange is dependent upon the hybridisation state of the carbon 
atom, a fifth set of compounds was analysed; chlorpromazine, a tri-oxidised 
chlorpromazine  metabolite,  a  di-oxidised  chlorpromazine  analogue, 
chloroquine,  hydroxychloroquine,  levomepromazine  and  protriptyline  (Figure 
7.19).  All of these compounds contain a γ-hydrogen, relative to the nitrogen 
atom, which is bonded to a sp
3 hybridised carbon atom.  The first-generation 
low-energy  CID  product  ion  spectra  of  chlorpromazine  (Figure  7.20)  show 
evidence of intra-ionic H/D exchange for the three most abundant product ions.  
The other compounds in the set also display intra-ionic H/D exchange (Figures 
7.21-7.26).  This suggests that the intra-ionic H/D exchange can take place with 
a γ-hydrogen relative to a nitrogen atom, irrespective of whether the hydrogen 
is bonded to an sp
2 or sp
3 hybridised carbon atom. 
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Figure 7.19  Molecular structures in Compound set 5 
 
 
 
 
 
Figure 7.20  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  chlorpromazine  (m/z  319)  and  b)  deuterated 
chlorpromazine (m/z 320) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on Chapter 7 
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Figure 7.21  First-generation  low-energy  CID  product  ion  spectra  of  a)  a 
protonated  tri-oxidised  chlorpromazine  metabolite  (m/z  367) 
and b) fully exchanged, deuterated tri-oxidised chlorpromazine 
metabolite  (m/z 369)  acquired  using  a  LCQ  Classic  QIT  mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.22  First-generation  low-energy  CID  product  ion  spectra  of  a)  a 
protonated di-oxidised chlorpromazine analogue (m/z 385) and 
b)  deuterated  di-oxidised  chlorpromazine  analogue  (m/z 386) 
acquired  using  a  LCQ  Classic  QIT  mass  spectrometer  with 
WideBand activation on Chapter 7 
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Figure 7.23  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  chloroquine  (m/z  320)  and  b)  fully  exchanged, 
deuterated chloroquine (m/z 322) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.24  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  hydroxychloroquine  (m/z  336)  and  b)  fully 
exchanged, deuterated hydroxychloroquine (m/z 339) acquired 
using  a  LCQ  Classic  QIT  mass  spectrometer  with  WideBand 
activation on 
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Figure 7.25  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  levomepromazine  (m/z  329)  and  b)  deuterated 
levomepromazine  (m/z 330)  acquired  using  a  LCQ  Classic  QIT 
mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.26  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  protriptyline  (m/z  264)  and  b)  fully  exchanged, 
deuterated protriptyline (m/z 266) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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A  further  set  of  compounds  was  analysed  to  investigate  the  intra-ionic  H/D 
exchange.  This set contained benzydamine and chlorphenamine (Compound 
set 6, Figure 7.27), both of which contain a γ-hydrogen relative to a nitrogen 
atom.  However,  the  carbon  bearing  the  γ-hydrogen  is  also  bonded  to  an 
electron-withdrawing group; an oxygen atom and a chlorinated phenyl ring for 
benzydamine and chlorphenamine respectively.  Neither of these compounds 
display intra-ionic H/D exchange in their first generation low-energy CID product 
ion  spectra  (Figures  7.28-7.29).    The  absence  of  intra-ionic  H/D  exchange 
suggests that the presence of an electron-withdrawing group adjacent to the 
carbon atom bearing the γ-hydrogen can prevent exchange from taking place.  
However,  the  properties  of  the  electron-withdrawing  group  appear  to 
determine whether the intra-ionic H/D exchange is precluded.  This is because 
the presence of the nitrogen atom bonded to the γ-carbon in chlorpromazine, 
the  tri-oxidised  chlorpromazine  metabolite,  the  di-oxidised  fluorinated 
chlorpromazine analogue and levomepromazine (Figure 7.19) does not prevent 
intra-ionic  H/D  exchange  in  these  compounds  (Figures  7.20-7.22  and  Figure 
7.25).  This observation may be consistent with the fact that nitrogen has a 
lower electronegativity than oxygen or a chlorinated phenyl ring.  However, the 
compounds available in this study did not provide an extensive enough dataset 
on which to draw any robust conclusions. 
 
 
Figure 7.27  Molecular structures in Compound set 6 
 
Finally, to address whether the chemical environment of the alkyl chain affects 
the  observation of  intra-ionic  H/D  exchange,  first-generation  low-energy  CID 
product ion spectra of a “linear” tertiary amine with a γ-hydrogen, hexylamine, 
were acquired (Figure 7.30).  Comparison of the product ion spectra shows thatChapter 7 
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Figure 7.28  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  benzydamine  (m/z  310)  and  b)  deuterated 
benzydamine (m/z 311) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.29  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  chlorphenamine  (m/z  275)  and  b)  deuterated 
chlorphenamine  (m/z 276)  acquired  using  a  LCQ  Classic  QIT 
mass spectrometer with WideBand activation on 
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no intra-ionic H/D exchange takes place (Figure 7.31).  The additional peaks 
observed under deuterated conditions that are not observed under protonated 
conditions  are  due  to  noise  i.e.  the  peaks  were  not  seen  repeatably.    The 
absence of intra-ionic H/D exchange suggests that the chemical environment 
provided by the molecule influences whether the deuterium label is transferred.  
Specifically,  the  molecules  for  which  intra-ionic  H/D  exchange  was  observed 
were all pharmaceutical compounds containing substructures such as aromatic 
rings.  These more complex molecules may provide chemical environments that 
facilitate intra-ionic H/D exchange.  However, the exact substructures that assist 
the intra-ionic H/D exchange could not be determined from the compounds 
that were available.  Additional experiments are being conducted to further 
investigate the facilitating substructures. 
 
 
Figure 7.30  Molecular structure of hexylamine 
 
 
 
 
Figure 7.31  First-generation  low-energy  CID  product  ion  spectra  of  a) 
protonated  hexylamine  (m/z  130)  and  b)  deuterated 
hexylamine  (m/z 131)  acquired  using  a  LCQ  Classic  QIT  mass 
spectrometer with WideBand activation on 
 
The experimental investigation has demonstrated the conditions under which 
the site-specific intra-ionic H/D exchange is observed.  The observations have 
relevance to structural elucidation studies by providing a simple, non-synthetic Chapter 7 
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means of introducing a deuterium label into the carbon skeleton of a molecule.  
If an analyst has a compound containing a tertiary amine or tertiary amine-N-
oxide with a γ-hydrogen, analysis in deuterated solvents will cause exchange of 
this hydrogen atom for the ionising deuteron under low-energy CID conditions.  
Thus, the product ions known to lose the nitrogen-containing group, but which 
display  intra-ionic  H/D  exchange,  must  retain  the  γ-carbon  relative  to  the 
nitrogen atom.  The γ-carbon can be either sp
2 or sp
3 hybridised but adjacent 
electron-withdrawing  groups  can  preclude  the  occurrence  of  intra-ionic  H/D 
exchange.    Further,  if  an  analyst  is  working  with  an  unknown  compound  in 
deuterated solvents, the observation of intra-ionic H/D exchange under low-
energy  CID  conditions,  which  is  rare,  may  indicate  that  a  tertiary  amine  or 
tertiary  amine-N-oxide  with  a  γ-hydrogen  not  adjacent  to  specific  electron-
withdrawing groups is present in the molecule. 
 
7.4  Conclusions 
Site-specific  intra-ionic  H/D  exchange  under  low-energy  CID  conditions  in  a 
series of protonated small molecules has been observed.  Experiments have 
shown that the exchange takes place between the deuteron that ionises either 
a tertiary amine or tertiary amine-N-oxide group and a γ-hydrogen relative to 
the nitrogen atom.  The presence of an electron-withdrawing group bonded to 
the carbon atom bearing the γ-hydrogen can prevent the site-specific intra-ionic 
H/D exchange in some circumstances.  Further, the chemical environment in 
which the γ-hydrogen relative to the nitrogen atom structural motif is present 
appears to influence the ion’s propensity to undergo site-specific intra-ionic H/D 
exchange.  The  observations  could  aid  structural  elucidation  studies  by 
providing a simple, non-synthetic means of introducing an isotopic label into the 
carbon  skeleton  of  a  molecule  in  a  site-specific  manner  when  a  particular 
structural motif is present in the compound.  This is of practical benefit because 
it would enable faster completion of structural elucidation studies, as well as 
reducing costs because a deuterium-labelled analogue would not have to be 
produced synthetically. Chapter 8 
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Chapter 8 
 
Concluding remarks 
 
8.1  Summary and conclusions 
The  aim  of  the  presented  study  was  to  elucidate  structurally  dependent 
dissociation pathways that could be used to rapidly and definitively identify and 
characterise  pharmaceutical  drug  metabolites  using  low-energy  CID-MS/MS.  
The work was initiated as a result of promising data from the study by Wright 
and  co-workers.
230  Their  work  demonstrated  that  distinctive  fragmentation 
behaviour under low-energy CID conditions could be used to characterise  S-
oxidised metabolites.  Very few other groups had demonstrated this approach 
to definitively identify oxidised metabolites i.e. through the understanding of 
the dissociation behaviour of the substructure containing the site of oxidation.  
Therefore, the lack of existing literature, in combination with the recognition of 
the  potential  of  the  approach  to  shift  the  accepted  bottleneck  in  modern 
pharmaceutical drug  metabolite  identification studies  i.e.  data  interpretation 
and the associated time-commitment of skilled analysts,
303 meant that further 
investigation was desirable.  
 
The study has been successful in identifying two potentially useful dissociation 
pathways  that  could  allow  definitive  characterisation  of  certain  S-  and  N-
oxidised metabolites (see Chapters 4 and 6).  These pathways were elucidated 
by understanding, through both experimental and computational approaches, 
the dissociation of the substructure containing the site of oxidation in a similar 
manner to Wright and co-workers.  It was recognised early in the study that the 
marginal change to a drug’s structure that occurs when oxidation takes place 
would  rarely  alter  the  dissociation  behaviour  significantly  enough  to  cause 
distinctly different product ions or losses for the metabolite compared to the Chapter 8 
141 
parent compound.  Thus, diagnostic product ions and losses arising solely from 
the S
+-O
-, N
+-O
- and C-OH moieties is unlikely because the structural change is 
almost  certainly  insufficient  to  create  a  substructure  that  will  drive  the 
dissociation differently.  Therefore, it is the author’s opinion that completely 
generic dissociation behaviour i.e. the same product ion or loss being formed 
due to the presence of S
+-O
-, N
+-O
- or C-OH bond in the metabolite regardless of 
the overall molecular structure, is not possible under low-energy CID conditions.  
However,  by  understanding  how  the  dissociation  is  driven  by  the  chemical 
environment in which the oxidised group is positioned, it is possible to elucidate 
structurally dependent dissociation pathways that can be used to definitively 
characterise pharmaceutical drug metabolites using low-energy CID-MS/MS, as 
evinced by the presented study.  As dissociation is known to be driven by the 
structure  of  the  molecule,  it  should  be  possible  to  determine  further 
substructures that drive particular fragmentation pathways.  Thus, further work 
in the area of understanding fragmentation under low-energy CID conditions is 
required due to the current lack of knowledge.  The potential benefit to the 
area  of  structural  elucidation,  including  metabolite  identification,  and  the 
likelihood of success is demonstrated by the presented study.  Furthermore, the 
investigation of the dissociation of pharmaceutical drug metabolites using other 
ion activation techniques should be conducted.  In particular, electron capture 
dissociation  (ECD)  is  garnering  interest  as  a  method  to  dissociate  small 
molecules.
304  Recent work has shown that, contrary to widespread belief, singly 
charged molecules can be dissociated using ECD.
305  The study demonstrated 
that the product ions formed are complementary to those observed under low-
energy CID conditions.  Most interestingly, the work reports cleavages across 
benzene  rings,  which  are  resistant  to  fragmentation  under  low-energy  CID 
conditions.    ECD  may  therefore  enable  definitive  assignment  of  the  site  of 
hydroxylation on a benzene ring, which is a challenging proposition using the 
current  technology  and  approaches.    A  related  ion  activation  technique, 
electron transfer dissociation (ETD),
306 has yet to be applied to the area of small 
molecule  structural  elucidation.    It  is  therefore  the  author’s  opinion  that 
investigation  of  the  application  of  both  types of  radical-induced dissociation Chapter 8 
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techniques should be performed, as they could provide useful additions to the 
small molecule structural elucidation approaches.  Further studies of MS/MS 
dissociation, regardless of the employed ion activation technique, will also be of 
use  to  developers  of  in  silico  packages  for  fragmentation  prediction.    These 
software packages generally use rules derived from EI mass spectra for small 
molecule  fragmentation  prediction,
234  which  are  not  necessarily  directly 
applicable to CID, ECD or ETD product ion spectra, or are based on case-specific 
information derived from compiled MS/MS databases.
307  Therefore, increased 
knowledge and understanding of MS/MS dissociation would be useful to make 
these packages more accurate and robust, and hence more useful. 
 
In  addition  to  the  original  aim  of  the  study,  extensive  interrogation  and 
interpretation of product ion spectra has enabled an increased understanding of 
ion-chemistry  under  low-energy  CID  conditions.    Each  chapter  has  made  a 
contribution to the body of knowledge in this area.   Chapter 4 showed that 
sequential radical losses can take place from an even-electron precursor ion 
under low-energy CID conditions.  This would not be expected on energetic 
grounds  based  upon  the  even-electron  rule.
251  Further,  the  experimental 
observations suggested a preference for the formation of planar product ion 
structures under low-energy CID conditions.  This proposal was supported by 
the  observations  detailed  in  Chapter  5,  which  again  suggested  that  planar 
product ion structures are preferentially formed over those that have a greater 
number  of  bonds  which  have  free  rotation.    Chapter  5  also  showed  that 
unexpected rearrangements take place under low-energy CID conditions.  This 
highlighted  the  need  for  an  analytically  rigorous  experimental  methodology 
when  performing  structural  elucidation  studies  to  prevent  incorrect  ion 
structure assignments.  Chapter 6 demonstrated that dialkyl tertiary amines and 
their N-oxides generally dissociate in a predictable way, with the neutral loss of 
this  group  observed  in  the  low-energy  CID  product  ion  spectrum.    The  loss 
appeared to be governed by ionisation taking place at this substructure and is 
likely to only occur when this prerequisite is fulfilled.  The data also suggested 
that  the  product  ions  formed  through  the  loss  of  the  dialkyl  tertiary  amine Chapter 8 
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group or its N-oxidised analogue are relatively unstable and thus susceptible to 
further dissociation.  Finally, Chapter 7 illustrated that site-specific intra-ionic 
H/D exchange can take place such that the ionising deuteron can be swapped 
with  a  non-exchangeable  γ-hydrogen  and  thus  be  inserted  into  the  carbon 
skeleton of the compound.  This is a rare observation, and the site-specificity of 
the exchange also allows it to be a useful tool for structural elucidation studies. 
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Appendix 1 
 
Table A1  Molecular structures of compounds containing a dimethylamine 
substructure 
 
Compound  Molecular structure 
Alimemazine 
 
Almotriptan 
 
Amitriptyline 
 
Amlodipine structural 
analogue 1 
 
Amlodipine structural 
analogue 2 
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Amlodipine structural 
analogue 3 
 
Amlodipine structural 
analogue 4 
 
Benzydamine 
 
Chlorphenamine 
 
Chlorpromazine 
 
Chlorpromazine 
structural analogue 1 
 
Chlorpromazine 
structural analogue 2 
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Chlorprothixene 
 
Citalopram 
 
Clomipramine 
 
Cyclopentolate 
 
Demeclocycline 
 
Dibenzepin 
 
Diltiazem 
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Diphenhydramine 
 
Doxepin 
 
Doxycycline 
 
Imipramine 
 
Iprindole 
 
Levomepromazine 
 
Metformin 
 
Moxisylyte 
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Olopatadine 
 
Orphenadrine 
 
Promazine 
 
Promethazine 
 
Ranitidine 
 
Rivastigmine 
 
Sibutramine 
 
Sumatriptan 
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Sunitinib structural 
analogue 
 
Tamoxifen 
 
Tetracaine 
 
Tramadol 
 
Trimipramin 
 
Venlafaxine 
 
Zimelidine 
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Table A2   Molecular structures of compounds containing a diethylamine 
substructure 
 
Compound  Molecular structure 
Amiodarone 
 
Amlodipine structural 
analogue 5 
 
Chloroquine 
 
Cinchocaine 
 
Clomifene 
 
Dicycloverine 
 
Disulfiram 
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Lidocaine 
 
Macrogol 
 
Metoclopramide 
 
Naftidrofuryl 
 
Oxybuprocaine 
 
Oxybutynin 
 
Procainamide 
 
Procaine 
 
Sunitinib 
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Table A3  Molecular  structures  of  compounds  containing  an  N,N-
dimethylhydroxylamine substructure 
 
Compound  Molecular structure 
Amitriptyline-N-oxide 
 
Chlorpromazine-N-oxide 
1 
 
Chlorpromazine-N-oxide 
2 
 
Chlorpromazine 
structural analogue-N-
oxide 1 
 
Chlorpromazine 
structural analogue-N-
oxide 2 
 
Diphenhydramine-N-
oxide 
 
Ephedrine structural 
analogue-N-oxide 
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Tamoxifen structural 
analogue-N-oxide 1 
 
Tamoxifen structural 
analogue-N-oxide 2 
 
Tetracaine-N-oxide 
 
 
 
 
Table A4  Molecular  structures  of  compounds  containing  an  N,N-
diethylhydroxylamine substructure 
 
Compound  Molecular structure 
Cinchocaine-N-oxide 
 
Sunitinib-N-oxide 
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Table A5  Relative abundances (RA) for the product ion formed through 
the  loss  of  dimethylamine  from  a  series  of  pharmaceutical 
compounds  using  QqTOF-MS  and  QIT-MS  at  various  collision 
energies 
 
Compound  RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Alimemazine  6  4  1  41  37 
Almotriptan  52  100  31  17  16 
Amitriptyline  76  64  20  100  100 
Amlodipine 
structural 
analogue 1 
11  4  1  94  89 
Amlodipine 
structural 
analogue 2 
23  18  -  100  100 
Amlodipine 
structural 
analogue 3 
2  1  -  63  71 
Amlodipine 
structural 
analogue 4 
5  4  2  100  100 
Benzydamine  11  5  1  100  100 
Chlorphenamine  100  100  100  100  100 
Chlorpromazine  4  3  2  100  100 
Chlorpromazine 
structural 
analogue 1 
-  -  -  7  7 
Chlorpromazine 
structural 
analogue 2 
1  8  3  21  21 
Chlorprothixene  100  100  66  100  42 
Citalopram  8  2  -  12  16 
Clomipramine  6  4  3  100  100 
Cyclopentolate  -  -  -  -  - 
Demeclocycline  -  -  -  -  - 
Dibenzepin  100  100  100  100  100 
Diltiazem  19  3  -  18  33 
Diphenhydramine  -  -  -  -  - 
Doxepin  39  18  9  100  100 
Doxycycline  -  -  2  3  - 
Imipramine  4  3  2  21  15 Appendix 1 
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Iprindole  2  4  5  1  1 
Levomepromazine  8  4  4  100  99 
Metformin  33  23  14  15  14 
Moxisylyte  9  5  1  100  100 
Olopatadine  8  13  6  16  19 
Orphenadrine  -  -  -  -  - 
Promazine  7  4  3  55  47 
Promethazine  15  12  5  100  100 
Ranitidine  7  2  -  71  100 
Rivastigmine  100  49  11  100  100 
Sibutramine  -  -  -  -  - 
Sumatriptan  100  71  12  100  81 
Sunitinib 
structural 
analogue 
100  63  33  89  100 
Tamoxifen  2  1  -  100  100 
Tetracaine  11  10  5  16  17 
Tramadol  -  2  -  16  - 
Trimipramin  4  4  2  21  18 
Venlafaxine  -  -  -  -  - 
Zimelidine  14  6  3  79  80 
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Table A6  Relative abundances (RA) for the product ion formed through 
the  loss  of  diethylamine  from  a  series  of  pharmaceutical 
compounds  using  QqTOF-MS  and  QIT-MS  at  various  collision 
energies 
 
Compound  RA using 
QqTOF-MS 
at 15 eV / 
% 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Amiodarone  -  -  2  100  100 
Amlodipine 
structural 
analogue 5 
3  1  -  59  61 
Chloroquine  100  100  100  100  100 
Cinchocaine  100  100  81  100  100 
Clomifene  -  1  -  7  7 
Dicycloverine  41  59  24  100  100 
Disulfiram  -  -  -  18  13 
Lidocaine  -  -  -  -  - 
Macrogol  100  100  64  100  100 
Metoclopramide  100  100  100  100  100 
Naftidrofuryl  8  3  -  38  55 
Oxybuprocaine  28  28  26  46  53 
Oxybutynin  -  -  -  -  - 
Procainamide  100  100  51  100  100 
Procaine  50  46  21  100  100 
Sunitinib  100  100  80  100  100 
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Table A7  Relative abundances (RA) for the product ion formed through 
the  loss  of  N,N-dimethylhydroxylamine  from  a  series  of 
pharmaceutical  compounds  using  QqTOF-MS  and  QIT-MS  at 
various collision energies 
 
Compound  RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Amitriptyline-N-
oxide 
100  65  22  100  100 
Chlorpromazine-
N-oxide 1 
2  5  3  6  5 
Chlorpromazine-
N-oxide 2 
13  52  13  100  100 
Chlorpromazine 
structural 
analogue-N-oxide 
1 
79  100  26  100  100 
Chlorpromazine 
structural 
analogue-N-oxide 
2 
32  100  73  100  100 
Diphenhydramine-
N-oxide 
-  -  -  -  - 
Ephedrine 
structural 
analogue-N-oxide 
97  30  9  21  19 
Tamoxifen 
structural 
analogue-N-oxide 
1 
-  2  1  31  43 
Tamoxifen 
structural 
analogue-N-oxide 
2 
1  2  1  29  35 
Tetracaine-N-
oxide 
100  100  44  100  100 
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Table A8  Relative abundances (RA) for the product ion formed through 
the  loss  of  N,N-diethylhydroxylamine  from  a  series  of 
pharmaceutical  compounds  using  QqTOF-MS  and  QIT-MS  at 
various collision energies 
 
Compound  RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Cinchocaine-N-
oxide 
100  100  96  100  100 
Sunitinib-N-oxide  100  100  100  100  100 
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